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The use of advanced and newly developed biostatistical methods usually lag behind 
their initial discovery by a period ranging from a few years to decades. Most clinical 
research use well-established “classical” statistics to make statistical inference, for example, 
presence of association. However, when analyzing research data with complex study 
designs or data structure, simply relying on “classical” statistical methods such as t-tests or 
standard procedures from generalized linear model may be inappropriate as the data do not 
satisfy the underlying model’s assumptions. This thesis will introduce and focus on the use 
of modern Bayesian methods to address research questions encountered in different areas 
of clinical and epidemiological research with a focus on eye diseases. The thesis will 
analyze data with questions that may be difficult to address using “classical” statistics. The 
application of Bayesian analysis using modern Bayesian computation techniques may pose 
a challenge for clinical researchers and hence a documented “step-by-step” R codes to help 
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Uncertainty plays a very important role in clinical medicine and research as the 
translation of scientific discoveries and clinical diagnoses are usually not straightforward. 
Statistical modeling enables various sources of uncertainty (e.g. sampling or measurement 
errors) to be accounted for in biomedical research, to improve scientific inference and 
predictions, aiding clinicians make better diagnostic, prognostic and therapeutic decisions.  
In research fields such as ophthalmic epidemiology, analyzing research data relying 
only on “classical” or conventional statistical methods presents severe bottleneck for 
today’s science. A recent article by Nuzzo (2014) in Nature, titled “P-values, the ‘gold 
standard’ of statistical validity, are not as reliable as many scientists assume” have likened 
P-values to “mosquitoes, the emperor’s new clothes or a tool of sterile intellectual rake” 
and ‘fishing’ practices have the effect of “turning discoveries from exploratory studies, 
what look like sound confirmations but vanish on replication”.1 Statistical thinking in the 
Bayesian way was suggested as a possible solution, which offers a flexible alternative 
approach to data analyses.  
1.1.1 Bayesian Perspectives on Some Common Problems of the “classical” Statistics 
Concerns in Meta-analysis (refer Bayesian application in Chapter 5) 
Meta-analysis methods used to synthesize evidence from related research studies to 
provide an overall pooled effect, were frequently formulated in the “classical” approach 
using random effects model. The random effects model assumes that each individual 
observed study result is estimating its own unknown underlying effect that originates from 
a common population mean, and hence allows for both within and between study 
variability. Inference based on asymptotic properties from “classical” approach usually 
requires large sample sizes. Bayesian models mirrored the “classical” formulation, but 
provides a number of specific advantages performed in the Bayesian framework.2  
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We illustrate using an example of a previous systematic review and meta-analysis to 
summarize the prevalence of age-related macular degeneration in Asian populations and 
investigate ethnic differences with reported prevalence in white populations. This work 
was conducted by Kawasaki et al. (2010)3 and they had used the random effects model. 
Their analyses could have benefited from the flexibility in Bayesian’s approach. Firstly, 
the data manipulation and exclusion of studies could be avoided in the analysis step to fully 
utilize all data in eligible studies. Four of the nine eligible papers reviewed containing 
potential information for the meta-analysis were excluded because of the different age 
range or unavailable age-specific prevalence data. Analysis was further restricted to 
include data only for age range from 40 to 79, due to small numbers for data for age ≥ 80. 
Furthermore, data was manipulated in the form of re-classifying some reported prevalence 
(up to ≥ 5 years in age ranges for each age category), e.g. prevalence for ages 43-54 years 
to be counted in the “40-49 years” age category. Bayesian approach allows layers of 
specifications for all model parameters to overcome the above issues, particularly useful 
for units of analysis with small sample sizes by borrowing strength from other units, and 
has the ability to include other pertinent information that would otherwise be excluded. 
Secondly, a separate meta-regression was performed to test for difference in prevalence of 
disease between Asians and whites, restricted to include only (white populations) studies 
with ≥ 1000 study subjects. It would be more desirable to model for ethnic-specific (Asian 
and whites) prevalence of disease, accounting for all sources of uncertainty within a single 
comprehensive Bayesian model. Ethnicity effect can then be examined by computing the 
Bayes factors. Thirdly, intuitive interpretations on probability statements (from Bayesian 
analyses) can be made directly on the pooled prevalence, e.g. there is 95% probability that 
prevalence of age-related macular degeneration in Asian populations is from 4.6% to 8.9%. 
Lastly, our simulation study results in Study 3 (Appendix 2, Supplementary Figure 5.2) 
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showed that estimated prevalence from Bayesian model is more accurate than random 
effects model, especially for small sample sizes < 100.  
Multiple Comparisons Issue 
Researchers often have a set of hypotheses that they wish to test simultaneously, such 
as the evaluation of relationships between several potential risk factors and disease 
outcomes. Such practice will lead to an increase (with each additional test) in the likelihood 
of the researcher wrongly conclude that there is at least one statistically significant effect 
across a set of tests, even if there is no real effect at all. For example, if we performed 20 
null tests each at a 5% significance level, there will be a 64% chance that at least one them 
will be statistically significant resulting in a false positive finding.  
“Classical” procedures such as the popular Bonferroni correction4 accounts for  
multiple comparisons by adjusting the p-values to maintain the overall significance level 
at 5%, which is very conservative and may lead to a high rate of false negatives (reduces 
power to detect an important effect). Other “classical” corrections include controlling for 
family-wise error rate or false discovery rate. 5 
However, the multiple comparison issue can be accounted for in the Bayesian model. 
Multilevel models naturally incorporate all relevant research questions as parameters in 
one coherent model, and hence addresses multiple comparisons problem faced with 
“classical” statistics.6-7 Once we work within a Bayesian multilevel modeling framework 
and model these relationships appropriately, we are able to get more reliable and effective 
estimates, especially in settings with low group-level variation which is where multiple 
comparisons are a particular concern. 
No Gold Standards Problem (refer to Bayesian application in Chapter 4) 
“Classical” approach assess newly developed diagnostic tests or classifiers using 
calculated measures such as sensitivity, specificity, positive and negative predictive values 
and overall accuracy, require a reference or gold standard test to establish the disease 
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outcome of a patient.8 Conditional on disease state, the tests are assumed to be independent. 
The assumption may not be reasonable when the biological basis of the tests is the same 
and ignoring it may lead to biased sensitivity and specificity estimates. Furthermore, in the 
absence of a reference test, the true disease status is unknown. Statistical modeling in 
Bayesian framework can better handle these issues by allowing for conditional dependence 
of tests and the incorporation of informative priors based on expert opinion.9-10  
Bayesian perspective offers flexibility to craft useful solutions tailored for specific 
research conditions. Above are some specific advantages described to overcome 
difficulties faced by using common statistical techniques. 
1.1.2 Advantages of Bayesian Approach in Epidemiological Research  
We often have some or partial information of what we wonder about, re-think or adjust 
our beliefs as we acquire new information but we all hope to predict something based on 
our past experiences. Such logic reasoning is reflected in Bayes’ rule, a simple and intuitive 
theorem on updating our initial belief about an event of interest with new objective 
information. Bayesian methodology is a promising field of statistics, increasingly adopted 
across the disciplines of science and leading medical journals.11-14 Its applications are 
particularly useful in clinical and epidemiological research.15  
Firstly, research data structure can be complex, such as repeated measurements or 
multiple observations nested within subjects, or subjects may be clustered according to 
treatment sites with random effects model. Similarly, the hierarchical Bayesian (HB) 
approach is naturally suited to the modeling of various layers of conditional data, i.e. first 
level describes multiple measurements per subject, second level describes subjects within 
sites etc. Furthermore, even well-designed research data may be subjected to multiple 
sources of uncertainty. Bayesian methods allow for the modeling of complex data 
structures and the attachment of uncertainty to parameters to account for all the 
uncertainties at play. Such reflection of uncertainty is important in honest assessment of 
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post-data knowledge, especially in facing new treatments that affect clinician’s inferential 
advice to patients in their course of actions. Lastly, in epidemiology, we often have partial 
knowledge of many exposure-outcome relationships from past experiences, previous 
literature and various limitations of measurements from data collection, implies that not all 
relevant parameters can be estimated consistently from the data. Past information are useful 
for cumulative scientific knowledge and for leveraging inference. Bayesian approach 
allows for accumulated results (as priors) to be integrated into analysis of subsequent 
research data, to update our previous beliefs and refine conclusions. 
This thesis will focus on the application of modern Bayesian methodology in context 
to several areas of clinical and epidemiological problems faced in ophthalmology (where 
the above described advantages prevail). 
1.2 BAYESIAN FRAMEWORK 
1.2.1 Defining the Bayesian Approach 
The Bayesian approach quantifies a measure of belief that lies in the gray areas 
between absolute truth and total uncertainty, derived from new evidence and 
approximations from other sources of information. Bayesian statistics considers unknown 
parameters as random variables and computes probability distributions (i.e. posteriors) – 
by updating prior knowledge with new data, expressed formally by integrating the 
likelihood function (study data) and the prior distribution (previous information), to which 
probabilistic statements about parameters of interest can be made from the posterior 
distribution. For example, 95% credible intervals are the 2.5th to 97.5th percentile of the 
posterior distribution of interest. 
1.2.2 Bayesian versus “classical” Statistics 
It is important to recognise that both Bayesian and “classical” statistics have their 
respective strengths and limitations. The thesis focused on the application of Bayesian 
modeling in complex research scenarios to one’s advantage, when it is difficult to resolve 
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using the “classical” approach or common statistical techniques. “Classical” and Bayesian 
statistics are analysis tools and can be thought of as complementary statistical approaches.  
“Classical” approach considers inference problem in a repeated sampling framework, 
where experiments are repeatable and research data represents one of the many possible 
random samples from the population. Model parameters are treated as fixed quantities 
(unknown parameters but not random variables) and inference are based on hypothetical 
replications of the experiments. For example, P-value describes how likely it would be to 
find an observation as large as or larger than our observed (from current experiment data), 
if we were to repeat the experiment many times, assuming the null hypothesis was in fact 
true. Its interpretation is often confused to correspond to the probability of false positives. 
On the other hand, Bayesian offers an intuitive statistical philosophy that allows us to make 
probability statements of the underlying reality. Its statistics framework allows for proper 
adjustments to work around limitations faced in “classical” methods, such as when our data 
violates common model assumptions that may be due to imperfections in data collection 
procedure or the complexity of study design, and in keeping other sources of variation 
under control. Table 1.1 summarizes the advantages and disadvantages of the two 
approaches. 
However, the application of Bayesian analysis using modern Bayesian computation 
techniques16 (such as Markov chain Monte Carlo methods) may pose a challenge for non-
quantitative researchers. The Bayesian implementation procedures, to implement a MCMC 
algorithm to simulate draws from the posterior distribution of the unobserved quantities 
given what is observed may seem daunting for beginners. WinBUGS and JAGs are special 
software available (free and good start) to perform automated computations for complex 
Bayesian modeling.17-18 While well-known “classical” statistics have long-established 
guidelines for specialized techniques to correspond with data types, straightforward 
implementations and remains acceptable in practice, there is increasing trend of 
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computational intensive needs to handle large and increasing complexity of datasets. On-
going developments of new and modern statistics improves efficiency and reliability of 
data analysis and its applications should be embraced to advance science – using statistical 
techniques that is closer to being right given the structure of the problem, together with 
good scientific judgement. 
1.2.3 Prior Information 
Objectivity and precision are expected of science but Bayesian analysis framework 
incorporates prior knowledge deemed as subjective beliefs, naturally became the main 
target of criticism from scientists uncomfortable with the approach. Prior knowledge varies 
from different people may lead to different answers and hence the concern on objectivity. 
The current practice to evaluate the properties or effect of prior distributions on our analysis 
model is to conduct sensitivity analyses, i.e. to perform cross-validation on multiple trial / 
mock data, or to test on a range possible / reasonable informative (and non-informative) 
priors to validate our model results. Varying posterior distributions should be observed 
with the application of multiple trial data (i.e. changing likelihood functions) to suggest 
that posterior distribution was driven by the likelihood (i.e. data) incorporated with prior 
information rather than prior distribution over-influencing the results. Similarly, 
consistency in inferences based on a range of reasonable priors will boost confidence in 
results. Serious disagreement between prior beliefs and the calculated posterior signals the 
need to re-evaluate your model, where the real challenge comes in constructing realistic 
models and in assessing their fit. Relevant sections of textbooks “Bayesian approach 
Bayesian Data Analysis” by Gelman et al. (2004) and “Statistical Decision Theory and 
Bayesian Analysis” by Berger (1985) provided in-depth discussion to handle criticisms of 
Bayesian methods. 
1.3 GENERALIZATION FROM LITERATURE REVIEWS 
Statistics Used in Ophthalmic Journals 
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“Statistical Techniques in Ophthalmic Journals” published in 1992 at JAMA 
Ophthalmology (formerly Archives of Ophthalmology) was the only article found to have 
reviewed and examined the frequency of statistical methods previously used in ophthalmic 
literature.19 In total, 947 articles were reviewed from the ARCHIVES for years 1970, 1980, 
and 1990; American Journal of Ophthalmology (AJO) for 1990; and Ophthalmology for 
1990. It was found that readers familiar with “classical” statistical techniques would have 
“statistical accessibility” to 88.9% of 1990 articles. Measures of central tendency (65.0%) 
was the most common technique, followed by dispersion (50.3%), t-test (20.3%), and 
contingency tables (16.6%). Nonparametric tests (8.3%) and survival analysis (5.4%) were 
considered advanced statistics then. 
Recently, an article revealed on the current “Use of Statistical Analyses in the 
Ophthalmic Literature” (2014), based on 780 peer-reviewed articles for the type of 
statistical methods used in AJO, Ophthalmology and Archives of Ophthalmology, from 
January 2012 through December 2012.20 A variety of statistical methods were currently 
used in analysis in ophthalmic research, moving beyond merely descriptive statistics 
observed two decades ago. More applications of specific techniques such as reliability tests, 
generalized estimating equations and Rasch analysis were used. However, only 0.5% of 
the 780 reviewed articles employed the Bayesian approach for analysis shows the 
unfamiliarity of Bayesian methods to eye-researchers. Table 1.2 shows the distribution and 
ranks of current statistical methods used. 
Biostatistics Research 
Generalized linear models (GLMs), survival analysis, categorical data analysis, spatial 
statistics, and Bayesian methods (in diagnostic, epidemiological and clinical trials contexts) 
as well as meta-analysis (as a tool for evidence-based medicine) were popular areas of 
statistics used in medical research during mid-1990s, observed by Armitage in his book 
“Statistical Methods in Medical Research”.  
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In 1994, Altman and Goodman21 suggested that the following new statistical methods 
will play a key role in biomedical research over coming years: (i) bootstrap (and other 
computer-intensive methods); (ii) Gibbs sampler (and other Bayesian methods); (iii) 
generalized additive models; (iv) classification and regression trees (CART); (v) models 
for longitudinal data (general estimating equations); (vi) models for hierarchical data; and 
(vii) neural networks.  
In 1997, Houwelingen22 likewise suggested that the future would be marked by new 
biomedical applications (in epidemiology, historical data on oncological patients and their 
families; in ecology, spatial data); by new philosophies (causal models instead of 
randomized clinical trials; prediction versus prognostic modeling); new models (graphical 
chain models, random effects models); new computational facilities (with an impact on the 
other aspects); new techniques (graphic techniques, exact methods, pseudo-likelihood); 
and new forms of collaboration (databases for meta-analysis, Internet software, Internet 
publications). 
A recent review on current research in biostatistics was conducted in 2009 by 
Abdelmonem A. Afifi and Fei Yu and was published in AJO.23 Table 1.3 below shows the 
list of leading biostatistical journals and issued reviewed and Table 1.4, the frequency of 
statistical methods used. Briefly, the category with the highest frequency covers 
nonparametric and semi-parametric approaches to inference techniques, GLM, regression 
models, and variable selection. Following category is regression analysis, including 
survival analysis and parametric approaches to GLM. Next is the high-dimensional data 
category, which includes handling time series data, spatial temporal data, data mining, 
discrimination and classification models and neural networks. The next category includes 
general Bayesian analysis methodology as well as Bayesian approaches to genetics/ 
ecology, stochastic processes, model selection, nonparametric analysis, and experimental 
design. Post hoc analysis includes missing data analysis and parametric model and variable 
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selection, as well as multiple comparisons. Study design encompasses experimental design 
research, design of clinical trials, and survey sampling. The general inference category 
includes “classical” statistical inference methods, such as hypothesis testing and 
confidence intervals. Genetic analysis contains statistical methodology and applications to 
genetic data, such as gene sequence, population genomic data, and gene expression 
microarry data. Causal inference encompasses methods that aim to uncover whether 
observed phenomena reflect statistical association or a true causal relationship, such as the 
propensity score methods discussed in this series. Lastly, “other” category consists 
methods that does not fit into the above categories, such as quality control, meta-analysis, 
and graphical theory, stochastic processes. 
Conclusions 
The tremendous breadth of modern and new methods appearing in biostatistics 
research is at a greater speed than its application into biomedical research.16 The advantages 
and flexibility of Bayesian approach to customize statistical models for specific data 
structure is particularly useful in clinical and epidemiology research. Bayesian methods are 
among the popular and promising fields of current biostatistics research.7, 24-30 However, 
Bayesian methods are yet to be widely utilized to solve ophthalmic research problems. This 
may be due to the inclination to stay with known methods and the ease of “classical” 
methods application while they remain acceptable in practice, or the lack of communication 
between statisticians and clinician scientists resulting in an unappealing alternative due to 
limited statistical knowledge. Also, the application of Bayesian analysis using modern 
Bayesian computation techniques (such as MCMC methods) may pose a challenge for non-
quantitative researchers. Hence, the need for the role of an effective interdisciplinary 
biostatistician, to facilitate communication of modern statistical techniques (being able to 
explain difficult concepts to non-quantitative researchers or clinician scientists) and its 
applications into health research projects.  
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The purpose of this thesis is to develop Bayesian models to address some common 
but complex research problems (where the above described advantages prevail) 
encountered in different areas of clinical and epidemiology research in ophthalmology, and 
to advocate the use of Bayesian methods when handling complex research scenarios with 
documented “step-by-step” R codes to help researchers to perform their own Bayesian 
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1.5 Chapter 1 Tables 
 
Table 1.1 Comparison of Bayesian versus “classical” Approach 
Bayes  “Classical” 
Advantages  Disadvantages 
Able to formally incorporate prior information  Unable to include external information 
Inferences are conditional on observed data  Inferences are based on repeated sampling framework, on data conditional on fixed but unknown parameters 
Intuitive interpretation 
e.g. 95% probability that the true value is in the credible interval 
 
Awkward interpretation 
e.g. in hypothetical repetition of the same experiment, 95% of confidence 
intervals contain the true value. 
e.g. p-value is the long-term probability of obtaining data at least as unusual as 
what was actually observed. 
Reasons for stopping experiment does not affect inference  
Stopping conditions statistical test results/decisions 
e.g. two experiments with identical likelihoods could result in different p-
values if the experiments were designed differently.  
Analyses follow directly from the posterior.  
e.g. no separate theories of estimation, testing, multiple comparisons etc. 
are needed. 
 
Strict rules and assumptions to follow. 
e.g. hypothesis testing applicable only for nested hypotheses and can only offer 
evidence against the null hypothesis. 
e.g. multiple testing inflates Type I error (false positives) 
Procedures are consistent and estimators are optimal, even for small samples 
and complex models  Require large samples for asymptotic properties. 
Disadvantages  Advantages 
Less efficient  Fully efficient when samples are large 




Table 1.2 Distribution of Statistical Methods used in Selected Ophthalmic Journals 
during 2012 
 Statistical Method 
Articles containing the method 
Number* % 
0   No statistical methods or descriptive statistics only 162 20.8 
1   t-test 246 31.5 
2   Contingency tables 266 34.1 
3   Nonparametric tests 170 21.8 
4   Epidemiologic statistics   42 5.4 
5   Adjustments for epidemiologic statistics  15 1.9 
6   Diagnostic proportions 40 5.1 
7   Multiple comparison 49 6.3 
8   Pearson's correlation 67 8.6 
9   Spearman’s correlation 49 6.3 
10  Kappa statistics for agreement  25 3.2 
11  Bland-Altman 17 2.2 
12  Analysis of covariance 99 12.7 
13  Analysis of covariance 25 3.2 
14  Transformation 51 6.5 
15  Simple linear regression 64 8.2 
16  Multiple linear regression 66 8.5 
17  Multi-way tables 6 0.8 
18  Simple logistic regression 77 9.9 
19  Multiple logistic regression 89 11.4 
20  Survival methods 85 10.9 
21  Power analyses and sample size calculations 58 7.4 
22  Cost-benefit analysis 15 1.9 
23  Sensitivity analysis 21 2.7 
24  Repeated-measures analysis 18 2.3 
25  Missing-data methods 23 2.9 
26  Receiver operating characteristic 27 3.5 
27  Resampling 17 2.2 
28  Generalized estimating equations 41 5.3 
29  Linear mixed models 58 7.4 
30  Bayesian analysis 4 0.5 
31  Meta-analysis 8 1 
32  Rasch analysis and item response theory 3 0.4 
33  Generalized linear models (excluding linear and logistic) 10 1.3 
34  Other methods 25 3.2 
      Totals 2038  




Table 1.3 List of Statistical Journals and Issues Reviewed 
Journal Title Impact Factor Journals Issues Reviewed 
No. of 
Articles 
Biostatistics 3.394 October 2008 - April 2009 45 
Journal of the Royal Statistical Society, 2.835 November 2008 - September 2009 47 
Annals of Applied Statistics 2.448 September 2008 - June 2009 55 
Journal of the American Statistical Association 2.394 September 2008 - March 2009 92 
Annals of Statistics 2.307 February 2009 - June 2009 52 
Statistical Methods in Medical Research 2.177 October 2008 - August 2009 33 
Statistical Science 2.135 November 2007 - September 2008 17 
Statistics in Medicine 2.111 January 2009 - May 2009 89 
Biometrics 1.97 September 2008 - March 2009 100 
Biometrika 1.405 September 2008 - March 2009 53 






Table 1.4 Categories of Statistical Research and Their Frequencies in Reviewed Journals
Category of Statistical Research Number (%) of Articles 
Nonparametric/semiparametric analysis 83 (14.2%) 
Regression analysis 81 (13.9%)* 
High-dimensional data 73 (12.5%) 
Bayesian analysis 71 (12.2%) 
Post hoc analysis 58 (9.9%) 
Study design 46 (7.9%) 
General inference 45 (7.7%) 
Casual inference 33 (5.7%) 
Genetic analysis 25 (4.3%) 
Other 68 (11.7%) 
Total 583 (100%) 








































2.1 SPECIFIC AIMS 
The goal of the thesis is to develop solutions via statistical models in the Bayesian 
perspective for four research problems that may face difficulty or limitations when using 
the “classical” approach, with focus in eye diseases. The specific aims are: 
1. To develop a conversion algorithm based on Bayes’ principal for the conversion 
of cataract prevalence between any two cataract grading systems, illustrated with 
the LOCS III and Wisconsin system.  
Current limitations: Direct comparisons of cataract prevalence estimates across 
epidemiological studies from current literature limit meaningful inferences due to 
substantial variability in the various grading protocols adopted (grading methods, 
definitions of lens opacities and examination techniques). 
 
2. To develop Bayesian model for evaluation and comparison of diagnostic tests for 
tuberculous uveitis, tuberculin skin test and two (dependent) interferon γ release 
assay tests in the absence of a gold standard. 
Current limitations: The estimations of sensitivity and specificity of diagnostic 
tests from the “classical” approach assume independence of tests and requires a 
reference or gold standard for true disease status. 
 
3. To perform systematic review and develop Bayesian model to perform meta-
analysis for the global prevalence and burden projection of age-related macular 
degeneration for 2020 and 2040. 
Current limitations: To perform global meta-analysis using “classical” approach 
may face many limitations and restrictions in handling and combining numerous 
studies, such as small samples studies, differences in age range and age-group 
specific breakdowns across studies and various sources of heterogeneity etc.   
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4. To develop hierarchical Bayesian one-stage “joint analysis” approach to account 
for measurement errors of vision-specific latent trait in regression models. 
Current limitations: Rasch analysis and linear regression results and inferences 
are fine on its own, but naïve combination / integration of statistical methods 
lacking proper statistical considerations may lead to biased inferences.   
 
2.2 STRUCTURE OF THESIS 
The thesis is organized as follows. Chapter 1 introduces the concept, advantages and 
flexibility of Bayesian approach in handling complex research scenarios, lending 
motivation in advocating Bayesian analysis methods in ophthalmic research. Analyses 
performed in the thesis included data from the Singapore Malay Eye Study (SiMES), 
prospective cohort of patients presented with uveitis to a tertiary institution and data 
extracted when conducting meta-analysis. Specific aims, study design, methods and data 
details were documented in Chapter 2.  
Chapter 3 (Study 1) begins with an intuitive application of Bayes’ principal to 
develop a conversion algorithm and applied to two cataract classification systems to enable 
fairer comparison of cataract prevalence from the diversity of grading systems 
implemented across epidemiological studies.  
In many areas of medicine, gold standard diagnostic techniques are rare, yet accurate 
diagnosis of infectious diseases is essential in primary health care. In particular, the 
diagnosis of uveitis associated with tuberculosis is controversial and there is no established 
“gold standard” to diagnose tuberculous uveitis which makes it difficult to evaluate new 
medical diagnostic tests. Chapter 4 (Study 2) uses Bayesian Latent Class modeling to 
evaluate three diagnostic tests available in the absence of a gold standard and incorporating 
prior information obtained from previous meta-analysis literature. As two of the diagnostic 
tests are not independent (both are whole-blood tests), our model also accounted for their 
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dependency and further investigated the optimal choice of diagnostic test to be used, which 
is more interest to ophthalmologists. 
Chapter 5 (study 3) is a study on Bayesian approach in the meta-analysis of 
population-based studies of age related macular degeneration worldwide. Various sources 
of heterogeneity and uncertainty (e.g. ethnicity, geographic regions etc.) were accounted 
for and tested in our statistical model. Pooled prevalence and to projections would provide 
useful guide for global strategies. 
Vision functioning is one of the key latent traits for vision-specific instruments / 
questionnaires and its data were commonly evaluated using Rasch analysis. Subsequent 
applications using “classical” statistics (e.g. linear regressions) for association analysis of 
latent data without accounting for its measurement error may lead to biased estimations 
and statistical inferences. Chapter 6 (study 4) demonstrates the effectiveness of a 
modeling framework that integrates Rasch and regression models using hierarchical 
Bayesian approach that accounts for latent trait measurement errors to produce more 
accurate estimation of association effects. 
The above studies elucidate some Bayesian modeling techniques that are useful to 
resolve hypotheses / questions with complex settings in various areas of ophthalmic 
research. Finally, Chapter 7 summarizes the key findings of this thesis and discuss 
possible extensions and recommendations for future research work. Instructions for “step-
by-step” R codes to help researchers to perform their own Bayesian analysis for similar 
research settings were documented in Appendix 1. 
2.3 STUDY POPULATIONS, DESIGN AND METHODS 
Many interesting research questions differing in complexity in data structures / study 
deigns were encountered in the years of experience working in Singapore Eye Research 
Institute. However, some cannot be easily resolved with “classical” statistics. To improve 
and advance ophthalmic research, this thesis advocate the advantages and flexibility of 
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modern Bayesian approach in different areas of clinical and epidemiology research. Study 
1 and 4 are research questions / issues based on data from the Singapore Epidemiology of 
Eye Disease (SEED) program, mainly using the Singapore Malay Eye Study (SiMES) data. 
Study 2 is a clinical question that is of direct relevance to ophthalmologists, a diagnostic 
accuracy study based on data collected from a prospective cohort of patients presented with 
uveitis to a tertiary eye institution. Study 3 is a systematic review and meta-analysis and 
hence analysis was based on data extracted from published literature identified from our 
systematic review. 
2.3.1 Singapore Malay Eye Study (SiMES) 
The Singapore Epidemiology of Eye Disease (SEED) is a program that consists the 
Singapore Malay Eye Study (SiMES)1 and Singapore Indian Chinese Cohort (SICC) Eye 
Study,2 with aims to investigate the prevalence, risk factors, and impact of major eye 
diseases in  Chinese, Indians and Malays in Singapore. The SEED program includes 
database from three population-based, cross-sectional studies, conducted between 2004 
and 2011 for Malays, Indian and Chinese adults aged 40 and older in the south-western 
Singapore (Figure 1).  
Using an age-stratified random sampling strategy, 5,600 Malay names, 6,350 Indian 
names, and 6,752 Chinese names were selected from the Ministry of Home Affairs. A total 
of 4,168 Malays, 4,497 Indians, and 4,605 Chinese were deemed eligible to participate.1-2  
“Ineligible” persons were those who had moved from the residential address, had not lived 
there in the past six months, or were deceased or terminally ill.  In total, 3,280 Malays, 
3,400 Indians and 3,353 Chinese participated in the SEED program, giving a response rate 
of 78.7%, 75.6%, and 72.8% respectively (Figure 2).1-2  
The study adhered to the Declaration of Helsinki, and ethics approval was obtained 
from the Singapore Eye Research Institute (SERI) Institutional Review Board with written 
informed consent obtained from all subjects before participation. All participants 
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underwent a comprehensive ocular examination that was carried out at SERI. A detailed 
interviewer-administered questionnaire was used to collect relevant information such as 
socioeconomic status, lifestyle data and medical history of eye diseases.   
Recruitment 
Participants were invited to attend a comprehensive eye and physical exam at the SERI 
via telephone, by mail, and/or by home visit. A booklet outlining the overall eye study 
findings and an invitation letter (reply-paid postage) were sent to all baseline participants 
to elicit a strong spirit of cooperation. 
Questionnaire 
A questionnaire based interview was administrated by trained interviewers. These 
questionnaires, listed below, were either validated in the Blue Mountains Eye Study 
(BMES), a landmark population-based eye study in Australia) or other studies: 
 Contact and demographic information 
 Socioeconomic characteristics (education, income level, occupation) 
 Family and medical history 
 Smoking status 
 Questionnaire on access and barriers to use of general health and eye care services, 
 Vision-related quality of life, including the modified visual function-14 
questionnaire (VF-14). 
Systemic and ophthalmologic examinations 
 Blood pressure, height, weight 
 Presenting and best-corrected distance visual acuity using the Early Treatment 
Diabetic Retinopathy Study (ETDRS) Logarithm of the Minimum Angle of 
Resolution (LogMAR) chart 
 Auto-refraction, keratometry and lensometry.  
 25 
 
 Axial length was measured using the IOL-Master®.  
 Central corneal thickness, anterior chamber and angle parameters were measured 
with anterior-segment Visante™ OCT (Carl Zeiss Meditec, Dublin, CA) 
 Gonioscopy and automated perimetry (Humphrey Visual Field Analyzer II, 24-2 
SITA, Carl Zeiss Meditec, Dublin, CA, USA) for all glaucoma suspects  
 Slitlamp biomicroscopy for anterior eye abnormalities and applanation intraocular 
pressure 
 After pupil dilation, slit-lamp based lens photographs were taken to measure 
nuclear cataract. Retroillumination photos of the anterior and posterior lens were 
taken on a Neitz digital cataract camera to measure cortical and posterior 
subcapsular cataract. The clinical grading of cataract was based on the Lens 
Opacities Classification System (LOCS III)3 
 ETDRS standard fundus fields 1 (optic disc) and 2 (macula) were taken using a 
digital retinal camera (Canon CR-1 Mark -II Nonmydriatic Digital Retinal Camera, 
Canon, Japan). Photographs then were graded using the BMES and Wisconsin 
protocols 
 Blood collection for assessment of HbA1c, serum glucose, lipid and CRP levels 
Imaging data 
 Signs of DR were graded from fundus photographs using the modified Airlie 
House classification system and a modification of the ETDRS severity system for 
DR. Graders assessed the presence/severity of diabetic macular edema, and sign 
of laser treatment scar.4-5 
 Presence of AMD was graded using the Wisconsin AMD grading system6 
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 Photography of lens through the dilated pupil for assessment of nuclear, cortical, 
and posterior subcapsular cataract were graded using the Wisconsin cataract 
grading system.7 
 Retinal vascular caliber are measured by using a semiautomatic computer-assisted 
program (Singapore I Vessel Assessment), according to standardized protocol.8 
Contributions 
My main contribution in the SEED program is in the management, consolidation and 
maintaining integrity of the database for the SiMES and SICC study (10,033 subjects) that 
includes questionnaire, clinic, imaging data and other sub-datasets. I have helped to 
organize and standardize definitions and codebooks across the studies, created data request 
forms for documentation of data sharing between collaborators, to ensure consistency of 
variables and that project topics do not overlap between researchers to avoid unnecessary 
conflicts.   
2.3.2 Diagnostic Accuracy Study 
We conducted a prospective study of all new consecutive patients with uveitis 
presenting to the Singapore National Eye Centre (SNEC) Ocular Inflammation and 
Immunology Service from 2008 to 2010. Ethics approval was obtained from our local 
institutional review board, and our research adhered to the tenets of the Declaration of 
Helsinki.  Patients were enrolled if they had clinical ocular signs indicative of tuberculous 
uveitis (TBU) and consented to participate in the study.   
All of the study subjects underwent a full systemic review, ocular examination, and 
standard baseline investigations.  Blood was taken for diagnostic tests T-SPOT.TB (Oxford 
Immunotec, Oxford, United Kingdom) before the tuberculin skin test (TST) was performed. 
Patients were excluded if they had (1) any other possible infectious or noninfectious cause 
that could account for the uveitis or (2) a T-SPOT.TB result that was “indeterminate”9 as 
these tests cannot be interpreted. Those suspected TBU were referred to infectious diseases 
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physician at Singapore General Hospital for evaluation. Anti-TB therapy (ATT) was 
prescribed if required. Patients’ treatment response and recurrence were monitored for six 
months after completion of ATT, if given, or 1 year if no ATT was given.  
From 1st January 2009, in addition to diagnostic tests T-SPOT.TB and TST, 
QuantiFERON-TB Gold In-Tube (Cellestis Incorporated, Carnegie, Australia) [QFT] was 
also performed for incoming patients. Blood was taken for QFT and T-SPOT.TB testing 
before the TST was performed to avoid any boosting effect (although it has been shown 
that this is unlikely to be significant).10-11 
Investigations 
 Complete blood count 
 Erythrocyte sedimentation rate analysis 
 Liver enzyme panel analysis 
 Infectious disease screen (which included Venereal Disease Research Laboratory 
test for syphilis, TST, urine microscopy) 
 Chest X ray 
 T-SPOT.TB was performed according to the manufacturer’s instructions,12 where 
two readers quantified the number of Interferon-gamma spot-forming T-cells 
visually and a third reader was consulted if the results were disparate. 
 TST was performed using the standard Mantoux method13 
 QFT was performed according to the recommended guidelines14 
Definitions 
 T-SPOT.TB considered positive if there were >8 spots compared to the negative 
control well; negative if there were <4 spots compared to the control well; or 
equivocal if the test wells had 5–7 spots more than the control.9 If the negative 
 28 
 
control well had >10 spots and/or <20 spots in the mitogen positive control wells, 
the result was considered to be ‘indeterminate’. 
 TST induration was measured at 72 h with a ruler and considered positive if it was 
more than or equal to 15 mm, as validated in our population.15 
 QFT considered positive if the response to the specific antigens was ≥0.35 IU/mL, 
regardless of the level of the positive control; negative if the response to the 
specific antigens was <0.35 IU/mL and the Interferon-gamma level of the positive 
control was ≥0.5 IU/mL; and indeterminate if both antigen-stimulated samples 
were <0.35 IU/mL and the level of the positive control was <0.5 IU/mL.14 
2.3.3 Data for Meta-analysis 
In Study 3, we performed a systematic literature review to identify all population-
based studies of age-related macular degeneration (AMD) published before May, 2013 by 
searching the electronic databases of PubMed, Web of Science, and Embase.  
Inclusion criteria 
 Population-based study from a defined geographic area with response rate >50% 
 Studies with standardized photographic assessment of AMD, i.e. using grading 
classifications according to the Wisconsin age-related maculopathy grading 
system16, the international classification for age-related macular degeneration17, or 
the Rotterdam staging system18.  
Definitions 
 Early AMD defined as either any soft drusen (distinct or indistinct) and pigmentary 
abnormalities or large soft drusen 125 μm or more in diameter with a large drusen 
area (>500 μm diameter circle) or large soft indistinct drusen in the absence of 
signs of late-stage disease  
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 Late AMD defined as the presence of any of the following: geographic atrophy or 
pigment epithelial detachment, subretinal haemorrhage or visible subretinal new 
vessel, or subretinal fibrous scar or laser treatment scar. 
Data Extraction from each Study 
 Age-gender specific prevalence for early and late AMD (total number of subjects 
and number of cases recorded) 




 Geographical region 
 Publication year 
 Response rate 
Meta-analysis was performed according to the Meta analysis Of Observational Studies in 
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Intuitive Application of Bayes’ Principle 
Study 1: Cataract Conversion assessment using Lens Opacity Classification System III 
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3.1 RESEARCH MOTIVATION and CONTRIBUTIONS 
Literature review on the prevalence of cataract across epidemiological studies varied 
substantially with the different prevailing grading protocols. Differences in grading 
methods, definitions of lens opacities and examination techniques limit meaningful 
inferences from the comparisons across studies conducted using different assessment 
methods. Conclusions based on naïve pooling of estimates without consideration of the 
differences in classification systems may not be accurate. Hence to fill this gap, we 
developed a conversion algorithm to determine the equivalence of construct measurements 
performed on different scales that would be especially useful for diseases where there is 
yet to be global consensus for the adoption of a simple definition and classification system 
(e.g. cataract, chronic kidney disease). 
Bayes’ theorem is a result that is of importance in the mathematical manipulation of 
conditional probabilities. Conditional probability which represents the likelihood of one 
system’s grading score category (A) given another (B), can be easily transformed to the 
other direction (i.e. the likelihood of B given A). This relationship described in Bayes’ 
theorem links and converts between two conditional probabilities, i.e. P(A|B) to P(B|A) 
provides a natural solution for the transformation between scales. Hence, we developed a 
general algorithm that approximates conversion between any two cataract systems and 
illustrated its application in two major cataract classification systems, LOCS III and 
Wisconsin system. Our conversion algorithm was validated by using cross-validation and 
can be extended for use in the conversion between any two scales. We also provided step 
by step instructions to facilitate the use of our conversion codes that automates the 
iterations of our collapsing algorithm using R, a free statistical computing software (refer 






 Age-related cataracts remain the leading cause of blindness worldwide, posing a 
big challenge to rapidly aging populations.1-3 Prevalence and incidence of cataracts have 
been well examined in many population-based epidemiologic studies.4-31 Understanding 
the burden of cataracts from these prevalence and incidence data is important in the 
planning of eye care services, particularly  health service delivery for cataract surgery.32 
 Several cataract classification systems have been developed and used to measure the 
presence and extent of cataracts including Lens Opacities Classification System (LOCS),6, 
8, 10, 11, 13-21, 27, 30 Wisconsin Cataract Grading System (Wisconsin system),7, 9, 23-26 Wilmer,12, 
33 Age-Related Eye Disease Study Grading System (AREDS),22, 31 World Health 
Organization Simplified Cataract Grading System (WHOSCGS),4 and Oxford Clinical 
Cataract Classification System (OCCGS)5 resulting in several arbitrary cut-offs derived 
within and across the various systems (Tables 3.1 and 3.2). It is important to note that 
direct comparison of prevalence of cataracts between different studies is hampered by the 
diversity of classification systems using various assessment methods.34 In fact, some 
studies adopted more than one classification system simultaneously to assess different 
cataract subtypes.13 Some other studies attempted to pool or compare prevalence of 
cataracts between studies despite having used different grading systems.19, 35 Few studies 
have developed conversion scores between cataract classification systems, such as the 
calibration performed for LOCS III and OCCGS.36 There is a gap in general formulas or 
conversion algorithm that enables one system’s grading to be converted into another to 
allow for reasonable comparison across centers or studies. 
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 In this study, we aim to develop a general algorithm that approximates conversion 
between any two cataract systems and illustrate the application in two major cataract 
classification systems, LOCS III and Wisconsin system. 
3.3 METHODS 
Study Population 
 The Singapore Malay Eye Study (SiMES) investigated the prevalence, causes and risk 
factors of blindness and visual impairment in the urban Malay community. SiMES is a 
population-based, cross-sectional epidemiological study of Asian Malays aged between 40 
and 80 years old living in south western Singapore. Comprehensive details of the study 
have been reported and published elsewhere.37-39 . Between August 2004 and June 2006, 
3280 (78.7% participation rate from a total of 4168 eligible) Malays were examined in our 
study clinic. In total, 6530 eyes from 3265 SiMES participants were graded for cataract 
using the LOCS III and Wisconsin system; data we used to derive the conversion algorithm. 
The SiMES study conducted adhered to the Declaration of Helsinki and ethics approval 
was obtained by the Singapore Eye Research Institute Institutional Review Board. The 
conversion algorithm was further validated in the Singapore Indian Eye Study40 (SINDI); 
a population-based cross-sectional study of 3400 (75.6% participation rate) Indian adults 
aged 40 and above using the same study protocol as in SiMES. 
Cataract Classification Systems and Grading Procedures 
 Lens opacity was assessed using both LOCS III and Wisconsin system , as described 
previously.34 Table 3 summarizes the main characteristics of the LOCS III41 and Wisconsin 
grading system42. Five study ophthalmologists examined all participants for cataract using 
slit lamp bio-microscopy with a Haag-Streit slit-lamp microscope (model BQ-900; Haag-
Streit, K¨oniz, Switzerland) in accordance to the LOCS III41,  comparing with standard 
photographic slides for nuclear opalescence, nuclear colour, cortical and posterior 
subcapsular  (PSC) cataract. Prior to the study, all study ophthalmologists were trained for 
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the standardized examination that includes documentation of clinical diseases according to 
written protocol (e.g., corneal pathology, diabetic retinopathy, etc), measurement of 
intraocular pressure and assessment of lens opacity using LOCSIII grading scale. Inter-rate 
reliability was assessed in a set of 30 patients with moderately high inter-rater reliability 
with intra-class correlation coefficients ranging from 0.70 to 0.85 between the study 
ophthalmologists. 
 Additionally, lens photographs were taken by digital slit-lamp (Topcon model DC-1 
with FD-21 flash attachment; Topcon, Tokyo, Japan) and retro-illumination (Nidek EAS-
1000, Nidek, Gamagori, Japan) cameras during the examination, and lens opacity was 
assessed using the Wisconsin system. The slit beam was adjusted to completely fill the 
pupil and to vertically bisect the lens at a 45o angle focusing on the sulcus of the lens. All 
photographs were graded by a single trained grader at the University of Sydney who also 
graded cataract for the Blue Mountains Eye Study. 14,378 photos were taken in total with 
at least two photos for each eye and only the best quality photo based on grader’s judgment 
was evaluated. These photographs were compared against a set of four standards to 
determine degree of nuclear opacity. Cortical and PSC cataracts were assessed from retro-
illumination photographs using an overlying grid to determine the location and percentage 
of lens involved by the opacity. Percentage of lens area involvement by cortical and PSC 
cataract were estimated for each segment of the grid in order to calculate the total 
percentage area of involvement. Adjudication was provided for images with positive 
nuclear cataract by a senior researcher and PSC cases were confirmed by a senior 
ophthalmologist. The intra-grader reliability was high, with an intra-class correlation 
coefficient of 0.95 (95% confidence interval: 0.93-0.97) in a random sample of 100 




 All statistical analyses were performed using R version 2.14.2 (http://www.R-
project.org/, provided in the public domain by R Development Core Team, 2012).43 Box 
plots were provided for graphical display of relationship between LOCS III and Wisconsin 
system for each cataract subtype.  
Conversion algorithm 
 A contingency table was used to record and analyze the multivariate frequency 
distribution of modified categorical LOCS III and Wisconsin system. In order to increase 
the power and also the counts in each cell of the contingency table, a collapsing method 
was performed as in the following algorithm:  
 1) Calculate the conditional frequency distribution;  
 2) Compare conditional frequency distribution of any two contiguous categories;  
 3) Collapse the two contiguous categories with smallest distance or similar 
distribution; 
 4) Repeat the first three steps until desired number of contiguous categories is 
achieved.  
In this algorithm, the smallest distance was defined as the least absolute shrinkage in terms 
of L1-norm.  
Conversion Application using LOCS III and Wisconsin System 
For nuclear opalescence score, LOCS III ranged from 0.1 to 6.9 with one decimal, 
while Wisconsin system used a five-point scale by comparing participant photographs of 
the eye with the set of four Wisconsin standard photographs. Also, a decimalized system 
of nuclear grading of one decimal place was estimated on a continuous scale between each 
standard by the grader (e.g., 3.8). We first start by collapsing the grading scheme used for 
LOCS III to encompass only half-unit steps: 0.1 to 0.4, 0.5 to 0.9, 1.0 to 1.4, 1.5 to 1.9 … 
6.5 to 6.9 before applying our algorithm in the contingency table with Wisconsin system 
using five-point scale.  LOCS III cortical and PSC scores ranged from 0.1 to 5.9, while 
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Wisconsin system measured the percentage of area involved. LOCS III cortical and PSC 
grading schemes were collapsed similarly as for nuclear score into half-unit steps. 
Continuous Wisconsin system for cortical was re-coded into fewer categories of 5% 
incremental steps from 0 to 100 while PSC was initially collapsed as 0 (since 0 may 
potentially be used as cut-offs), 1 to 4, and 5% increment steps thereafter from 5 to 100. 
Conversion algorithm was then applied to collapse LOCS III and Wisconsin system for all 
three cataract subtypes until we obtain five contiguous categories (i.e., 5 by 5 contingency 
table). The order of collapsing has little influence on the results. 
 The final collapsed contingency tables of nuclear opalescence, cortical, and PSC 
cataract were used as guidelines for conversion between LOCS III and Wisconsin system. 
This method works as a classification approach that tries to minimize the difference within 
each category and at the same time maximize the variability between any categories. We 
attempted to maximize the likelihood of the multivariate frequency distribution while 
restricting to five categories for each classification system. The conversion between LOCS 
III and Wisconsin system was based on conditional probabilities which reflect the 
likelihood of falling into corresponding LOCS III or Wisconsin system categories. 
Data cleaning 
 We started with the initial contingency table having maximal contiguous categories 
collapsed arbitrarily.  Data points in any cells of the final collapsed contingency table that 
have conditional probabilities of lesser than 10% were regarded as noise data (may be due 
to measurement errors) and were removed. Conditional probabilities were then 
standardized to ensure they summed up to one. 
Validation 
 The conversion was validated  using the cross-validation method.44 Our data was 
randomly divided into 10 subsets. Nine subsets of data were used to construct the collapsed 
contingency table to propose the conversion guideline. The remaining subset of data was 
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used to test the conversion trained by the nine parts of data. We further validated our 
conversion algorithm with the SINDI population. 
3.4 RESULTS 
Figure 3.1 shows the distributions of individual cataract subtypes in SiMES. We observed 
possible quadratic or non-linear relationship.  
     As the relationship between LOCS III and Wisconsin system is not one-to-one due to 
the differences in score ranges and interval sizes, the conversion from LOCS III to 
Wisconsin system was different from the reverse direction of Wisconsin system to LOCS 
III (i.e. not vice versa). We therefore performed collapsed algorithm for the conversion 
between the two systems, and the results of our final collapsed contingency table was 
tabulated in Appendix 2, Supplementary Table 3.1. Figure 3.2 illustrates our proposed 
conversion approximation results for nuclear, cortical, and PSC cataracts individually from 
LOCS III to Wisconsin system and the reverse order of Wisconsin system to LOCS III. 
Figure 3.3 shows our validation analysis performed in 10% test SiMES data and in SINDI 
data. Relative frequencies of subjects in corresponding collapsed categories after 
conversion is almost identical to that of original scale for moderate to severe cataract. 
     The guide to use Figure 3.2 is as follows: for example, to find the corresponding 
LOCS III score from Wisconsin system scale for nuclear opalescence, refer to the top left 
graph in Figure 3.2. Assuming the scale in Wisconsin system is 1, Figure 3.2 shows that 
two corresponding LOCS III categories, “0.1-2.9” and “3.0-3.9” are most likely to match 
this Wisconsin system scale of 1 with conditional probability of 0.65 and 0.35, respectively. 
We may infer that it is 65% likely to be in the “0.1-2.9” category and 35% likely to be in 
the “3.0-3.9” category. Hence, in the consideration of prevalence, this subject with 





 We applied our proposed algorithm to approximate the conversion between two major 
cataract grading systems, LOCS III and Wisconsin system by collapsing the multivariate 
frequency distribution contingency table. Our conversion algorithm can be extended and 
applied to other cataract grading systems. There is a need for such method of conversion, 
as prevalence and incidence of cataract cannot be compared directly between studies that 
were assessed using different classification systems. 
     The estimation of prevalence of cataract varies substantially with different grading 
protocols,34 which may be often neglected in the pooling and comparison of estimates seen 
in a few studies.19, 35 The lack of universal epidemiologic definition of cataract cut-offs 
added to the inaccurate comparison of cataract prevalence even within studies using 
common grading systems. Pooling of cataract prevalence in the United States35 was 
performed to include Barbados Eye Study (BES) with LOCS II,8 Beaver Dam Eye Study 
(BDES) with Wisconsin,7 Blue Mountain Eye Study (BMES) with Wisconsin,9 Salisbury 
Eye Evaluation Project with Wilmer,12 and Melbourne Visual Impairment Project with 
Wilmer.45 Differences in grading methods, definitions of lens opacities and examination 
techniques limit the accuracy of conclusion with regards to pooled prevalence of cataract.  
The application of our proposed conversion method provided a conversion 
approximation to transform between LOCS III and Wisconsin system. For example, 
converting nuclear opalescence from Wisconsin system to LOCS III in our data gave 
estimated prevalence of 24.8% (based on the “classical” or optimal cut-off of ≥ 4) 
compared with prevalence of 26.7% from direct use of LOCS III with the same cut-off. 
The reverse conversion of nuclear opalescence from LOCS III to Wisconsin system gave 
estimated prevalence of 17.8% (based on the “classical” or optimal cut-off of ≥ 4) 
compared to prevalence of 16.8% from direct use of Wisconsin system. The small 
difference in the converted prevalence and original prevalence on the same scale suggests 
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good approximation derived from our conversion algorithm. Conversion for cortical and 
PSC had similar performance. Our conversion algorithm allows fairer and more accurate 
inferences based on the same scale than current naïve comparisons of prevalence and 
pooling analysis performed directly across studies using different systems. In addition, the 
cross-validation analysis (Figure 3) demonstrated that our method was very robust and that 
our conversion algorithm may be extended to other population data for all three cataract 
subtypes.  
Our findings have important insights and implications. We provided a general 
conversion algorithm and its application to approximate the conversion between LOCS III 
and Wisconsin system to improve the pooling or comparison of prevalence of cataracts. 
Wisconsin system for assessment of cataracts was also used in BMES and BDES, the two 
landmark epidemiological studies in eye research. At present, there continues to be 
important new papers on epidemiology of cataract from these two studies using the 
Wisconsin system,46, 47 while more recent studies have used LOCS III. Our study is 
therefore important by being the first study to directly compare the two systems. 
Large overlaps observed in early cataract scores between grading systems suggests 
difficulty in the discrimination of subtle lens opacity changes and the detection of early 
cataract. Newer methods under development such as Quasielastic or Dynamic Light 
Scattering (QELS or DLS) with Scheimpflug imaging system may be more objective and 
promising as such methods in clinical use have shown that a growing cataract can be 
detected at the molecular level using the technique of dynamic light scattering48.  
     The strengths of our study include a large sample size from two population-based 
samples, and having performed two standardized cataract grading protocols in the same 
population. Our main limitation in the study application is the grading variability between 
clinical grading at the slit-lamp compared to grading lens photos. However, in many 
clinical and epidemiological studies and multi-center trials, clinical grading at the slit-lamp 
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may be the only feasible (and less expensive and complex) approach, particularly when 
cataract is important but of secondary interest (e.g., many landmark trials on anti-VEGF 
injection treatment for age-related macular degeneration (AMD) had clinical LOCS 
grading for cataract such as [CATT]49, Anti-VEGF antibody for the treatment of 
predominantly classic choroidal neovascularization in AMD [ANCHOR]50, Minimally 
Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of 
Neovascular AMD [MARINA],51 and a Study of rhuFAB V2 [Ranibizumab] in Subjects 
with Subfoveal Choroidal Neovascularization Secondary to AMD [PIER]52, 53). Our 
conversion algorithm application is therefore more practically relevant and allows 
comparison and conversion of clinical LOCS III grading performed at the slit lamp with 
grading of photographs using Wisconsin system. Further investigation needs to be 
conducted to ensure our conversion algorithm is widely applicable in other population data. 
Conversion based on original protocols of grading systems or lens images should be further 
explored.  
     In conclusion, we proposed a general algorithm that approximates conversion between 
any two cataract systems and illustrated its application in two major cataract classification 
systems, LOCS III and Wisconsin system. The transformation is not one-to-one and is 
validated by using cross-validation. The results of our study suggest that prevalence rates 
of cataract need to be converted to the same scale before comparison between different 
grading systems, and ideally with standardized universal epidemiologic definition of cut-




3.6 Chapter 3 References 
1. Thylefors B. The World Health Organization's programme for the prevention of 
blindness. Int Ophthalmol 1990;14(3):211-9. 
2. Thylefors B, Negrel AD, Pararajasegaram R, Dadzie KY. Global data on blindness. 
Bull World Health Organ 1995;73(1):115-21. 
3. Pascolini D, Mariotti SP, Pokharel GP, et al. 2002 global update of available data 
on visual impairment: a compilation of population-based prevalence studies. Ophthalmic 
Epidemiol 2004;11(2):67-115. 
4. Congdon N, West SK, Buhrmann RR, et al. Prevalence of the different types of 
age-related cataract in an African population. Invest Ophthalmol Vis Sci 
2001;42(11):2478-82. 
5. Deane JS, Hall AB, Thompson JR, Rosenthal AR. Prevalence of lenticular 
abnormalities in a population-based study: Oxford Clinical Cataract Grading in the Melton 
Eye Study. Ophthalmic Epidemiol 1997;4(4):195-206. 
6. Giuffre G, Giammanco R, Di Pace F, Ponte F. Casteldaccia eye study: prevalence 
of cataract in the adult and elderly population of a Mediterranean town. Int Ophthalmol 
1994;18(6):363-71. 
7. Klein BE, Klein R, Linton KL. Prevalence of age-related lens opacities in a 
population. The Beaver Dam Eye Study. Ophthalmology 1992;99(4):546-52. 
8. Leske MC, Connell AM, Wu SY, et al. Prevalence of lens opacities in the Barbados 
Eye Study. Arch Ophthalmol 1997;115(1):105-11. 
9. Mitchell P, Cumming RG, Attebo K, Panchapakesan J. Prevalence of cataract in 
Australia: the Blue Mountains eye study. Ophthalmology 1997;104(4):581-8. 
10. Nirmalan PK, Krishnadas R, Ramakrishnan R, et al. Lens opacities in a rural 
population of southern India: the Aravind Comprehensive Eye Study. Invest Ophthalmol 
Vis Sci 2003;44(11):4639-43. 
11. Seah SK, Wong TY, Foster PJ, et al. Prevalence of lens opacity in Chinese 
residents of Singapore: the tanjong pagar survey. Ophthalmology 2002;109(11):2058-64. 
12. West SK, Munoz B, Schein OD, et al. Racial differences in lens opacities: the 
Salisbury Eye Evaluation (SEE) project. Am J Epidemiol 1998;148(11):1033-9. 
13. Krishnaiah S, Vilas K, Shamanna BR, et al. Smoking and its association with 
cataract: results of the Andhra Pradesh eye disease study from India. Invest Ophthalmol 
Vis Sci 2005;46(1):58-65. 
14. Athanasiov PA, Casson RJ, Sullivan T, et al. Cataract in rural Myanmar: 
prevalence and risk factors from the Meiktila Eye Study. Br J Ophthalmol 
2008;92(9):1169-74. 
15. Athanasiov PA, Edussuriya K, Senaratne T, et al. Cataract in central Sri Lanka: 
prevalence and risk factors from the Kandy Eye Study. Ophthalmic Epidemiol 
2010;17(1):34-40. 
16. Duan XR, Liang YB, Wang NL, et al. Prevalence and associations of cataract in a 
rural Chinese adult population: the Handan Eye Study. Graefes Arch Clin Exp Ophthalmol 
2012. 
17. Husain R, Tong L, Fong A, et al. Prevalence of cataract in rural Indonesia. 
Ophthalmology 2005;112(7):1255-62. 
18. Ostberg A, Loth A, Gustafson D, Lindblom B. Skovde cataract study: I. Prevalence 
of lens opacities in a Swedish community. Ophthalmology 2006;113(6):970-5. 
19. Tsai SY, Hsu WM, Cheng CY, et al. Epidemiologic study of age-related cataracts 




20. Varma R, Torres M. Prevalence of lens opacities in Latinos: the Los Angeles 
Latino Eye Study. Ophthalmology 2004;111(8):1449-56. 
21. Vashist P, Talwar B, Gogoi M, et al. Prevalence of cataract in an older population 
in India: the India study of age-related eye disease. Ophthalmology 2011;118(2):272-8 e1-
2. 
22. Xu L, Cui T, Zhang S, et al. Prevalence and risk factors of lens opacities in urban 
and rural Chinese in Beijing. Ophthalmology 2006;113(5):747-55. 
23. Kanthan GL, Wang JJ, Rochtchina E, et al. Ten-year incidence of age-related 
cataract and cataract surgery in an older Australian population. The Blue Mountains Eye 
Study. Ophthalmology 2008;115(5):808-14 e1. 
24. Klein BE, Klein R, Lee KE. Incidence of age-related cataract over a 10-year 
interval: the Beaver Dam Eye Study. Ophthalmology 2002;109(11):2052-7. 
25. Klein BE, Klein R, Lee KE, Gangnon RE. Incidence of age-related cataract over a 
15-year interval the Beaver Dam Eye Study. Ophthalmology 2008;115(3):477-82. 
26. Klein BE, Klein RE, Lee KE. Incident cataract after a five-year interval and 
lifestyle factors: the Beaver Dam eye study. Ophthalmic Epidemiol 1999;6(4):247-55. 
27. Leske MC, Wu SY, Nemesure B, et al. Nine-year incidence of lens opacities in the 
Barbados Eye Studies. Ophthalmology 2004;111(3):483-90. 
28. McCarty DJ, Fu CL, Harper CA, et al. Five-year incidence of diabetic retinopathy 
in the Melbourne Visual Impairment Project. Clin Experiment Ophthalmol 
2003;31(5):397-402. 
29. Panchapakesan J, Mitchell P, Tumuluri K, et al. Five year incidence of cataract 
surgery: the Blue Mountains Eye Study. Br J Ophthalmol 2003;87(2):168-72. 
30. Varma R, Richter GM, Torres M, et al. Four-year incidence and progression of 
lens opacities: the Los Angeles Latino Eye Study. Am J Ophthalmol 2010;149(5):728-34 
e1-2. 
31. Zhang JS, Xu L, Wang YX, et al. Five-year incidence of age-related cataract and 
cataract surgery in the adult population of greater Beijing: the Beijing Eye Study. 
Ophthalmology 2011;118(4):711-8. 
32. Rao GN, Khanna R, Payal A. The global burden of cataract. Curr Opin Ophthalmol 
2011;22(1):4-9. 
33. McCarty CA, Mukesh BN, Dimitrov PN, Taylor HR. Incidence and progression 
of cataract in the Melbourne Visual Impairment Project. Am J Ophthalmol 2003;136(1):10-
7. 
34. Tan AC, Wang JJ, Lamoureux EL, et al. Cataract prevalence varies substantially 
with assessment systems: comparison of clinical and photographic grading in a population-
based study. Ophthalmic Epidemiol 2011;18(4):164-70. 
35. Congdon N, Vingerling JR, Klein BE, et al. Prevalence of cataract and 
pseudophakia/aphakia among adults in the United States. Arch Ophthalmol 
2004;122(4):487-94. 
36. Hall AB, Thompson JR, Deane JS, Rosenthal AR. LOCS III versus the Oxford 
Clinical Cataract Classification and Grading System for the assessment of nuclear, cortical 
and posterior subcapsular cataract. Ophthalmic Epidemiol 1997;4(4):179-94. 
37. Foong AW, Saw SM, Loo JL, et al. Rationale and methodology for a population-
based study of eye diseases in Malay people: The Singapore Malay eye study (SiMES). 
Ophthalmic Epidemiol 2007;14(1):25-35. 
38. Wong TY, Chong EW, Wong WL, et al. Prevalence and causes of low vision and 




39. Chong EW, Lamoureux EL, Jenkins MA, et al. Sociodemographic, lifestyle, and 
medical risk factors for visual impairment in an urban asian population: the singapore 
malay eye study. Arch Ophthalmol 2009;127(12):1640-7. 
40. Lavanya R, Jeganathan VS, Zheng Y, et al. Methodology of the Singapore Indian 
Chinese Cohort (SICC) eye study: quantifying ethnic variations in the epidemiology of eye 
diseases in Asians. Ophthalmic Epidemiol 2009;16(6):325-36. 
41. Chylack LT, Jr., Wolfe JK, Singer DM, et al. The Lens Opacities Classification 
System III. The Longitudinal Study of Cataract Study Group. Arch Ophthalmol 
1993;111(6):831-6. 
42. Klein BE, Klein R, Linton KL, et al. Assessment of cataracts from photographs in 
the Beaver Dam Eye Study. Ophthalmology 1990;97(11):1428-33. 
43. R Development Core Team. R: A Language and Environment for Statistical 
Computing. 2.14.2 ed. Vienna, Austria: R Foundation for Statistical Computing, 2012. 
44. Stone M. Cross-validation: A review. Math Operationsforsch Statist, Ser: Statistics 
1978;9(1). 
45. Livingston PM, Guest CS, Stanislavsky Y, et al. A population-based estimate of 
cataract prevalence: the Melbourne Visual Impairment Project experience. Dev 
Ophthalmol 1994;26:1-6. 
46. Kanthan GL, Mitchell P, Burlutsky G, et al. Pseudoexfoliation Syndrome and the 
Long-Term Incidence of Cataract and Cataract Surgery: The Blue Mountains Eye Study. 
American Journal of Ophthalmology 2012. 
47. Klein BE, Howard KP, Lee KE, et al. The relationship of cataract and cataract 
extraction to age-related macular degeneration: the Beaver Dam Eye Study. 
Ophthalmology 2012;119(8):1628-33. 
48. Ansari RR, Datiles MB, 3rd. Use of dynamic light scattering and Scheimpflug 
imaging for the early detection of cataracts. Diabetes Technol Ther 1999;1(2):159-68. 
49. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for 
neovascular age-related macular degeneration. N Engl J Med 2011;364(20):1897-908. 
50. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for 
neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432-44. 
51. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related 
macular degeneration. N Engl J Med 2006;355(14):1419-31. 
52. Jonas JB, Spandau UH, Schlichtenbrede F. Short-term complications of 
intravitreal injections of triamcinolone and bevacizumab. Eye (Lond) 2008;22(4):590-1. 
53. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-
controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER 









3.7 Chapter 3 Tables and Figures 
Table 3.1 Prevalence of Nuclear Opalescence, Cortical, and PSC with Various Cut-offs used from Population-based 
Studies 
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Table 3.3 Characteristics of LOCS III and Wisconsin Cataract Grading System, 
WHOSCGS 
 
System LOCS III 40  Wisconsin system 41 
Method 
Clinical assessment with slit lamp or 
grading performed on retro-
illumination photographs 
 
Slit lamp photos for nuclear cataract; 
Retro-illumination photographs for 
cortical and PSC cataract 
Category NC 0-6.9  NO 0-5 
 NO 0-6.9  Cortical % involved 
 Cortical 0-5.9  PSC % involved 
 PSC 0-5.9    
Decimal Yes   No  




Figure 3.1 Scatter plots and box plots for each cataract subtypes (nuclear opalescence, cortical and PSC) using Wisconsin 







Figure 3.2 Conversion between LOCS III and Wisconsin system. Nuclear: nuclear 
opalescence; bold lines and numbers in plots were estimated from the conditional 
probabilities given either LOCS III or Wisconsin (conditional on the grading system 






Figure 3.3 Validation of Conversion Algorithm on Relative Subject Frequency in 10% Test data and SINDI data. Columns 
A, C: Original: percent of subjects in original LOCS III grade; Converted: percent of subjects using converted LOCS III 
grade (i.e. after conversion from Wisconsin to LOCS III scale). Columns B, D: Original: percent of subjects in original 
Wisconsin grade; Converted: percent of subjects using converted Wisconsin grade (i.e. after conversion from LOCS III to 
Wisconsin scale). 
 
Relative Frequency in collasped categories (10% test data) 
                             A                                                              B 
Relative Frequency in collasped categories (SINDI data) 
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4.1 RESEARCH MOTIVATION and CONTRIBUTIONS 
It is important and essential for infectious diseases to be accurately diagnosed in the 
primary healthcare setting for the timely management of patient’s disease. However, gold 
standard diagnostic techniques are rare in many areas of medicine. Furthermore, the lack 
of established gold standards makes it harder to evaluate new diagnostic tests. In our area 
of research interest, the diagnosis of tuberculous uveitis is controversial. The widely used 
Mantoux test (TST) has a low specificity due to a false-positive response in patients 
infected with nontuberculous mycobacterium (NTM) or vaccinated with Bacille 
CalmetteeGuérin (BCG). Interferon-gamma (IFN-g)-release assays (IGRAs) are newer 
diagnostic tests based on in vitro detection of IFN-g released by T-cells in response to 
antigens specific to Mycobacterium tuberculosis (MTB). Clinicians may face diagnostic 
and therapeutic dilemma, especially with the availability of various tests. Diagnostic test 
comparisons and criteria guidelines would be useful information to aid ophthalmologists 
in interpretation of test results and advise course of actions for patients, such as the need 
and sequence of performing additional diagnostic tests or treatments. 
Our analysis approach is to use latent class model via Bayesian methods (avoids 
computational restrictions in “classical” approach), to model the relationship between 
results of several diagnostic tests and latent disease status to estimate the diagnostic 
accuracy (in terms of sensitivity and specificity) of all tests under consideration without 
explicitly using any of the tests as gold standard. This approach is increasingly used in the 
analysis of diagnostic accuracy studies without gold standards but yet to be commonly 
adopted in the field of ophthalmology, probably due to the statistical and programing 
complexity in modeling and implementation. We developed and described our models for 
the type and structure of our study data to estimate sensitivity and specificity of each 
diagnostic test, prevalence of disease and proposed sequential testing guidelines based on 
decision theory. We also provided step by step instructions to guide the implementation of 
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our model analyses in R (a free statistical computing software), that can be easily used by 
researchers without advanced statistical training (refer to Appendix 1). 
4.2 INTRODUCTION 
Tuberculosis (TB) remains one of the leading causes of morbidity and mortality 
worldwide, with 8.7 million incident cases in 2011.1 Currently, the diagnosis of TB still 
depends on the century-old Mantoux or tuberculin skin test (TST).2 However, TST has poor 
specificity due to false-positives in persons infected with non-tuberculous mycobacterium 
or vaccinated with Bacille Calmette–Guérin (BCG).3,4 Interferon-gamma (IFN-γ) release 
assays (IGRAs) are based on in-vitro detection of IFN-γ released by T-cells, in response to 
antigens specific to Mycobacterium tuberculosis (MTB);5 as opposed to TST which uses a 
crude extract of proteins from MTB i.e. purified protein derivative.6, 7 Commercially 
available IGRAs include the T-SPOT.TB (Oxford Immunotec, Oxford, United Kingdom) 
and QuantiFERON-TB Gold In-tube [QFT] (Cellestis Incorporated, Carnegie, Australia).8  
The main advantage of IGRA is that it is an objective, reproducible blood test that 
requires only one visit.8 However, its main disadvantages are higher cost, logistical issues 
as the samples are time and temperature sensitive, and the need for trained personnel to 
analyze the results. Though similar, there are some key differences between T-SPOT.TB 
and QFT. In T-SPOT.TB the number of IFN-γ producing T-cells are counted, after 
stimulating isolated peripheral blood mononuclear cells with early secretory antigenic 
target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10), using an enzyme-linked 
immunospot assay.9 On the other hand, QFT is a whole blood assay that quantifies IFN-γ 
produced by T-cells in response to ESAT-6, CFP-10 and TB7.7 using an enzyme-linked 
immuno-sorbent assay.10  
Today, TB-associated uveitis is essentially a presumptive diagnosis. It is diagnosed 
when uveitis is present with a positive TST or IGRA and chest x-ray (CXR) findings 
suggestive of pulmonary TB and/or evidence of associated systemic TB infections in the 
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absence of other underlying disease.11 Few ocular biopsies3 are positive on culture, acid-
fast bacilli (AFB) smear or polymerase chain reaction (PCR) analysis.11 Thus, the impact 
of IGRAs in the diagnosis of TBU has become increasingly important as these may 
potentially affect treatment and prognosis.12 While the role of IGRAs in diagnosing 
tubercular uveitis has been studied, to our knowledge,13-15 there is currently no head-to-
head comparison between QFT and T-SPOT.TB specifically for the diagnosis of TBU. 
Thus, we conducted a prospective, direct comparative study to compare these two 
commercially available IGRAs to diagnose TBU in our population.  
4.3 METHODS 
Overview of Management 
We conducted a prospective study of consecutive patients presenting with new onset 
of uveitis to the Singapore National Eye Centre Ocular Inflammation and Immunology 
Service from 2008 – 2010 and added the QFT diagnostic test from 1st January 2009 
onwards.  Ethical approval was obtained from our Singapore Health Services Centralized 
Institutional Review Board, and our study adhered to the tenets of the Declaration of 
Helsinki. After obtaining informed consent, all patients underwent a full systemic review, 
ocular examination, and standard baseline investigations as previously described.13 We 
included all patients who were undergoing systemic review for acute uveitis and gave 
informed consent to be enrolled in the study. We excluded patients who did not consent to 
the minimum follow-up period of 1 year after completion of ocular and/or systemic therapy.  
Investigations 
At presentation, all patients were tested with a standard panel of investigations as 
described,13 essentially: a complete blood count, erythrocyte sedimentation rate analysis, 
liver enzyme panel analysis, and infectious disease screening, which included a venereal 
disease research laboratory (VDRL) test for syphilis, TST, urine microscopy, and a CXR.  
Other tests such as HLA-B27 screen, an AFB smear from throat swabs, and PCR assays 
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for TB DNA from ocular samples were performed if the patient consented to the procedure. 
Blood was taken for QFT and T-SPOT.TB testing before the TST was performed, to avoid 
any boosting effect (albeit shown that this is unlikely to be significant).16, 17 The TST was 
performed with the standard Mantoux method: intradermal injection of 0.1 ml (2 tuberculin 
units) purified protein derivative (PPD) (RT23 SSI – 2T.U./0.1 ml Statens Serum Institut, 
Copenhagen, Denmark).18 Induration was measured at 72 hours with a ruler and considered 
positive if it was more than or equal to 15 mm (as validated in our population).13  
T-SPOT.TB was performed according to the manufacturer's instructions.19 For each 
patient, 8 ml of blood was collected in Lithium Heparin tubes and processed within 8 hours 
of sampling. Peripheral blood mononuclear cells were prepared by density gradient 
centrifugation over Ficoll Paque™Plus (GE Healthcare). 250 000 cells were seeded in each 
of four wells of the assay plate. The cells were stimulated for 16–20 h (under 5% carbon 
dioxide at 37°C) with GIBCO AIM-V™ medium (nil control), phytohaemagglutinin 
(mitogen-positive control) or the TB-specific peptide antigens (peptide pools for ESAT-6 
and CFP-10 in separate wells) in a total volume of 150 μL per well. Two readers quantified 
the number of IFN-γ spot forming T-cells visually, and a third reader was consulted if the 
results were disparate. The T-SPOT.TB test was considered positive if there were >8 spots 
compared to the negative control well; negative if there were <4 spots compared to the 
control well; or equivocal if the test wells had 5–7 spots more than the control.14 If the 
negative control well had >10 spots and/or <20 spots in the mitogen positive control wells, 
the result was considered to be ‘indeterminate’. 
QFT was performed according to the recommended guidelines.10 Whole blood from 
each patient was divided into three tubes of 1 ml each (nil control, positive control and TB 
specific antigens [ESAT-6, CFP-10 and TB7.7]). Samples were incubated with the 
stimulating antigens for 16–24 h at 37C. Afterwards, plasma samples were harvested and 
the amount of IFN-γ released was measured via ELISA. The result obtained in the nil 
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control was subtracted from the mitogen control and the antigen-stimulated samples. The 
result was considered positive if the response to the specific antigens was 0.35 IU/mL, 
regardless of the level of the positive control; negative if the response to the specific 
antigens was <0.35 IU/mL and the IFN-γ level of the positive control was 0.5 IU/mL; and 
indeterminate if both antigen-stimulated samples were <0.35 IU/mL and the level of the 
positive control was <0.5 IU/mL. 
Treatment and Management of patients 
The infectious diseases physicians at the Singapore General Hospital independently 
evaluated all patients with a high clinical index of suspicion for TB. Those found to have 
associated systemic or pulmonary TB infection received anti-tuberculosis therapy (ATT), 
while uveitis patients with latent TB were advised on the risk-benefit ratio of ATT.20 
Patients consenting to treatment received standard ATT according to CDC guidelines 
(isoniazid 5 mg/kg daily, rifampicin 450-600 mg daily, pyrazinamide 30 mg/kg daily and 
ethambutol 15 mg/kg daily for 2 months, followed by 2 drugs for a 4 month continuation 
phase, for a total minimum of 6 months duration).20, 21 In patients with posterior segment 
inflammation where ATT was not indicated, oral prednisolone was used at a starting dose 
of 1mg/kg body weight, tapering slowly over the clinical course. Any anterior segment 
inflammation was treated with topical corticosteroids. The therapeutic response was 
monitored by one ophthalmologist (SPC), where a two-step decrease in inflammation 
(SUN working group activity score) was considered an improvement in clinical activity 
and a positive response to treatment.22  
Statistical Analysis 
In the diagnosis of tubercular uveitis, there is currently no gold standard, i.e. a 
diagnostic test with 100 percent sensitivity and specificity.23, 24 Bayesian statistics are used 
to compute probability distributions (i.e. posteriors) for parameters of interest in our 
 60 
 
statistical models by updating prior knowledge with new data, expressed formally by 
integrating the prior distribution and the likelihood function. We used Bayesian latent class 
models to evaluate the frequencies of true positives derived from diagnostic tests as well 
as their sensitivities and specificities. As the ‘true’ numbers of patients with tuberculous 
uveitis are unknown, these were termed as ‘latent data’. In the first part of the study, we 
performed analysis for TST and T-SPOT.TB data.25 In the second part where we collected 
data for another diagnostic test, QFT in addition to TST and T-SPOT.TB for a new group 
of uveitis patients where T-SPOT.TB and QFT are IGRAs and hence closely related tests, 
we modified our model to take into consideration their dependency in the estimation of 
sensitivities and specificities. Furthermore, in addition to using non-informative prior for 
the prevalence of tuberculous uveitis in our model, we have conducted a separate meta-
analysis to estimate pooled prevalence, to incorporate informed prior knowledge as part of 
our sensitivity analysis.  
In summary, we performed the analysis in four major parts: (A) Estimation of 
Prevalence, Sensitivity, Specificity, Negative, and Positive Predictive Value; (B) Analysis 
of the tuberculin skin test, T-SPOT.TB and QFT in combination; (C) Optimal choice of 
diagnostic test; and (D) Sensitivity Analysis, where technical details are described below.26, 
27 The Gibbs sampler algorithm, an iterative Markov-chain Monte Carlo technique, was 
used for estimations using the R and JAGS program.28, 29 We used the JAGS software 
(version 3.3.0), running from R version 3.0.2 (R Development Core Team, 2013) to 
implement the Gibbs sampler, using specific marginal posterior densities.28, 29 Convergence 
of estimation was checked and confirmed using the Gelman–Rubin convergence 
diagnostic.28, 29 
The sensitivity (S) and specificity (C) of each test, as well as the prevalence of 
tuberculous uveitis (π), were the proposed model parameters to be estimated. Positive 
predictive value (PPV) and negative predictive value (NPV) can then be calculated with 
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the three estimated parameters using Bayes’ formula. Prior information for sensitivity and 
specificity of T-SPOT.TB, QFT and TST were obtained from a previous meta-analysis of 
tests for latent tuberculosis infection.23 To obtain relevant prior information from similar 
studies on the prevalence of tuberculous uveitis for patients with uveitis, we performed a 
meta-analysis of published literature using a similar Bayesian approach (Appendix 2, 
Supplementary Table 4.1 and Figure 4.1) and updated the information in the model as 
part of our sensitivity analysis. 
A. Estimation of Prevalence, Sensitivity, Specificity, Negative, and Positive Predictive 
Value 
Our Bayesian latent model describes the number of patients screened with tuberculin 
skin test (independent from IRGA tests) having tuberculous uveitis (ݕ௧௦௧ሻ as distributed 
binomially:   ݕ௧௦௧~ܤ݅݊݋݈݉݅ܽሺ݊௧௦௧, ݌௧௦௧ሻ  where ݊௧௦௧ is the number of patients and ݌௧௦௧ is 
the probability of a positive tuberculin skin test result. We calculate  ݌௧௦௧ ൌ ߨ ∗ ܵ௧௦௧ ൅
ሺ1 െ ߨሻ ∗ ሺ1 െ ܥ௧௦௧ሻ where S and C represents the sensitivity and specificity of each test, 
and   is the prevalence of disease, i.e. tuberculous uveitis. 
 IGRAs T-SPOT.TB and QFT tests are closely related and our interest lies in 
estimation of sensitivities of T-SPOT.TB (ܵଶ) and QFT test (ܵଷ) and their respective 
specificities (ܥଶ	ܽ݊݀	ܥଷሻ while accounting for the correlation between test outcomes for a 
given patient. The cross-classified test results for T-SPOT.TB and QFT tests are assumed 
to follow a multinomial distribution: ݕ~ܯݑ݈ݐ݅݊݋݈݉݅ܽሺ݊, ሺ݌ଵଵ, ݌ଵଶ, ݌ଶଵ, ݌ଶଶሻሻ , and the 
multinomial cell probability of test-outcome combination ij is given by ݌௜௝ ൌ ߨ௜௝ ∗ ௜ܵ௝ ൅
൫1 െ ߨ௜௝൯ ∗ ܥ௜௝  , for i, j = 1, 2. ݕଵଵ  (ݕଶଶ ) is the number of patients that test positive 
(negative) on both tests and ݕଵଶ (ݕଶଵ) is the number of patients that test positive (negative) 
on 1 test and negative (positive) on the other test. We account for the correlation between 
diagnostic tests by incorporating covariance terms for sensitivity and specificity, i.e. ܵଵଵ, 
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the sensitivity for cell with positive result on both is given by ଵܵ ∗ ܵଶ ൅ ܿ݋ݒܽݎ݅ܽ݊ܿ݁_ܵ and 
ܥଶଶ is given by ܥଵ ∗ ܥଶ ൅ ܿ݋ݒܽݎ݅ܽ݊ܿ݁_ܥ. Note that the two sensitivities and specificities 
are functions of the model parameters: ܵଶ ൌ ܵଵଵ ൅ ܵଵଶ, ܵଷ ൌ ܵଵଵ ൅ ܵଶଵ, ܥଶ ൌ ܥଶଶ ൅ ܥଶଵ 
and ܥଷ ൌ ܥଶଶ ൅ ܥଵଶ . 
As the “true” numbers of patients with tuberculous uveitis are unknown, ݕ is the latent 
variable of interest in our analysis. The sensitivity (S) and specificity (C) of each test, as 
well as the prevalence of tuberculous uveitis ( ), were the proposed model parameters to 
be estimated. Positive predictive value (PPV) and negative predictive value (NPV) for 
individual tests can then be calculated as ܸܲܲ ൌ గ∗ௌௌ∗గ	ା	ሺଵି஼ሻ∗ሺଵିగሻ  and ܸܰܲ ൌ
ሺଵିగሻ∗஼
గ∗ሺଵିௌሻ	ା	஼∗ሺଵିగሻ. Correlations between sensitivities and specificities were also investigated 
in the construction of our final statistical model. 
Beta distribution is a very flexible distribution family that applies to an unknown 
quantity that takes values between 0 and 1 (i.e. proportions). Hence it is appropriate to be 
used as the prior distribution for the prevalence of tuberculous uveitis, sensitivity and 
specificity of each test.  The shape of the beta distribution is determined by two parameter 
specification,   and  . Based on the obtained prior information,   and   were 
calculated to be 219.84 and 90.01 for prior distribution of sensitivity of tuberculin skin test; 
22.14 and 10.27 for specificity of tuberculin skin test; 17.64 and 17.64 for sensitivity of T-
SPOT.TB; 560.31 and 58.48 for specificity of T-SPOT.TB; 245.18 and 136.72 for 
sensitivity of QFT and 718.30 and 3.97 for specificity for QFT. Prior information for 
sensitivity and specificity of T-SPOT.TB, QFT TST were obtained from a previous meta-
analysis of tests for latent tuberculosis infection.23 Uniform prior distributions were used 





B. Analysis of the TST and T-SPOT.TB and QFT in combination 
With the model described above, we also estimated the number of “true positives” in 
the multinomial cells for pair-wise diagnostic tests and reported the results as median with 
95% Bayesian credible interval (Crl). The multinomial cell probability of disease given 
joint test results can be derived using Bayes’ formula. The posterior distributions of “true 
positives” for discordant pair-wise diagnostic test results were also examined. 
C. Optimal Choice of Diagnostic test 
The choice of the diagnostic test sequence was analyzed using statistical decision 
theory by choosing the smallest risk of the decision rules.26 A “0-1 loss function” was used 
to calculate the risk of performing a diagnostic test where a loss or a risk was calculated 
for misclassification, i.e. false positive or false negative. The formulae used to calculate 
the risk of a diagnostic test, i.e. the misclassification rate is given by ܴ݅ݏ݇ ൌ ߨ ∗ ሺ1 െ ܵሻ ൅
ሺ1 െ ߨሻ ∗ ሺ1 െ ܥሻ. 
D. Sensitivity Analysis 
Sensitivity analyses were performed to validate our model results. Multiple trial or 
mock data were applied into our Bayesian model to investigate if our data or the priors are 
driving model results. Varying posterior distributions should be observed with the 
application of multiple trial data (i.e. changing likelihood functions) to suggest that 
posterior distribution was calculated by the likelihood (i.e. data) incorporated with prior 
information rather than prior distribution alone influencing the results. Analysis using non-
informative prior was also perform. Also, we have performed meta-analysis using similar 
Bayesian approach on similar published studies for prevalence of tuberculous uveitis 
amongst patients with uveitis to be used as prior information for  (Supplementary Table 
1 and Figure 1). The model results updated with prior knowledge from our meta-analysis 




Based on data in the second part of our prospective study, we enrolled 120 patients 
(of whom 106 patients completed follow-up) with valid QFT and T-SPOT.TB test results. 
Mean age of our patients was 48  17 years, with an equal gender ratio (1:1, n = 52 males). 
Majority of the patients in our study were of Chinese ethnicity (65/106, 61.3%), followed 
by Indian (22/106, 20.8%) and Malay (7/106, 6.6%) - reflective of the racial distribution 
in our South-East Asian population. Of the 106 patients (152 eyes), 46 patients (43.4%) 
presented with bilateral uveitis. Uveitis was predominantly anterior (91/152, 59.9%), 
intermediate (4/152, 2.6%), or posterior (23/152, 15.1%); while 34 eyes (22.4%) presented 
with panuveitis.  Suggestive clinical features of a tubercular cause such as granulomatous 
inflammation (38 eyes, 25.0%), extensive posterior synechiae (29 eyes, 19.1%), vasculitis 
(19 eyes, 12.5%), single nodular or serpinginous choroiditis (1 eye, 0.7%) were observed 
in our study cohort. We found no significant differences in terms of age, gender, race or 
anatomical classification of uveitis when we compared the different QFT, T-SPOT.TB and 
TST test results for the patients. We also did not have any definite cases of ocular TB 
infection i.e. culture-positive TB from ocular samples, in this study cohort.  One patient 
(0.9%) had Mycobacterium tuberculosis smear-positive sputum samples, and 1 patient 
(0.9%) had positive PCR results for Mycobacterium fortuitum from the urine sample.  The 
majority of patients (n=90, 84.9%) had CXR findings that were not suggestive of 
pulmonary TB infection. None of the study subjects were found to be 
immunocompromised nor had BCG vaccinations within 10 years from the study enrolment. 
Using all diagnostic tests results, we had more data to improve estimations for 
individual tests (Table 4.1) and found that the QFT was estimated to be more specific (QFT: 
0.995, 0.988-0.999) than T-SPOT.TB (0.905, 0.879–0.926); and slightly less sensitive 
(QFT: 0.64, 0.60-0.69) compared to T-SPOT.TB (0.67, 0.60–0.74). TST, as a reference 
has sensitivity (0.69, 0.64–0.74) and specificity (0.74, 0.60–0.85).  The correlations for 
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sensitivities between QFT and T-SPOT.TB was estimated to be 0.62 (0.43-0.77) but 
specificities was not found be correlated. The pooled prevalence of tuberculous uveitis 
from our meta-analysis of similar studies was 1.62 (95% CrI: 0.88, 2.81) (Appendix 2, 
Supplementary Figure 4.1). Comparisons between estimations for our final model and 
the model updated with prior knowledge from our meta-analysis for prevalence of 
tuberculous uveitis were also shown in Table 4.1. Sensitivity and specificity estimates 
were similar. Predictive values differ greatly but was not surprising as they are dependent 
on the prevalence of disease.  
Table 4.2 shows the estimated number of “true positives” corresponding to each of 
the four possible outcomes of the diagnostic tests. All tested QFT and T-SPOT.TB positive 
in our study were estimated to be ‘true positive’. However, amongst discordant results, 
QFT was significantly more accurate compared to T-SPOT.TB (QFT positive 98% versus 
T-SPOT.TB positive 76% with ratio 1.28, 95%Crl: 1.11-1.72 i.e. 95%Crl > 1.0, strong 
statistically evidence). Similarly, both QFT (0.99 95%Crl 0.98-1.00) and T-SPOT.TB 
(0.90 95%Crl 0.82-0.96) were more accurate than the tuberculin skin test amongst the 
discordant results. Using the estimated sensitivity and the specificity of each diagnostic test 
(TST, T-SPOT.TB and QFT), we then calculated the risk of each test expressed as the 
function of probability of tuberculous uveitis (Figure 4.1).  Based on statistical decision 
theory, QFT is the first-line test and should be performed ahead of T-SPOT.TB and the 
TST for diagnosis of tuberculous uveitis. Our sensitivity analysis confirmed that posterior 
distribution of parameters with mock data varied appreciably with the changing likelihood 
functions suggesting that our results are data driven and were not overly influenced by 
priors. Furthermore, the optimal choice of diagnostic test is QFT as seen in Figure 4.1, 




There is increasing evidence that suggests that Interferon-gamma release assays are 
more specific and/or accurate for the diagnosis of TB compared to the TST.30-33 The 
improved specificity of Interferon-gamma release assays over tuberculin skin testing has 
been shown to reduce unnecessary ATT.34 There have also been several studies which 
suggest that Interferon-gamma release assays are more useful than tuberculin skin test in 
the diagnosis and management of patients with uveitis and TB infection.13, 15, 25, 35-37 
However, there have been no direct comparative studies between QFT and T-SPOT.TB for 
the diagnosis of tuberculous uveitis. In the first part of our study data, we found that T-
SPOT.TB is more specific but less sensitive than TST and should be used in preference to 
TST in low TB-prevalence populations. When used in conjunction, the likelihood of 
tuberculous uveitis is greatest if both T-SPOT.TB and TST are positive.25 Based on new 
patient data in the second part of data collection, QFT was estimated to be more specific 
than T-SPOT.TB in diagnosing tuberculous uveitis. A recent meta-analysis suggested that 
QFT was more specific but less sensitive as compared to T-SPOT.TB, albeit for diagnosis 
of active TB instead of tuberculous uveitis.38 Our final model incorporates the covariances 
between related estimates QFT to be more specific than T-SPOT.TB; while the sensitivity 
of T-SPOT.TB was better in diagnosing tuberculous uveitis compared to previous studies 
(0.50 to 0.67). We then derived the optimal risk of using either the QFT or the T-SPOT.TB, 
while varying the prevalence or probability of tuberculous uveitis. Our analysis using 
statistical decision theory suggested that whether the prevalence of tubercular uveitis in TB 
endemic subpopulations is low or relatively high, the QFT remains superior and should be 
used as a first-line test.  
Of note and more important to clinician, is the fact that the QFT has a high PPV with 
a moderate NPV, i.e., a positive QFT assures you that the result of the test is reliable. The 
estimated sensitivity and specificity for each diagnostic test (final model seen in Table 4.1) 
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is particularly useful in the calculation of PPV, NPV and post-test odds for a new patient 
to aid the clinician in advising their patient. For example, if a new patient in a low TB 
endemic population (e.g. prevalence of tuberculous uveitis is assumed to be 2%) is positive 
for QuantiFERON-TB Gold In-Tube, using the estimated sensitivities and specificities in 
Table 4.1, the PPV of the patient is calculated to be 0.72 and the post-test odds is 2.62. 
This suggests that given positive QFT result, the patient has a 72% probability of having 
disease and is about thrice as likely to have the disease than not. Predictive values are 
influenced by the prevalence of disease in the population being screened,39 and for low 
disease prevalence, diagostic tests have low sensitivities as there would be fewer “affected” 
or “diseased” subjects. Predictive values of Interferon-gamma release assays can be 
increased by performing these diagnostic tests only in patients with a high clinical index 
of suspicion - for example, if they have clinical signs consistent with tuberculous uveitis.40 
We also studied the usefulness of performing both tests in combination, QFT and the 
T-SPOT.TB.  If both were positive, it increased the likelihood of a tubercular cause in our 
patients who present with suggestive clinical signs to 100% in our data.  However, if both 
tests were negative, there is still the possibility of excluding a tubercular cause, i.e. there 
was a 46% chance that the patient may have tuberculous uveitis.  For discordant results, 
QFT was more accurate than T-SPOT.TB; of note, both QuantiFERON-TB Gold In-Tube 
and T-SPOT.TB were more accurate than the tuberculin skin test. These results suggest 
that performing QFT and T-SPOT.TB tests increases the accuracy of diagnosing 
tuberculous uveitis, although discordant or negative results are less useful.  
Both the QFT and T-SPOT.TB provide an objective, single-visit blood test that detects 
and quantify Interferon-gamma release from T-cells in persons infected with TB. However, 
the QFT uses more peptide-simulating specific TB antigens: ESAT-6, CFP-10, and TB7.7 
(p4), as opposed to T-SPOT.TB which only uses ESAT-6 and CFP-10. This may explain 
the higher specificity in QFT as compared to T-SPOT.TB.38 Nonetheless, as these antigens 
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are absent from all BCG strains and most NTM, both QFT and T-SPOT.TB impart greater 
specificity than tests using PPD, which is reflected in most studies including ours.33 T-
SPOT.TB also differs from QFT in that the former involves harvesting and counting viable 
peripheral mononuclear blood cells (PMBCs) that release Interferon-gamma; while the 
latter uses an enzyme-linked immuno-sorbent assay (ELISA) to study Interferon-gamma 
release from T-cells in whole blood. The technique used in T-SPOT.TB may provide better 
resolution of blood samples with reduced T-cell numbers (e.g. samples from 
immunocompromised individuals) that would usually give indeterminate QFT results.8 
However, in individuals undergoing immunosuppressive therapy, both QFT and T-
SPOT.TB appear to have comparable efficacy. 41-43 
The main aim of this current study is to compare QFT and T-SPOT.TB. However, 
TST results were also included as a reference and to allow comparisons with previous 
studies. Our results confirm that both QFT and T-SPOT.TB have lower sensitivity 
compared to the tuberculin skin test. This means that a negative or indeterminate result is 
difficult to interpret, and may not be useful in diagnosing tuberculous uveitis. 
Indeterminate QFT or T-SPOT.TB results can occur, due to low mitogen levels, heterophile 
antibodies or high background IFN- Interferon-gamma levels; while equivocal T-SPOT.TB 
results are likely to be negative but require repeat testing.14 The other setback of Interferon-
gamma release assays is the high cost and technical difficulty. Cost-effectiveness studies 
have thus affected clinical practice and guidelines: the UK-based National Institute for 
Health and Care Excellence (NICE) guidelines advocate a two-step approach using 
tuberculin skin testing and chest radiography as first line investigations, with subsequent 
confirmatory Interferon-gamma release assays testing in cases with positive tuberculin skin 
test results. These guidelines have been widely accepted in the rest of Europe. In contrast, 
the USA Centers for Disease Control and Prevention (CDC) guidance recommends one-
step Interferon-gamma release assays testing for screening of latent TB infection. This lack 
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of agreement likely reflects the current areas of uncertainty with regards to Interferon-
gamma release assays and will continue to evolve as ongoing research rapidly fills the gaps 
in our current knowledge. 44, 45 
The limitation with all studies involving extrapulmonary TB, including “ocular TB,” 
is the small number of patients who actually have a positive TB culture from ocular samples, 
which is the ‘gold standard’ for diagnosis.46 Thus, most studies use a diagnosis of 
“presumed” tubercular uveitis or employ meta-analysis to evaluate new diagnostic tests 
such as T-SPOT.TB.  We used the Bayesian technique, which has also been employed in 
a variety of studies of other infectious diseases that face the same diagnostic dilemmas as 
tubercular uveitis.47-53 We had previously compared the tuberculin skin test and T-
SPOT.TB using a similar Bayesian analysis, in patients with clinical signs suggestive of 
tuberculous uveitis;25 as opposed to the current study where we included all patients who 
presented with uveitis for the first time. Due to small numbers of patients who are culture-
positive or have evidence of AFB on smears or MTB DNA using PCR from ocular biopsies, 
it is difficult to evaluate the QFT or T-SPOT.TB as a diagnostic test using ‘classical’ 
hypothesis testing.  Our Bayesian analysis using the established latent class model 
considered estimation of the accuracy of two correlated tests and a third test that is 
conditionally independent of the two tests of interest, allowed contemporary comparison 
of the T-SPOT.TB and QFT accuracy without a gold standard. We recognize the limitation 
of applying prior information into our model with relatively limited data as priors are 
subjective and may influence the final results. However, our choice of prior distribution 
used was based on prior information derived from a recent meta-analysis performed on 
published studies 23, 24. Moreover, our sensitivity analyses confirmed that our results and 
models were robust, and not overly influenced by prior information. However, we 
recognize that these results may only apply to patients who present with uveitis to a tertiary 
eye centre.  
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In conclusion, this head-to-head comparison of two commercially available 
Interferon-gamma release assays suggests that QFT is the optimal choice test to diagnose 
patients with tuberculous uveitis. This analysis was consistent after performing sensitivity 
analyses and varying the prevalence or probability of tuberculous uveitis. In the absence of 
a gold standard test, our study confirms that a combination of any two Interferon-gamma 
release assays or “classical” tests such as tuberculin skin testing can improve the diagnostic 
accuracy using Bayesian modeling. However, further study into the most optimal or cost-
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4.7 Chapter 4 Tables and Figures 
 
Table 4.1 Estimated sensitivity and specificity and the positive and negative predictive values for the TST, T-SPOT.TB and 
QFT  
 
Data presented as median (95% Bayesian Credible Interval) using data from all diagnostic tests 
*Prior distribution and data derived from meta-analysis (Reference 23) 
†Final model, accounted only for correlated sensitivities between tests 
Model 1 considers correlated sensitivities and specificities between tests; Model 2 accounted only for correlated specificities between tests 
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Table 4.2 Estimated “true positives” in our study data 
 
*Study data are counts 




Study Data*  Estimated “true positive” Counts† 
T-SPOT.TB 
QFT 
Total  T-SPOT.TB 
QFT 
Total 
+ - + - 
+ 72 16 88  + 72 (1.00 ,1.00-1.00) 12 (0.76 ,0.57-0.88) 84 
- 7 57 64  - 7 (0.98 ,0.93-1.00) 27 (0.46 ,0.30-0.67) 34 
Total 79 73 152  Total 79 39 118 
         
T-SPOT.TB 
TST 
Total  T-SPOT.TB 
TST 
Total 
+ - + - 
+ 57 27 84  + 56 (0.98 ,0.96-0.99) 24 (0.90 ,0.82-0.96) 80 
- 18 43 61  - 14 (0.75 ,0.56-0.89) 14 (0.32 ,0.18-0.54) 28 
Total 75 70 145  Total 70 38 108 
         
QFT 
TST 
Total  QFT 
TST 
Total 
+ - + - 
+ 55 20 75  + 55 (1.00 ,1.00-1.00) 20 (0.99 ,0.98-1.00) 75 
- 20 50 70  - 15 (0.75 ,0.56-0.88) 16 (0.31 ,0.19-0.53) 31 
Total 75 70 145  Total 70 36 106 
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Figure 4.1 Optimal Choice of Diagnostic Test, QFT or T-SPOT.TB?  
The risk (misclassification rate) of all tests increases with the prevalence of tuberculous uveitis.  In our study, the risk of QFT was 
the lower than T-SPOT.TB even as the prevalence of tuberculous uveitis varied, suggesting that QFT should be performed ahead of 
T-SPOT.TB. Risk for tuberculin skin test was included as for reference. 
 
Non-informative Prior for Prevalence† 
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5.1 RESEARCH MOTIVATION and CONTRIBUTIONS 
It is desirable and useful to have available updated summarized evidence of diseases, 
be it treatment or exposure relationships consolidated from the many related but 
independent health research studies of various design types (i.e. randomized controlled 
trials, cross-sectional studies, cohort studies and case-control studies) provides better 
confidence and guidance in clinical decisions and future research directions. However, the 
key challenge faced in integrating results across studies conducted by investigators 
worldwide is the involvement of multiple sources of uncertainty, such as the variability in 
clinical practices between multi-centers, measurement uncertainties of exposures and 
differences in patient populations such as social-demographics like ethnicities and 
geographical regions. In epidemiology, pooled prevalence of diseases and effect sizes is 
essential information for the healthcare planning of disease burden. 
We conducted a literature review to incorporate recently published population based 
studies data to provide an updated pooled global prevalence and projections (to the UN 
data) of age-related macular degeneration (AMD) for years 2014 to 2040 by ethnicity and 
geographical regions using the Hierarchical Bayesian approach. Ethnicity, geographical 
regions, gender and publication year effects were assessed with Bayes factor. Our model 
carefully took into account the various levels of uncertainty and pulls strength across 
studies in estimating both the study specific effects and population effect, giving robust 
estimation to study prevalence especially for studies with small sample sizes. We also 
compared and evaluated our model of AMD prevalence estimation with “classical” 
random-effect model in a simulation study. Detailed instructions to run our model analyses 
in R (free statistical computing software) were given in Appendix 1 (requires some 
perseverance for researchers with little statistical and computing experience). Our codes 





Age-related macular degeneration (AMD) is responsible for 8.7% of all global 
blindness and is the most common cause of blindness in developed countries,1-5 particularly 
in elderly people above 60 years. The prevalence of AMD is likely to increase globally as 
a consequence of exponential population ageing. There have been significant advances in 
the management of exudative or “wet” AMD with the introduction of anti-angiogenesis 
therapy and patients now have effective treatment options that can prevent blindness, and 
in many cases, even restore vision.6-10 However, these treatments are expensive, and not 
available to all patients in many countries.11-14 Thus, understanding the prevalence, burden 
and population impact of AMD is essential for adequate health care planning and provision, 
and this requires both precise and contemporary estimates of disease prevalence.  
Although there have been many population-based studies of AMD around the world, 
there are no summarized data to guide global strategies. Furthermore, studies have 
suggested substantial racial/ethnic differences in prevalence of AMD. In the Baltimore Eye 
Study, persons of European (white) ancestry were more likely to have early and late AMD 
than those of African ancestry.15, 16 Two meta-analyses conducted in populations of 
European 17 and Asian ancestry4 suggest that among persons ages 40-79, age-specific 
prevalence of late AMD in Asians (0.56%) appears comparable to Europeans (0.59%), but 
early AMD signs were less common among Asians (6.8%) than Europeans (8.8%). There 
are no studies that have systematically compared the prevalence of AMD amongst 
Europeans or Asians with Africans or Hispanics, nor across geographical regions.  
To address this gap, we performed a systematic review of the literature on AMD to 
estimate the prevalence of AMD, to determine differences by ethnicity, region and gender, 





Sources and Methods of Literature Search 
We systematically reviewed publications that reported prevalence of AMD by 
searching the electronic databases of PubMed, Web of Science and EMBASE for relevant 
papers published up to May, 2013, with the following search terms (formatted for PubMed 
search): 
1. (“Macular Degeneration”[Mesh] AND (“Prevalence”[Mesh] OR “Epidemiology”[Mesh] 
OR “Cross-Sectional Studies” [Mesh] OR “Cohort Studies”[Mesh])) 
2. ((“age-related maculopathy”[All Fields] OR “age-related maculopathy”[All Fields] OR 
“age-related macular degeneration”[All Fields] OR “age related macular degeneration”[All 
Fields] OR “macular degeneration”[All Fields]) AND (“prevalence”[All Fields] OR 
“incidence”[All Fields] OR “epidemiology”[All Fields] OR “risk factors”[All Fields])) 
The strategy identified all articles used in previous reviews.4, 17 In addition, reference lists 
of identified reports were scanned to identify other relevant studies. Initial search was 
scrutinized in detail by clinician scientist XYS and reviewed by senior clinician scientist 
CYC. Data checks were conducted by statisticians (WLW, XL). Disagreements were 
resolved by discussion. 
Inclusion and Exclusion Criteria 
Our meta-analysis was conducted according to the meta-analysis of observational 
studies in epidemiology (MOOSE) guideline.18 The full texts of potentially relevant articles 
were reviewed to identify studies which met the inclusion and exclusion criteria. The 2 
criteria for inclusion were (I) population-based study from a defined geographic area and 
(II) standardized photographic assessment of AMD.  
For (I), studies were included if they quantified the prevalence of AMD (including 
early, late and exudative or neovascular AMD [nvAMD], and geographic atrophy [GA]) 
in population-based samples, with clearly defined methods of sampling. A response rate of 
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50% or higher is considered adequate for the purpose of this meta-analysis19 with the 
exception of the European Eye Study (EUREYE) study20 as it was a large population study 
but sensitivity analysis showed almost no effect on our robust model estimates (Appendix 
2, Supplementary Table 5.2). Surveys or audits of hospital eye departments or clinics 
were excluded. Studies inviting nonspecific volunteers or particular professions were 
excluded, as were studies that relied on self-reported diagnoses or carried out fundus 
examinations only in those with reduced vision.  
For (II), we included studies that had used retinal photography and standardized 
grading methods to diagnose and classify AMD lesions (i.e., grading of retinal photographs 
following either the Wisconsin Age-Related Maculopathy Grading System [WARMGS],21 
the International AMD classification22 or the Rotterdam Staging System23) with 
reproducible grading results.   
Studies fulfilling any one of the following were excluded:  (1) used only clinical 
examination by ophthalmoscopy or slit-lamp biomicroscopy for diagnosis of AMD (i.e. 
lack of any grading reproducibility assessment), (2) reports of number of eyes with AMD 
as opposed to the number of individuals, (3) studies in which determination of AMD 
prevalence was not one of the primary study objectives (e.g. studies determining AMD risk 
factors) and (4) not population based, but were interview based or audits of hospital eye 
departments. Although we did not specifically exclude non-English literature, studies 
included in the final analysis were all written in English. 
Appendix 2, Supplementary Figure 5.1 shows the flow chart of the selection process 
to identify relevant studies. A total of 2,751 published original research articles, letters, 
abstracts, and review articles based on abstracts and titles were identified as of May 2013 
from our literature search. After initial abstract review, 54 potentially eligible articles were 
retrieved for evaluation. Of these, we applied the inclusion and exclusion criteria and 
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identified 39 eligible articles reporting on 39 population-based studies (12,727 any AMD 
cases in 129,664 participants) (Appendix 2, Supplementary Figure 5.1). 
Definition of Early, Late and Any AMD 
The classification systems used to define those with early, late and any AMD (GA and 
NVAMD) in each study was recorded, that is, the Wisconsin Age-Related Maculopathy 
Grading System [WARMGS]21 or the International AMD classification22. Early AMD was 
defined by either any soft drusen (distinct or indistinct) and pigmentary abnormalities or 
large soft drusen 125μm or more in diameter with a large drusen area (> 500μm diameter 
circle) or large soft indistinct drusen in the absence of signs of late AMD. Late AMD was 
defined by the presence of any of the following: geographic atrophy or pigment epithelial 
detachment, subretinal hemorrhage or visible subretinal new vessel, or subretinal fibrous 
scar or laser treatment scar for AMD. Any AMD was defined by presence of either Early 
or Late AMD. 
Modeling and Hierarchical Bayesian Approach 
Because intrinsic difficulties exist when conducting meta-analysis to summarize the 
overall prevalence of data from varied studies with differing characteristics such as disease 
definition, age distribution of the sample, and prevalence estimates stratified by age and 
gender versus single prevalence estimates, we constructed statistical models to best 
describe and fit our extracted data in this study. Heterogeneity issues were addressed in our 
pooled meta-analysis using a Hierarchical Bayesian (HB) approach to determine the 
prevalence of AMD globally. The HB approach models the hierarchical structure of data 
extracted, taking into account the difference in age distribution across studies and effects 
of ethnicity, gender and region to ensure greater precision in AMD estimates. 
Meta-analysis can be naturally described in a hierarchical structure in a HB model. 
The number of people with AMD (ݕ௜௝ሻ  can be specified as binomially distributed: 
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ݕ௜௝~ܤ݅݊݋݈݉݅ܽ൫݊௜௝, ݌௜௝൯ , where ݊௜௝  is the total number of participants and ݌௜௝  is the 
prevalence of AMD in the ݅௧௛ study of the ݆௧௛ category of the varying covariate (e.g. each 
study may consist of more than one ethnicity). 
In the Bayesian approach, prevalence of AMD, ݌௜௝ is considered as a random variable 
(that has a probability density distribution) in contrast to a fixed unknown parameter (an 
unknown value) in the “classical” approach. Hence, the logit transformation of ݌௜௝ follows 
a Normal distribution:  ݈݋݃݅ݐ൫݌௜௝൯ ൌ ݑ௜௝ and ݑ௜௝~ܰ݋ݎ݈݉ܽ൫ߤ௜௝, ߪଶ൯, where ߪଶ ൌ 1/߬. 
To investigate and account for the heterogeneity within and between studies, we 
modeled ߤ௜௝ as a linear combination of covariates that varies across studies (i.e. age, gender, 
ethnicity, regions). Hence, our base model to pool the overall prevalence of AMD was: 
ߤ௜௝ ൌ ߚ଴ ൅ ߚଵ ∗ ݈ܽ݃݁௜௝ ൅ ߚଶ ∗ ܽ݃݁ݑ௜௝ ൅ ߚଷ ∗ ܽ݃݁ݑ݅௜௝  , where ݈ܽ݃݁௜௝  and ܽ݃݁ݑ௜௝  are the 
centered and standardized lower and upper bounds of the age group range for participants 
of each study and ܽ݃݁ݑ݅௜௝ is a right censoring indicator for studies with right-censored age 
range data for the upper bound, i.e. 80+ years. The lower and upper bounds of age range 
was centered to 45 and 85 years respectively and then standardized by dividing by their 
respective standard deviations to ensure that pooled estimates are comparable as they were 
being mapped onto the same age range, i.e. 45 to 85 years. Gender, ethnicity and regions 
covariates were then individually added to the base model to determine their impact and 
for covariate-specific pooled prevalence. The percentage of variability in prevalence 
estimates due to various sources of heterogeneity compared to chance alone were examined 
(refer to heterogeneity analysis described in Appendix 2, Supplementary text 5.1). 
Finally, non-informative prior (to represent ignorance) was specified for residual 
variability ߬  using the conjugate gamma distribution: ܩܽ݉݉ܽሺ0.01,0.01ሻ . Gamma 
distribution is applicable to unknown quantities that take values between 0 and ∞. All age 
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coefficients and intercept in the model were specified with non-informative Normal priors, 
i.e. ߚ~ܰ݋ݎ݈݉ܽሺ0,0.0001ሻ.  
The Gibbs sampler algorithm, an iterative Markov-chain Monte Carlo technique, was 
used to estimate the posterior distributions of our random variables using the R and JAGS 
program.24, 25 We used the JAGS software (version 3.3.0), running from R version 3.0.2 (R 
Development Core Team, 2013) to implement the Gibbs sampler, using specific marginal 
posterior densities.24, 25 Convergence estimation was assessed by calculating the Gelman–
Rubin convergence statistics.24, 25 
Ethnicity, Region and Gender Effects 
Bayesian hypothesis testing was performed to examine the effect of ethnicity, 
geographic regions and gender on the prevalence of any, early and late AMD using Bayes 
factors (BF) to compare hypotheses of differences between groups, implementing the 
Gibbs variable selection as proposed by Dellaportas et al.26 using the JAGS software. The 
comparison of the posterior probabilities of hypothesis is given by: 
PሺHଵ|݀ܽݐܽሻ/PሺH଴|݀ܽݐܽሻ = Pሺ݀ܽݐܽ|Hଵሻ/Pሺ݀ܽݐܽ|H଴ሻ * PሺHଵሻ/PሺH଴ሻ 
         (posterior odds)                  (Bayes factor)              (prior odds) 
where H଴ is the null hypothesis and Hଵis the alternative hypothesis. Jeffreys27 proposed an 
interpretation scheme for the magnitude of BF in terms of weak (BF 1-3), substantial (BF 
3-10), strong (BF 10-30), very strong (BF 30-100), and decisive (BF > 100) for Hଵ, while 
BF < 1 suggests support for ܪ଴.  
We evaluated four major ethnic groups (European ancestry populations [Europeans], 
African ancestry populations [Africans], Asian, and Hispanics) and six geographic regions 
(Africa, Asia, Europe, Latin America and the Caribbean, Northern America and Oceania). 
Publication year was also tested to assess the trend of prevalence over the years for 
consideration in projection estimates. 
Simulation Study to Compare Hierarchical Bayesian and Random-Effect Methods 
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Because the random effect (RE) model is the most frequently used meta-analytic 
method to account for the heterogeneity between the studies by incorporating a random 
effect estimate of between-study variation in the weighting, we performed simulation study 
to assess and compare HB and RE methods. This analysis is presented in Appendix 2, 
Supplementary text 5.2 and Figure 5.2.  
Projection Estimates 
Model ߤ௜௝௞ ൌ ߚ଴௞ ൅ ߚଵ௞ ∗ ܽ݃݁௜௝ ൅ ߚଶ ∗ ܽ݃݁ݑ݅௜௝ ൅ ߚଷ ∗ ݏݐݑ݀ݕ௜ was used to estimate 
the prevalence for each year increase in age for the ݇௧௛ region. Global and region effects 
were incorporated as fixed and random effects in ߚ଴௞ and ߚଵ௞. Age-specific prevalence 
was often reported as interval (e.g. 40-49) or censored (e.g. 80+) age range in the published 
papers and hence the median of interval was used to represent the age interval while 
censored age range was taken as the age with a censoring indicator in the analysis model. 
The estimated prevalence were used to calculate the global and region specific total number 
of individuals with AMD in 2020 and 2040 by multiplying the age- and region-specific 
estimated prevalence rates to the population projection data in World Population Prospects 
of the United Nations.28 Age group-specific prevalence rates were assumed to be constant 
over the next 27 years for our global projection to year 2040 as Bayesian hypothesis testing 
of publication year covariate suggests no evidence to support any trend for prevalence from 
year 1989 to 2013 in our reviewed literature data. 
5.4 RESULTS 
Our meta-analysis included 129,664 individuals in 39 published articles from 39 
population-based studies comprising of 5 ethnic ancestry groups with details listed in 
Appendix 2, Supplementary Table 5.1. Any, early and late AMD were pooled separately. 
Of the study participants, 43.5% were of European ancestry, 12.4% were of African 
ancestry, 33.1% were Asian, 9.7% Hispanic and 1.3% were others.   
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Forest plots in Figure 5.1 show the overall and ethnic-specific pooled prevalence of 
AMD. The lack of overlaps in credible intervals from graphical inspection of forest plots 
suggest presence of heterogeneity. Further analysis showed that heterogeneity in ethnicity 
and geographic regions for any AMD were 99.5% (95% CrI: 99.2%, 99.8%) and 99.7% 
(95% CrI: 99.5%, 99.9%) respectively (Appendix 2, Supplementary Table 5.4). The 
pooled global prevalence (accounting for various sources of heterogeneity) of early and 
late AMD in adult populations were 8.01% (95% CrI: 3.95%, 15.49%) and 0.37% (95% 
CrI: 0.18%, 0.77%), respectively. The overall prevalence of any AMD was 8.69% (95% 
CrI: 4.26%, 17.40%). Detailed estimated prevalence by AMD subtypes, ethnicity and age 
groups from meta-analysis using HB approach are provided in Appendix 2, 
Supplementary Table 5.5. Appendix 2, Supplementary Table 5.6 provides further 
detailed prevalence estimates stratified by geographic regions.  
Early AMD was found to be more prevalent in populations of European ancestry 
(11.2%) than in Asians (6.8%), with a BF of 3.9, suggesting substantial evidence for the 
difference between groups (Figure 5.2A and Appendix 2, Supplementary Table 5.3). 
Likewise, any AMD was more prevalent in populations of European ancestry compared to 
Asians (12.3% vs. 7.4%; BF = 4.3). Compared to African ancestry populations, European 
ancestry populations had higher prevalence of early, late or any AMD (late AMD: 12.3% 
vs. 7.5%; BF = 31.3, suggesting very strong evidence). Geographically, early and any 
AMD were less prevalent in Asia, compared to Europe and Northern America (all BFs > 
2) (Figure 5.2B and Appendix 2, Supplementary Table 5.3). There was no evidence of 
difference in the prevalence of early, late, or any AMD between gender (all BFs < 0.05, 
Appendix 2, Supplementary Table 5.3). 8 (21%) out of the 39 studies examined provided 
information on GA and nvAMD subtypes. Sub-group analysis showed similar overall 
prevalence of GA and nvAMD, 0.44% (95% CrI: 0.15%, 1.36%) and 0.46% (95% CrI: 
0.18%, 1.08%) respectively. European has evidence of higher prevalence of GA as 
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compared to African, Asian and Hispanic (1.11 [95% CrI: 0.53%, 2.08%] compared to 
0.14% [95% CrI: 0.04%, 0.45%], 0.21% [95% CrI: 0.04%, 0.87%] and 0.16% [95% CrI: 
0.05%, 0.46%] respectively). There was no difference in prevalence of nvAMD between 
ethnicities. 
The prevalence of early and late AMD increased with age in each of the ethnic groups 
and regions (Figure 5.3). Prevalence of late AMD in European ancestry populations 
increased most rapidly after age 75 and similar trend was observed in Europe and Oceania 
regions. 
The projected number of people with AMD by regions in years 2014, 2020 and 2040 
are provided in Figure 5.4. In year 2040, projected AMD cases globally are 288 million 
(95% CrI: 205, 399). Asia will have the largest number of people with AMD. Appendix 2, 
Supplementary Table 5.7 provides more detailed data on the projected number of people 
with AMD from 2012 to 2040. Pairwise comparison between geographical regions were 
presented in Appendix 2, Supplementary Table 5.8 and showed statistical evidence for 
the larger projected number of people with any AMD in 2040 in Asia compared to Latin 
America and the Caribbean, Northern America and Oceania and up to 2038 for Africa. 
5.5 DISCUSSION 
This systematic review and meta-analysis provided comprehensive and up-to-date 
pooled estimates of early, late and any AMD prevalence in the four major ethnic groups 
pooled from 39 studies and nearly 130,000 persons conducted in the six geographic regions 
around the world. Estimated prevalence were also projected for these geographically 
regions and worldwide to obtain number of people with AMD in years 2014 to 2040. We 
showed that 8.7% of the population globally have AMD, and the projected number of 
people with AMD is 196 million in 2020, increasing to 288 million in 2040. We describe 
ethnic and regional variations. Our study provides data that reflect the substantial burden 
of AMD which can be used for planning health care services around the world. 
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Our meta-analysis updates two earlier reviews focused on single ethnicities, one 
carried out in Europeans by Rudnicka et al17 and one in Asians by Kawasaki et al4. In our 
study, compared to the Asian meta-analysis, we included four additional Asian studies 
published after 2010, including the Handan Eye Study29, the Central India Eye and Medical 
Study30, one multiethnic Asian cohort study in Singapore31 and one study in Thailand32. In 
comparison to Rudnicka et al, six studies published earlier in the 1970s to 1990s were 
excluded as they relied only on eye examinations without taking fundus photos and on 
study-specific definitions.33-38 In our current study, we included only those with 
internationally recognized definitions of AMD21, 22 confirmed using retinal photographs.  
Our study provides estimates on ethnic differences in AMD prevalence. First, we 
found substantial evidence that early AMD was more prevalent in Europeans than Asians 
but that late AMD was similar. This results confirms the previous meta-analysis4 and multi-
ethnic population-based studies.15 It has been suggested that Asians (Chinese) may be more 
likely to develop exudative or nvAMD than whites,15, 33 but our sub-group analysis suggest 
no evidence for ethnicity difference. Also, most population-based studies were unable to 
reliably diagnose polypoidal choroidal vasculopathy (PCV), which often manifests like 
exudative AMD. Taking into consideration that PCV is markedly more common in Asians 
compared to Europeans, we may be overestimating the true prevalence of late AMD in 
Asians.39-41 Second, our study provided substantial to very strong evidence that early, late 
and any AMD are more prevalent in people of European ancestry than those of African 
ancestry, which validates observations derived from previous individual studies, such as 
the Baltimore Eye Study.15, 16 These patterns are in line with a previous multi-ethnic 
population-based study in the US, whereby the prevalence of early AMD was highest in 




Analysis of pooled prevalence by geographical regions showed greater variability, 
indicated by the larger 95% credible intervals as compared to prevalence pooled by ethnic 
ancestry groups. This could be due to heterogeneity contributed by various ethnic groups 
within each region. This lends further support to the hypothesis that inherited genetic 
factors determined by ethnic ancestry play a substantial role in AMD,42-44 in addition to 
established environmental risk factors such as smoking. Northern America and Europe 
were found to have higher pooled prevalence of early and any AMD as compared to Asia, 
in accordance with the higher prevalence of AMD in people of European ancestry 
compared to Asians as reported both in the literature and substantiated in our meta-analysis 
study. 
Female gender was considered a weak risk factor with inconsistent association for late 
AMD.45, 46 In our meta-analysis, there was no evidence of gender difference in both early 
and late AMD prevalence. This is consistent with previous reviews in people of European 
ancestry, where no significant gender difference was found in the prevalence of nvAMD 
or GA47. Similarly in Asians, men do not have a higher prevalence of late AMD compared 
to women after adjusting for risk factors such as smoking.48-50   
Asia is the most populous continent, accounting for over 60% of the world population 
and hence will see the largest projected number of AMD cases (113 million [95%CrI: 60, 
203] in 2040, a third of AMD cases globally) and is expected to increase more rapidly than 
other regions over the years, despite having the lowest estimated prevalence. Europe, being 
the third most populous region (11%) with the highest AMD prevalence, follows after Asia 
in the number of projected AMD cases (69 million [95%CrI: 40, 109] in 2040), with 
moderate increase over the years. Our models project that in 2040 there will be 39 million 
[95%CrI: 12, 93] people with AMD in Africa, 39 million [95%CrI: 15, 82] in Latin 
America and the Caribbean, 25 million [95%CrI: 15, 38] in the North America and 2 
million [95%CrI: 1, 5] in Oceania. The trends and differences are mainly influenced by the 
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demographic progression in population structure (e.g. aging population) of the regions 
based on the population projection data by the United Nations.28 These data are important 
as more than 2/3 of the AMD patients in Asia, Africa and Latin America may not have 
access to expensive anti-angiogenesis therapies now widely used in North America and 
Europe 
Our study has a number of strengths. First, we pooled data that used fundus 
photography and standardized protocols to assess AMD. Our study was limited by the fact 
that despite the large number of studies included in this meta-analysis, our sub-group 
analysis on the prevalence of late AMD subtypes (i.e nvAMD vs. GA) with ethnicity was 
based on data from only 8 studies. Moreover, there is evidence that without harmonization 
of classification systems and definitions of AMD lesions, estimates of early AMD may 
substantially vary due to a variety of factors. These include varying definitions used for 
grading AMD and inconsistencies in quality of images.51 Although there are inherent 
disadvantages in performing a meta-analysis based on data sets pooled together from 
disparate population studies, we have attempted to circumvent this issue by only including 
studies in which standard protocols are used to grade fundus photos.  
In conclusion, our study estimates reflect the significant present and future burden of 
AMD globally. There is substantial evidence for higher prevalence of early AMD in people 
of European ancestry than in Asians, and early and late AMD in people of European 
ancestry than those of African ancestry. We observed that late AMD prevalence increases 
rapidly after age 75, especially in people of European ethnicity and in Europe and Oceania 
regions, but Asia will see the largest number of people with AMD despite having the lowest 
prevalence. These data provide important information for the design and implementation 
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5.7 Chapter 5 Tables and Figures 
Figure 5.1 Forest Plots of Overall and Race-specified Pooled Prevalence of AMD: (A) 
Early AMD, (B) Late AMD and (C) Any AMD. Dashed line refers to the overall pooled 













































Figure 5.4 Projection of Number of People with Early and Late AMD by Regions in 2014, 2020 and 2040 
 
 
World Region Early AMD (million)  Late AMD (million)  Any AMD (million) 
2014 2020 2030 2040  2014 2020 2030 2040  2014 2020 2030 2040 
Africa 15.36 18.47 25.67 35.53  0.77 0.93 1.30 1.80  16.87 20.29 28.20 39.06 
Asia 55.51 66.29 86.22 105.76  4.59 5.52 7.66 9.92  59.16 70.68 92.14 113.21 
Europe 47.81 50.87 56.28 58.65  2.57 2.79 3.29 3.69  54.98 58.78 65.82 69.32 
Latin America & Caribbean 19.87 23.59 30.47 36.95  0.86 1.02 1.32 1.61  20.93 24.80 31.90 38.53 
Northern America 14.77 16.70 19.80 21.30  0.76 0.90 1.20 1.36  17.07 19.41 23.25 25.08 
Oceania 1.21 1.43 1.79 2.07  0.09 0.11 0.15 0.19  1.37 1.62 2.06 2.40 
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6.1 RESEARCH MOTIVATION and CONTRIBUTIONS 
Objective means of measuring frequency of disease, magnitude of associations 
between exposure and disease and the collective impact on public health are the building 
blocks of epidemiologic research. Assessing whether observed study results represent valid 
associations that reflect the true relationships between the exposures and the disease, is a 
matter of determining the likelihood that alternative explanations such as chance, bias, 
measurement errors, or confounding could account for the findings. Vision-specific 
functioning is an intangible aspect of visual impairment. Vision-specific quality-of-life 
questionnaires are designed to assess the impact of vision impairment in patients. However, 
the statistical modeling and estimation of association effects are not straightforward when 
dealing with quality-of-life survey with many questions, collectively measuring a single 
latent construct. Our literature review of association analyses involving vision-specific 
instruments revealed current inappropriate handling of measurement errors of vision 
functioning, one of the key latent traits using Rasch analysis. 
Hence in this study, we developed a statistical model that is appropriate for the 
assessment of association effects related to vision-specific latent trait, with proper 
treatment of its associated measurement error to produce accurate and contemporary 
estimates of association effects. We demonstrated the effectiveness this modeling 
framework that integrates Rasch and regression models using Hierarchical Bayesian 
approach and documented the model codes in Appendix 1 which can be altered to conform 







There is increasing recognition that patient-reported outcomes [PRO] (commonly 
referred as questionnaires or instruments) is important to assess the impact of vision loss 
in ophthalmic research.1-9 For vision-specific instruments, vision functioning is one of the 
key latent traits. Recently, Rasch analysis has been used to estimate and evaluate latent 
traits, producing Rasch-scaled scores in preference to raw scores from questionnaire data. 
Numerous vision-specific instruments have been rigorously validated using Rasch analysis 
for daily living activities dependent on vision10, 11 and for a spectrum of eye conditions such  
cataract,8, 12, 13 diabetic retinopathy,6 age-related macular degeneration,4, 14 and glaucoma.7, 
15, 16 A literature review for instruments for the assessment of vision-specific quality of life 
identified 22 instruments.17  
However, the handling of latent variables and their interpretation can be challenging 
as they are not observed scores and so estimation of latent variables comes with uncertainty 
commonly termed as measurement error. Subsequent applications of “classical” statistics 
such as t-tests and linear regressions are not strictly appropriate for association analysis of 
latent data as they require dependent/outcome variables to be known. The analysis of latent 
variables requires the associated measurement error to be accounted for as failure to do so 
may lead to biased estimates of correlations, associations and statistical inferences.18, 19 
Multilevel item response theory (MLIRT) models have been shown to allow for a better 
estimation of relationships between predictor variables and MLIRT latent traits.20, 21 
However, appropriate handling of measurement errors of latent dependent variable in 
multilevel models are only more often practiced in some fields, such as in educational22, 23 
and psychometric24, 25 research.  
The purpose of our study was to demonstrate the effectiveness of a modeling 
framework that integrates Rasch and regression models using Hierarchical Bayesian (HB) 
approach that accounts for latent trait measurement errors. This modeling is appropriate 
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for the assessment of association effects related to vision-specific latent trait, with proper 
treatment of its associated measurement error for a more accurate and contemporary 
estimates of association effects. We compared the one-stage “joint analysis” and two-stage 
“separate analysis” model results using real data and assessed the performance of the 
methods in a simulation study based on the frequently used Andrich rating scale model26.  
6.3 MATERIALS AND METHODS 
Literature Review 
We systematically reviewed publications that used Rasch analysis by searching the 
electronic databases of PubMed in the top four Ophthalmic journals (Ophthalmology, 
American Journal of Ophthalmology [AJO], British Journal of Ophthalmology [BJO] and 
Investigative Ophthalmology & Visual Science [IOVS]) for relevant papers published up 
to July, 2013, with the following search terms (formatted for PubMed search): 
1. (rasch[All Fields] AND ("analysis"[Subheading] OR "analysis"[All Fields])) AND 
"Ophthalmology"[Journal] 
2. (rasch[All Fields] AND ("analysis"[Subheading] OR "analysis"[All Fields])) AND 
("Am J Ophthalmol"[Journal] OR "american journal of ophthalmology"[All Fields]) 
3. (rasch[All Fields] AND ("analysis"[Subheading] OR "analysis"[All Fields])) AND ("Br 
J Ophthalmol"[Journal] OR "british journal of ophthalmology"[All Fields]) 
4. (rasch[All Fields] AND ("analysis"[Subheading] OR "analysis"[All Fields])) AND 
("Invest Ophthalmol Vis Sci"[Journal] OR "investigative ophthalmology and visual 
science"[All Fields]) 
The strategy identified 70 articles and the full texts were reviewed (by WLW and XL) 
to identify studies having performed Rasch analysis on visual functioning questionnaire 
data. Of the 70 articles identified, two were letters,27, 28 one study applied Rasch model to 
investigate inter-reader agreement,29 and another focused on the genetic components of the 
optic nerve head30 were excluded. The remaining 66 articles related to visual functioning 
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data were reviewed for choice of Rasch model, implementation software and sample size 
of studies (Table 6.1). 
Pitfalls in Observed Analysis Framework (two-stage “separate analysis” procedure) 
All 66 articles reviewed performed Rasch analysis to evaluate the validity, reliability 
and measurement characteristics of instruments (i.e. visual functioning) for their 
population sample data. Most (86.4%) performed further statistical analysis on the Rasch-
scaled score (i.e. vision-specific latent trait), such as performing correlations or linear 
regressions with visual acuity, demographic or clinical data to assess the impact of visual 
impairment and other patients’ characteristics or factors on visual functioning . 
However, none of the articles mentioned or discussed the potential bias in estimation 
of association effects and the underestimation of their standard errors31 having ignored the 
associated uncertainties involved in the estimation of the latent trait when used naively in 
subsequent association analysis. In the first stage, the vision-specific latent trait (i.e vision 
functioning) was modeled and estimated given a set of item responses using a polytomous 
Rasch model (e.g. Andrich rating scale model when item response options are more than 
dichotomous i.e. three or more). In the second stage, relationships between the estimated 
Rasch-scaled data (treated as known outcome variable) and risk factors were analyzed 
using regression techniques. Ignoring the uncertainty regarding the abilities within the 
regression model may lead to biased estimation of association effects. Underestimation of 
standard errors may also result in false identified positive factors and hence mislead 
statistical inferences.  
Moreover, a key assumption in Rasch model states that a change in the latent variable 
is completely described by the item characteristic functions (the relationship of the latent 
trait and responses of the items) and hence any association analysis on the latent trait with 
other covariates performed in the second stage can violate and contradict the key 
assumptions in the first stage of Rasch analysis (having assumed that vision-specific latent 
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trait only dependents on item response data). Such estimation procedure can cause serious 
underestimation of the standard errors of the model parameters. 
Our literature review also observed that studies assessing visual functioning traits 
were often conducted for moderately small sample sizes (median 240 with interquartile 
range of 497) and together with response data (and Rasch-scaled scores) that are typically 
non-normally distributed; it is precarious to rely on asymptotic approximations and the 
properties of conditional maximum likelihood estimates obtained from analysis software 
without showing them to be accurate.32 Similarly, validation inference based on 
correlations may not be accurate.  
Our study analysis and discussion will focus on the Andrich rating scale26 because it 
is the most frequently used polytomous Rasch model for vision-specific instruments. 
Andrich Rating Scale Model 
The Andrich rating scale26 model is an extension of the Rasch model33 for 
polychotomous responses (i.e. three or more categories). The natural log of the likelihood 
ratio of adjacent response category probabilities is given by 
lnሺ ௜ܲ௞,௬/ ௜ܲ௞,ሺ௬ିଵሻሻ ൌ ߠ௜ െ ߟ௞ െ ߛ௬ 
where ௜ܲ௞,௬  is the probability of person ݅ on encountering item ݇ would be observed in 
category ݕ. ߠ௜ is ability trait for the ݅th person (i.e. i = 1, …, n) , ߟ௞ is the item ݇ difficulty 
parameter (i.e. k items means k = 1, …, k) and ߛ௬ is the threshold for category ݕ (e.g. items 
with 5 categories means y is in the range of integers 1 to 5), which is constant across items.  
Proposed Analysis Framework (one-stage “joint analysis”) 
A rigorous alternative is to combine the observed two-stage analysis procedure to 
overcome the problematic issues described above. Item response data structure are 
hierarchical since item responses are nested within respondents and respondents may also 
be nested (e.g. patients nested in hospitals). Such relationships can be adequately explained 
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by the multilevel Rasch model using the Hierarchical Bayesian (HB) approach. Model 
parameters can also be incorporated and estimated from the item response data without 
having to condition on estimated person ability parameter (i.e. latent trait). In Appendix 2, 
Supplementary Figure 6.1, a path diagram of this multilevel Rasch model is depicted and 
explained.  
For example, the combined model for linear regression (i.e. continuous latent trait 
outcome) can be written as 
൜ 			lnሺ ௜ܲ௞,௬/ ௜ܲ௞,ሺ௬ିଵሻሻ ൌ ߠ௜ െ ߟ௞ െ ߛ௬					ߠ௜ ൌ ߚ ൈ ௜ܺ ൅ ߝ௜																																					. 
where ߚ is the beta coefficient from linear regression, ௜ܺ  is the observed covariates of 
person ݅  and ߝ௜	 is the residual random error. The HB approach provides an elegant 
execution of the multilevel Rasch modeling framework that allows the incorporation of 
explanatory variables or covariates at different levels of hierarchy by specifying parameters 
to come from a specific distribution with parameters and possibly hyper-parameters that 
are, themselves, estimated prior information.31 All model parameters can then be estimated 
simultaneously using the Monte Carlo Markov Chain method with the JAGS software.34, 35 
The proposed procedure enables direct estimation of beta coefficients for association 
effects without having to explicitly know the latent trait measurements, i.e. personal ability. 
The JAGS codes used to fit our example model in one-stage “joint analysis” HB approach 
is provided in the Appendix 1, can be altered readily to conform to different data structure. 
Comparison of Methods Using Real Data 
Both the HB one-stage “joint analysis” and the two-stage “separate analysis” methods 
were performed to assess the relationship of reading and writing literacy on visual 
functioning (measured by a modified VF-9 questionnaire) using data from the Singapore 
Malay Eye Study (SiMES)36, a population-based cross-sectional study of 3,280 
Singaporean Malays aged above 40. Previous studies suggest an association of inadequate 
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literacy with systemic health and hence the influence of literacy on vision functioning (in 
addition to visual impairment), another aspect contributing to vision-specific quality of life 
is important.37, 38 Association of reading and writing literacy with visual functioning were 
adjusted for age, gender, language of interview, body mass index, occupation, marital 
status, income, housing type, education, smoking status and presenting visual acuity in the 
better-seeing eye. 
Simulation Study 
As there is no “gold standard” in the comparison of methods using real data, we 
conducted a simulation study to demonstrate the performance of our proposed HB one-
stage “joint analysis” approach as compared to the observed two-stage “separate analysis” 
procedure. Two independent covariates ( ௜ܺଵ ,	 ௜ܺଶ ), a continuous variable data such as 
standardized age and a binary variable such as gender were simulated with pre-specified 
association effects (ߚଵ,	ߚଶ) for the impact of these two covariates with the latent visual 
functioning ability parameter and hence, these were considered as the “true” association 
effects or “gold standard” for reference when we re-run analysis on our simulated data 
using both analytical methods. Association estimates and their standard errors from both 
approaches were computed to assess their performance, where estimates closer to the “gold 
standard” indicate higher accuracy and smaller standard errors suggest greater precision. 
The calibration of nine item difficulty parameters, ߟ௞ was fixed according to Table 3 of a 
study conducted by Ecosse L. Lamoureux et. al.,39 that performed a systematic evaluation 
of the reliability and validity of the visual functioning questionnaire (VF-11) using Rasch 
analysis that was later modified to nine items (VF-9) to tailor fit to the Asian population. 
We also investigated the empirical power for both approaches. We provided detailed 




Table 6.1 shows the summary of articles reviewed in the four major ophthalmic 
journals that have performed Rasch analysis for visual functioning related instrument data. 
The majority (65.1%) performed Rasch analysis using Andrich rating scale model and most 
(68.2%) conducted Rasch analysis using Winsteps software. The median sample size of 
these studies was 240 with interquartile range of 497.  
Associations of inadequate reading and writing literacy with visual functioning 
adjusted for potential confounding variables (model 1 and 2 respectively) derived from 
both approaches analyzed on our simulated data were shown in Table 6.2. Comparison of 
both approaches for Model 1 assessing reading literacy showed no difference in terms of 
statistical evidence for factors identified but results were not consistent for writing literacy 
in Model 2. Inadequate writing was statistically significant based on the HB one-stage 
“joint analysis” but was not significant in the two-stage “separate analysis” approach. 
Smaller association effects were also estimated in the two-stage “separate analysis” 
approach which is consistent with the attenuation bias observed in simulation study. 
Simulation results on the association effects and their standard errors of a continuous 
measurement such as standardized age (ߚଵ) and that for a binary factor such as gender (ߚଶ) 
with the vision-specific latent trait compared to the “gold standards” for both approaches 
are depicted in Figure 6.1. There is greater inaccuracy (average of 5 folds increase in bias) 
in effect size estimations from the frequently used two-stage “separate analysis” procedure 
compared to the proposed HB one-stage “joint analysis” approach. We also observed an 
attenuation bias in estimations (shrunk towards zero) from the two-stage procedure. 
Smaller standard errors for estimates were expected for the two-stage procedure having 
assumed no uncertainty in the latent trait measurements but the slightly larger standard 
errors (average of one-tenth fold difference) from the HB approach suggest comparable 
precision for a more accurate estimation of associations. Furthermore, similar power (no 
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difference for beta ≥ 0.5 at 5% significance level and less than one-twelfth fold difference 
for beta at 0.2 for both continuous and categorical variables) in our proposed HB approach 
despite taking into account uncertainty in the latent trait (Appendix 2, Supplementary 
Table 6.1). 
6.5 DISCUSSION 
This is the first study to assess the performance of two regression models for visual 
functioning, comparing the frequently used two-stage “separate analysis” method (ignoring 
measurement error of the dependent latent trait) and our proposed one-stage “joint analysis” 
approach in terms of estimation accuracy of association effects, precision of their standard 
errors and power. Association effect sizes from our real data analysis were observed to be 
smaller in the two-stage “separate analysis” approach with slightly tighter intervals and the 
identification of significant factors between approaches were different. Our simulation 
study results (assessing methods performance) provided support for these observations. 
Attenuation bias, the shrinking of estimations towards zero, was found using the two-stage 
procedure (a phenomenon expected from ordinary least squares regression of explanatory 
variables with measurement errors) that explains the (artificial) smaller association effects 
observed in our real data analysis.  
One-stage “joint analysis” approach allows the estimation of all models parameters 
simultaneously and hence integrates visual functioning in the regression model accounting 
for its measurement errors. Simulation results also showed that the one-stage “joint analysis” 
method produced highly accurate estimations (average of 5 folds decrease in bias) with 
comparable precisions and power as compared to the commonly used two-stage “separate 
analysis” procedure. The magnitude of measurement error also affects the size of 
attenuation bias. Accurate estimation of effect size and its variance are both critical to 
statistical significance testing results that directly influence our interpretation of risk factors. 
Hence moving forward, the one-stage “joint analysis” approach is preferred when we 
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perform regression analysis with dependent outcome that is essentially a latent variable 
being derived from some prior analyses.  
Our model codes provided in the Appendix 1 can be altered readily to analyze data 
from any instruments/questionnaires with any choice of Rasch or item response theory 
models (e.g. Partial Credit model, Graded Response model etc.) and complexity of 
multilevel regression models as depicted in Appendix 2, Supplementary Figure 6.1 to 
adequately describe the hierarchical data structure, incorporate different sources of 
uncertainty and inclusion of explanatory covariates at different levels. Furthermore, latent 
variable can also be analyzed as independent covariate (as required) instead of an outcome 
variable used in our simulation example. 
In our literature review, visual functioning rating scale instruments/questionnaires 
were mainly validated using Rasch analysis for their well-known scaling and measurement 
properties. Without a realist interpretation of latent variables, actual Rasch-scaled scores 
do not have straightforward meaning and its interpretations are based on relative 
comparisons of the scaled scores (i.e. relative difference tells us how much more of persons’ 
visual functioning ability compared to another). Many reviewed articles provide ready-to-
use spread sheets that convert raw scores entered to Rasch-scaled scores for their respective 
instruments to benefit clinicians and researchers unfamiliar with Rasch analysis who may 
wish to use its scoring benefits. It is important to note that the population of respondents 
plays an important part in the probability model for each response and so the personal 
ability and item parameters will always be estimated with respect to a population. Hence, 
ready-to-use spread sheets should only be used on different samples of individuals from 
the same population as validated for in the article and that Rasch-scaled scores are not 
comparable between studies from different populations unless it happens (rarely) that both 
populations have identical item characteristic functions. Researchers were also unaware of 
the measurement errors associated with Rasch-scaled scores and performed further analysis 
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directly with simple statistical tests such as independent t-tests to examine between group 
differences in the instrument scores across various socio-demographic variables and levels 
of vision impairment. 
The strength of our study includes the simulating datasets with various pre-specified 
association effects that acts as “ground truth” to enable the comparison between methods. 
The simulating conditions in our study were however, limited to only the Andrich Rating 
Scale model with linear regression analysis for covariates at the respondents’ level. 
Statistical computations are necessary for applying our proposed analysis using the HB 
approach and some background in statistics and programming skills are needed to alter 
codes to conform to other conditions. 
In conclusion, there is a need to account for measurement error associated with vision-
specific latent trait in association analysis. We demonstrated that our HB one-stage “joint 
analysis” approach is a better method that produces greater accuracy with comparable 
power and precision in estimation of association effects compared to the frequently used 
two-stage procedure, despite taking into account greater uncertainty due to the latent trait. 
The study finding has direct implications in our inference drawn from statistical 
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6.7 Chapter 6 Tables and Figures 
 
Table 6.1 Summary of Articles Reviewed (N=66) 
AJO: American Journal of Ophthalmology; BJO: British Journal of Ophthalmology; 
IOVS: Investigative Ophthalmology & Visual Science; PCM: partial credit model.  
 
 
Major Ophthalmic Journals 
Total 
Ophthalmology AJO BJO IOVS 
No. of Articles 8 (12.1%) 3 (4.6%) 8 (12.1%) 47 (71.2%) 66 (100.0%) 
Method      
  Andrich 6 (75.0%) 1 (33.3%) 5 (62.5%) 31 (66.0%) 43 (65.1%) 
  PCM 0 (0.0%) 0 (0.0%) 1 (12.5%) 4 (8.5%) 5 (7.6%) 
Not indicated 2 (25.0%) 2 (66.7%) 2 (25.0%) 12 (25.5%) 18 (27.3%) 
Software      
  Winsteps 5 (62.5%) 2 (66.7%) 5 (62.5%) 33 (70.2%) 45 (68.2%) 
RUMM2020 3 37.5%) 0 (0.0%) 1 (12.5%) 10 (21.3%) 14 (21.3%) 
  BIGSTEPS 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (6.4%) 3 (4.5%) 
  Facets 0 (0.0%) 0 (0.0%) 1 (12.5%) 0 (0.0%) 1 (1.5%) 
Not indicated 0 (0.0%) 1 (33.3%) 1 (12.5%) 1 (2.1%) 3 (4.5%) 
Sample size      
  Median 1992 411 360 192 240 

















Table 6.2 Comparison between Approaches Using Real Data* 
*Based on SiMES data 
Model 1 adjusted for factors in table (excluding writing literacy);  
Model 2 adjusted for factors in table (excluding reading literacy) 
Data represented are difference in Rasch-scaled score with 95% Credible interval in 
parentheses 
P-value < 0.05 suggests evidence of associations in 2-stage “separate-analysis” approach 
95%Credible Intervals not including 0 suggests evidence of associations in 1-stage “joint-
analysis” approach 
 Model 1 (reading literacy)  Model 2 (writing literacy) 
Approach 2-Stage P  1-Stage  2-Stage P  1-Stage Approach 
Age, years 0.000 (-0.008, 0.008) 0.906  
-0.001 
(-0.020, 0.014)  
0.001 
(-0.007, 0.009) 0.892  
-0.002 
(-0.018, 0.014) 
Gender          
  Male vs. Female 0.012 (-0.161, 0.184) 0.894  
0.073 
(-0.330, 0.474)  
0.010 




interview          
  English vs. Malay -0.227 (-0.501, 0.046) 0.103  
-0.442 
(-1.026, 0.142)  
-0.229 
(-0.502, 0.045) 0.101  
-0.482 
(-1.001, 0.027) 
  Others vs. Malay 0.659 (-0.685, 2.002) 0.336  
6.389 
(-0.604, 26.143)  
0.649 
(-0.696,1.994) 0.343  
5.657 
(-0.515, 17.086) 
BMI 0.002 (-0.010, 0.014) 0.739  
0.003 
(-0.021, 0.027)  
0.002 
(-0.010, 0.014) 0.733  
0.005 
(-0.021, 0.028) 
Occupation          
  Office work Reference   Reference  Reference   Reference 
  Service work -0.060 (-0.263, 0.143) 0.559  
-0.127 
(-0.633, 0.380)  
-0.062 
(-0.265, 0.141) 0.549  
-0.133 
(-0.655, 0.343) 
  Factory work -0.186 (-0.451, 0.078) 0.166  
-0.402 
(-1.013, 0.226)  
-0.181 
(-0.446, 0.083) 0.178  
-0.396 
(-0.890, 0.212) 
  Homemaking -0.118 (-0.376, 0.141) 0.371  
-0.210 
(-0.809, 0.420)  
-0.104 
(-0.363, 0.155) 0.431  
-0.273 
(-0.797, 0.304) 
 Unemployed/others -0.091 (-0.334, 0.152) 0.463  
-0.197 
(-0.750, 0.424)  
-0.090 
(-0.333, 0.153) 0.468  
-0.227 
(-0.775, 0.339) 
Maratial Status          
  Never married Reference   Reference  Reference   Reference 
  Married 0.072 (-0.165,0.309) 0.552  
0.227 
(-0.304, 0.772)  
0.074 
(-0.164, 0.311) 0.543  
0.232 
(-0.216, 0.727) 
  Separate/divorced -0.218 (-0.527,0.091) 0.167  
-0.305 
(-0.866, 0.304)  
-0.213 
(-0.522, 0.097) 0.177  
-0.272 
(-0.828, 0.283) 
  Widowed 0.082 (-0.237,0.400) 0.615  
0.307 
(-0.348, 0.990)  
0.093 
(-0.227, 0.414) 0.568  
0.324 
(-0.253, 0.929) 
Income          
  > SGD$1000/month Reference   Reference  Reference   Reference 
  < SGD$1000/month 0.049 (-0.114, 0.212) 0.556  
0.106 
(-0.219, 0.475)  
0.049 
(-0.115, 0.212) 0.557  
0.082 
(-0.257, 0.406) 
  Retirement income 0.065 (-0.127, 0.256) 0.508  
0.105 
(-0.338, 0.570)  
0.067 
(-0.125, 0.259) 0.495  
0.135 
(-0.278, 0.491) 
Current housing status          
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  1/2 room flat Reference   Reference  Reference   Reference 
  3/4 room flat -0.259 (-0.416, -0.101) 0.001  
-0.580 
(-0.944, -0.182)  
-0.255 
(-0.413, -0.098) 0.002  
-0.526 
(-0.843, -0.214) 
  5 room/private house -0.281 (-0.477,-0.085) 0.005  
-0.617 
(-1.147, -0.194)  
-0.278 
(-0.474, -0.082) 0.006  
-0.547 
(-0.926, -0.192) 
Education          
  No formal education Reference   Reference  Reference   Reference 
  Primary education -0.164 (-0.394,0.066) 0.162  
-0.360 
(-0.930, 0.135)  
-0.160 
(-0.393, 0.074) 0.180  
-0.342 
(-0.789, 0.115) 
  Secondary education -0.152 (-0.411,0.107) 0.249  
-0.318 
(-0.976, 0.237)  
-0.151 
(-0.414, 0.112) 0.261  
-0.297 
(-0.794, 0.201) 
  Poly/University -0.124 (-0.427,0.180) 0.424  
-0.178 
(-0.965, 0.508)  
-0.120 
(-0.426, 0.187) 0.443  
-0.147 
(-0.75, 0.506) 
Smoking status          
  Past or never Reference   Reference  Reference   Reference 
  Current -0.203 (-0.359,-0.048) 0.010  
-0.461 
(-0.802, -0.141)  
-0.201 
(-0.356, -0.045) 0.012  
-0.411 
(-0.706, -0.159) 
PVA of better eye -0.934 (-1.165,-0.703) 0.000  
-1.568 
(-2.112, -1.085)  
-0.950 
(-1.180, -0.720) 0.000  
-1.468 
(-1.999, -1.022) 
Read          
  Yes vs. No 0.297 (0.026,0.568) 0.032  
0.578 
(0.051, 1.193)      
Write          






















Figure 6.1 Association Effects and Standard Errors: Comparison of Proposed One-Stage HB and Observed Two-Stage Analysis Framework 
from Simulation Results  
Attenuation Bias: red dots were shrunk towards zero and greater bias observed from the greater distance away from the black dots, the true value 
















Bias of Beta1  
(Beta 2 constant) 
Beta2 
-1 -0.5 0 0.5 1 
Two-stage; One-stage Two-stage; One-stage Two-stage; One-stage Two-stage; One-stage Two-stage; One-stage 
Beta1 
-1 0.105 (0.075);  -0.008 (0.084) 
0.104 (0.076);  
-0.028 (0.093) 
0.116 (0.077);  
-0.022 (0.094) 
0.137 (0.080); 
 -0.021 (0.087) 
0.167 (0.074); 
 -0.022 (0.091) 
-0.5 0.038 (0.056);  -0.006 (0.068) 
0.050 (0.053); 
 -0.005 (0.075) 
0.045 (0.052);  
-0.008 (0.073) 
0.076 (0.058); 
 -0.001 (0.076) 
0.070 (0.062); 
 -0.018 (0.065) 
0 -0.007 (0.056);  -0.013 (0.059) 
0.003 (0.049); 
 0.005 (0.057) 
0.001 (0.053);  
-0.002 (0.059) 
0.007 (0.059); 
 0.001 (0.058) 
0.001 (0.054); 
 0.003 (0.062) 
0.5 -0.038 (0.059);  0.017 (0.067) 
-0.039 (0.058); 
 0.004 (0.067) 
-0.052 (0.064); 
 0.005 (0.062) 
-0.071 (0.063); 
 0.012 (0.073) 
-0.087 (0.060) 
; 0.009 (0.076) 
1 -0.085 (0.081);  0.025 (0.089) 
-0.091 (0.076);  
0.020 (0.095) 
-0.118 (0.080); 
 0.020 (0.092) 
-0.150 (0.076); 
 0.022 (0.102) 
-0.176 (0.081); 
 0.010 (0.092) 
Bias of Beta2 
(Beta 1 constant) 
Beta2 
-1 -0.5 0 0.5 1 
Two-stage; One-stage Two-stage; One-stage Two-stage; One-stage Two-stage; One-stage Two-stage; One-stage 
Beta1 
-1 0.112 (0.122);  -0.031 (0.132) 
0.063 (0.117); 
 0.001 (0.128) 
-0.005 (0.122); 
 -0.003 (0.121) 
-0.073 (0.117);  
-0.006 (0.122) 
-0.153 (0.140); 
 0.007 (0.151) 
-0.5 0.082 (0.131);  -0.008 (0.133) 
0.031 (0.121);  
-0.006 (0.131) 
0.002 (0.107);  
-0.007 (0.126) 
-0.078 (0.116);  
0.007 (0.131) 
-0.145 (0.108);  
0.022 (0.129) 
0 0.081 (0.133);  -0.013 (0.116) 
0.063 (0.116); 
 -0.005 (0.110) 
-0.022 (0.103); 
 -0.005 (0.129) 
-0.054 (0.116);  
0.013 (0.126) 
-0.140 (0.129); 
 0.019 (0.121) 
0.5 0.069 (0.132);  -0.015 (0.131) 
0.047 (0.122);  
-0.009 (0.133) 
-0.014 (0.099); 
 0.010 (0.126) 
-0.068 (0.115); 
 0.010 (0.138) 
-0.165 (0.116);  
0.042 (0.139) 
1 0.061 (0.130);  -0.018 (0.147) 
0.030 (0.136); 
 0.004 (0.137) 
0.012 (0.134); 
 -0.018 (0.138) 
-0.059 (0.108);  
0.024 (0.138) 
-0.160 (0.128);  
0.038 (0.144) 
 
Based on 100 simulations using N=300; K=9; C=5  
Data represented as average bias of Two-stage and One-stage estimates of Beta1 (holding Beta2 constant) and Beta2 (holding Beta1 constant), with standard 


































In the first chapter (Chapter 1), we reviewed published literature on the types of 
statistics used in ophthalmic journals and the major areas of developments in biostatistics 
research in recent years. New statistics and advanced methods improve efficiency and 
reliability of analysis results, in which its developments are driven by dynamic clinical and 
research questions, where study designs and nature of data collected can be complex due 
to limited resources, restrictions and factors not within control. Mathematical statistics uses 
two major paradigms, “classical” and Bayesian approach. This thesis focuses on the 
Bayesian methods, which is less understood and not commonly applied in ophthalmic 
research as observed from a current literature review but offers an alternative solution to 
solve many of the difficulties faced by conventional methods. Bayesian approach is 
fundamentally sound, flexible, provides clear and direct inferences and makes use of all 
available information and the main criticism of using priors was also discussed. We 
developed statistical models and used Bayesian inference to resolve different areas of 
common but complex clinical and epidemiologic research questions in the thesis.  
Contributions were highlighted in each study chapter.  
The study design, methods and data details for analyses performed in the thesis were 
documented in Chapter 2. Clinical and epidemiologic research questions were 
encountered in my work experience with clinicians and scientists in the Singapore Eye 
Research Institute, and hence the study data were from the Singapore Malay Eye Study 
(SiMES), a prospective cohort of patients presented with uveitis to Singapore National Eye 
Center and also data extracted from literature review to conduct meta-analysis.  
Study 1 (Chapter 3)  
Few studies have developed conversion scores between cataract classification systems. 
There is a need for such a method of conversion, as prevalence and incidence of cataract 
cannot be compared directly between studies that were assessed using different 
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classification systems. In this study, we developed a conversion algorithm and applied our 
algorithm to transform between the LOCS III and Wisconsin system. The conversion 
between the two cataract classification systems is affected by the direction of 
transformation. The conversion algorithm was validated and R program codes to automate 
the collapsing iterations of the conversion algorithm was provided in Appendix 1. 
Extensions and future research 
 Our conversion algorithm can be applied to other cataract grading systems and be 
extended for use in other diseases that requires harmonizing of classification systems and 
definitions of lesions such as for age-related macular degeneration, or chronic kidney 
disease where the classification system may lack coherence1. The usefulness of our 
conversion algorithm should be further investigated in its application to other research 
areas or improved/modified to overcome limitations. 
Chapter 4 (Study 2) 
The clinical diagnosis of infectious disease such as tuberculous uveitis is controversial, 
and without an established “gold standard” diagnostic test, it is difficult to evaluate current 
and new diagnostic tests results using “classical” statistics without knowing the correct 
disease status. Furthermore, IGRAs tests are not independent which complicates modeling. 
Our study have shown how analysis can be performed using Bayesian approach to estimate 
parameters (sensitivity and specificity of diagnostic tests) of latent class model for 
tuberculous uveitis, accounting for tests dependency and considering all available 
information. We have also investigated the optimal choice of diagnostic test to be used.  
Extensions and future research 
Our statistical model can be extended or made to confirm to other situations or 
limitations for analysis of other diagnostic tests or screening programs, such as dilated 
ophthalmoscopy or retina image grading for screening of diabetic retinopathy2, or in 
assessment of rapid tests for dengue diagnosis3. Correct classification rate, validity, cost, 
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urgency and invasiveness of tests are some of the many factors to be considered in the in-
depth evaluation of diagnostic or screening tests. Further research can be done in the 
sequence of multiple tests to be performed, whether sequentially or simultaneously; and 
the reproducibility, repeatability and reliability of tests. 
Chapter 5 (study 3)  
Numerous population-based studies of age-related macular degeneration have been 
reported around the world, with the results of some studies suggesting racial or ethnic 
differences in disease prevalence. Integrating these resources to provide summarized data 
to establish worldwide prevalence and to project the number of people with age-related 
macular degeneration from 2020 to 2040 would be a useful guide for global strategies. In 
this study, we conducted a systematic literature review to identify all population-based 
studies of age-related macular degeneration published before May, 2013 and included only 
studies using retinal photographs and standardized grading classifications (the Wisconsin 
age-related maculopathy grading system, the international classification for age-related 
macular degeneration, or the Rotterdam staging system).  
Various sources of heterogeneity and uncertainty (e.g. ethnicity, geographic regions 
etc.) were accounted for and tested in our statistical model using Hierarchical Bayesian 
approach; and to estimate the pooled prevalence, the 95% credible intervals (CrI), and 
examine the difference in prevalence by ethnicity (European, African, Hispanic, Asian) 
and region (Africa, Asia, Europe, Latin America and the Caribbean, North America, and 
Oceania). We then projected the number of people affected in 2014 and 2040 based on the 
UN World Population Prospects. These estimates indicate the substantial global burden of 
age-related macular degeneration. Our study provided summarized evidence for 
understanding the effect of the condition and provide data towards designing eye-care 
strategies and health services around the world. 
Extensions and future research 
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Further research should be done in addressing the overall disease burden such as on 
visual acuity or the effect of vision loss on quality of vision and quality of life as suggested 
in commentary article by Jost B Jonas.4 Our study provided the first step in examination of 
the overall prevalence of age-related degeneration; the next step would require further 
investigation on the factors associated with age-related macular degeneration, whether the 
factors and its influence differs between countries or ethnicities or caused the prevalence 
varies between regions. The answers to these questions could help in the prevention of the 
disease, in elucidating the pathogenesis, and could give hints for the development of new 
therapeutic procedures. 
Chapter 6 (study 4) 
Numerous vision-specific instruments have been rigorously validated using Rasch 
analysis for daily living activities dependent on vision and for a spectrum of eye conditions 
such as cataract, diabetic retinopathy, age-related macular degeneration, and glaucoma. 
Vision functioning is one of the key latent traits for vision-specific instruments and Rasch 
analysis has been used to estimate and evaluate latent traits, producing Rasch-scaled scores 
in preference to raw scores from questionnaire data. Subsequent applications of “classical” 
statistics such as t-tests and linear regressions are not strictly appropriate for association 
analysis of latent data as they require dependent/outcome variables to be known. The 
analysis of latent variables requires the associated measurement error to be accounted for 
as failure to do so may lead to biased estimates of correlations, associations and statistical 
inferences.  
In this study, we demonstrated the effectiveness of a modeling framework that 
integrates Rasch and regression models using HB approach that accounts for latent trait 
measurement errors, producing accurate estimation of association effects in our simulation 
study compared to the frequently used approach. Both methods applied on real data showed 
different identification of significant factors between approaches. HB one-stage “joint 
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analysis” is a better approach, producing accurate effect size estimations and information 
about the independent association of exposure variables with vision-specific latent traits. 
Extensions and future research 
Our model codes could be further improved and made into a simple graphical user 
interface program with easy implementation, to reach out to more researchers. The 
application of advanced/improved bio-statistical methodology should be encouraged to 
advance analysis of research data. 
7.1.1 Significance and Impact on Health Research 
The discipline of biostatistics is clearly a fundamental scientific component of 
biomedical, public health and health services research.5 In particular, epidemiology and 
clinical trials are two major fields of medical research that depends on statistics as a 
fundamental tool in the achievement of their goals. The focus of this thesis is on 
epidemiologic research - the study of how often diseases occur, and reasons for differences 
in different groups of people.  
Epidemiological information is used to plan and evaluate strategies to prevent illness, 
and serves as a guide for the management of patients in whom disease has already 
developed. The involvement of biostatisticians contribute in advising on the conditions for 
valid inference, from the design of the study to concerns on various sources of uncertainty 
and bias due to possible confounding factors in the evaluation of effects of potential risk 
factors for diseases. These effects are quantified by measures of association such as the 
odds ratio or relative risk, involving probabilistic concepts to be estimated appropriately 
according to the type of study (e.g. case-control, cross-sectional, cohort) and specific 
conditions for individual research project. The variety of statistical methods required in 
epidemiology is immense, where the increase in diversity of new research questions has 




It is important for researchers to communicate with biostatisticians to take full 
advantage of newly developed and advanced statistical methods to advance cutting edge 
research and knowledge. This thesis contributes in the development of modern Bayesian 
models applied to different areas of clinical and epidemiology research, to bridge the 
transfer of advanced statistical methods into the mainstream of ophthalmic research. 
Bayesian approached is useful to resolve research questions that may be difficult with 
conventional statistics. A documented “step-by-step” R codes to help researchers to 
perform their own Bayesian analysis for similar research settings was proposed.  
7.1.2 Bayes Methods and Other Modern Statistics 
The thesis is limited to development of mainly hierarchical Bayesian models focusing 
on eye research topics in clinical and epidemiological settings. There are many other 
Bayesian techniques and its applications in other disciplines that were not discussed, such 
as Bayesian approach in handling missing data, in the analyses of longitudinal data, clinical 
trials, health economics, model selection methods or survival analysis.6-7 The empirical 
Bayes is another approach to Bayesian that uses observed data to estimate final-stage prior 
(e.g. hyper-parameters) and proceed as though the priors were known (as in our usual 
Bayesian approach), that may produce superior estimates of parameters.6-11 Continual 
explorations in Bayes applications provides potential analytic benefits to advance research.  
Because research questions health research are diverse, biostatistics has expanded its 
domain to include any quantitative methods that may be used to answer these questions. 
This thesis focused on Bayesian approach as an alternative to the “classical” approach. 
Literature review on current research in biostatistics in Chapter 2 revealed other current 
popular research to be in the area of nonparametric and semi-parametric approaches to 
inference techniques and variable selection. The management of high-dimensional data, 
data mining techniques, discrimination and classification models and neural networks are 




Restricting ourselves to the use of a single specific data analysis method may impede 
the progress of research. When various statistical methods come up with different answers, 
efforts in figuring out why would lead to a better understanding of the underlying reality. 
The arising diversity of clinical questions, new research problems with increasingly 
complex study designs require both continual development of “classical” techniques and 
the creation of new statistical methods crafted for specific research scenarios.12  
In summary, efficient methodological and modeling tools should be used, especially 
in cases where the usual modeling assumptions are not applicable to the data under 
consideration. Simulation studies and data analyses of research projects provided in this 
thesis illustrate the practical utility of the Bayesian approach helps to improve and advance 
ophthalmic research. These statistical models and analyses procedures formulated (and 
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APPENDIX 1: R programming Codes 
 
Points to take note: 
Comments are in green. 
Variable names to be used according to own research data are in blue. 
Data specifications to be changed according to own research preference are in red. 
 
R Codes for Chapter 3 
 
General steps to perform conversion algorithm: 
1) Organize data spreadsheet and read into R 
2) Recode/Categorize continuous scales 
3) Run collapsed algorithm to obtain collapsed frequency table to required categories (run 
twice if both scales needs to be collapsed) 
4) Data Cleaning (any cells with conditional probabilities of < 10% were regarded as 
noise) and calculation of conditional probabilities 
 
Step 1: Data input for R 
Data spreadsheet should be arranged in the below manner and saved as .csv file type, e.g. 
“locs_w.csv”. 
 
Data Legend: sno = unique subject identifier, i.e. study number; nl = LOCS nuclear 
score; nw = Wisconsin nuclear score; cl = LOCS cortical score; cw = Wisconsin cortical 





Step 2: R programming codes to convert scores between scales 
Converting Nuclear cataract  
### R to read “locs_w.csv” spreadsheet data saved on C drive 
data<-read.csv("C:/locs_l.csv",header=T) 
 
## Step 2a) Recode LOCS (range 0-6.9) into half unit steps (14 categories), i.e. 0-0.4 




## Display nuclear Wisconsin and LOCS 14 by 5 frequency table 
u<-!is.na(nl)&!is.na(nw) 
lik<-matrix(0,ncol=5,nrow=14) 
for(i in 1:14){ 




















# Have to collapse 9 times to get 5 categories from 14 categories  









xt   # Collapsed results (frequency counts) 
 
## Step 2c) Data Cleaning – any cells with conditional probabilities of < 10% were 
regarded as noise 
## Convert Wisconsin to LOCS  
## (To convert from LOCS to Wisconsin, swap the row and column variables) 
tem1<-nl_cb   # To convert LOCS to Wisconsin, replace tem1 with variable nw, 
i.e.“tem1<-nw”     
tem2<-nw    # To convert LOCS to Wisconsin, replace tem2 with variable nl_cb, i.e. 
“tem2<-nl_cb” 
table(tem1,tem2)->ct    # Rows are LOCS, columns are Wisconsin 
result<-matrix(0,ncol=5,nrow=5) 
for(i in 1:5){ 
sum(ct[,i])->si 
result[,i]<-ct[,i]/si 





round(result,2)    # Conversion results (conditional probabilities) 
write.csv(round(result,2),"R_conver.csv",row.names=F)    # Output results into MS excel 
 
Converting Cortical cataract  
## Step 2a) Recode/Categorize both scales 
## Recode LOCS (range 0-5.9) into half unit steps (12 categories), i.e. 0-0.4 coded as 1, 







## Recode Wisconsin (range 0-100%) into 5% unit steps (20 categories), i.e. 0-4.99 





## Display cortical LOCS and Wisconsin 12 by 20 frequency table 
u<-!is.na(cl)&!is.na(cw) 
lik<-matrix(0,ncol=20,nrow=12) 
for(i in 1:12){ 





## Step 2b) Collapsed algorithm to obtain collapsed frequency table 
library(gmodels) 




while(i<=7){    # Have to collapse 7 times to get 5 categories from 12 categories 
i<-i+1 
CrossTable(cl_cb,cw_cb,prop.c=F,prop.t=F,prop.chisq=F)->ct    # 12 rows (LOCS) by 20 

















xt     # Collapsed results (frequency counts) 
 
## Collapse Wisconsin 
i<-1 
while(i<=15){    # Have to collapse 15 times to get 5 categories from 20 categories 
i<-i+1 
CrossTable(cw_cb,cl_cb,prop.c=F,prop.t=F,prop.chisq=F)->ct    # 20 rows (Wisconsin) 















xt     # Collapsed results (frequency counts) 
 
## Step 2c) Data Cleaning – any cells with conditional probabilities of < 10% were 
regarded as noise 
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## Convert Wisconsin to LOCS  
## (To convert from LOCS to Wisconsin, swap the row and column variables) 
tem1<-cl_cb    # To convert LOCS to Wisconsin, replace tem1 with variable nw, i.e. 
“tem1<-cw_cb” 
tem2<-cw_cb    # To convert LOCS to Wisconsin, replace tem2 with variable nl_cb, i.e. 
“tem2<-cl_cb” 
table(tem1,tem2)->ct    # Rows are LOCS, columns are Wisconsin 
result<-matrix(0,ncol=5,nrow=5) 








round(result,2)    # Conversion results (conditional probabilities) 
write.csv(round(result,2),"R_conver.csv",row.names=F)    # Output results into MS excel 
 
Converting PSC cataract  
## Step 2a) Recode/Categorize both scales 
## Recode LOCS (range 0-5.9) into half unit steps (12 categories), i.e. 0-0.4 coded as 1, 




## Recode Wisconsin (range 0-100%) into 0%, 1-4%, then 5% unit steps (21 categories), 










for(i in 1:12){ 





## Step 2b) Collapsed algorithm to obtain collapsed frequency table 
library(gmodels) 




while(i<=7){    # Have to collapse 7 times to get 5 categories from 12 categories 
i<-i+1 
CrossTable(pl_cb,pw_cb,prop.c=F,prop.t=F,prop.chisq=F)->ct    # 12 rows (LOCS) by 















xt     # Collapsed results (frequency counts) 
 




while(i<=16){    # Have to collapse 16 times to get 5 categories from 21 categories  
i<-i+1 
CrossTable(pw_cb,pl_cb,prop.c=F,prop.t=F,prop.chisq=F)->ct    # 20 rows (Wisconsin) 
by 5 columns (LOCS)  
ct$prop.row->cpr 
  nrow(cpr)->nr 
  cprd<-numeric(nr-1) 
  for(j in 1:(nr-1)){ 
    sum(abs(cpr[j,]-cpr[j+1,]))->cprd[j] 
  } 
  which(cprd==min(cprd))->ij 
  as.numeric(row.names(cpr)[ij])->ij1 
  as.numeric(row.names(cpr)[ij+1])->ij2 
  pw_cb2<-pw_cb 
  for(k in 1:length(ij1)){    #  For more than 2 adjacent rows to be collapsed at a time 
    pw_cb2[pw_cb==ij1[k]&!is.na(pw)]<-ij2[k] 
    pw_cb<-pw_cb2 
  } 
  i=i+(length(ij1)-1)   
} 
table(pw_cb,pl_cb)->xt;  
xt     # Collapsed results (frequency counts) 
 
## Step 2c) Data Cleaning – any cells with conditional probabilities of < 10% were 
regarded as noise 
## Convert Wisconsin to LOCS  
## (To convert from LOCS to Wisconsin, swap the row and column variables) 
tem1<-pl_cb    # To convert LOCS to Wisconsin, replace tem1 with variable nw, i.e. 
“tem1<-cw_cb” 
tem2<-pw_cb    # To convert LOCS to Wisconsin, replace tem2 with variable nl_cb, i.e. 
“tem2<-cl_cb” 




for(i in 1:5){ 
sum(ct[,i])->si 
result[,i]<-ct[,i]/si 





round(result,2)    # Conversion results (conditional probabilities) 





























R Programming Codes for Chapter 4 
 
General steps in analyses: 
a) Organize data spreadsheet and read into R  
b) Building our Bayesian Latent model (QFT, TspotTB correlated, TST independent) to: 
i. Estimate prevalence of disease, sensitivity and specificity of diagnostic tests and 
calculate their PPV and NPV 
ii. To predict “true” cell counts and analyze discordant results 
iii. Develop decision rules to evaluate optimal choice of diagnostic tests 
c) Perform sensitivity analysis 
 
Step 1: Data input for R 
Data spreadsheet should be arranged in the below manner and saved as .csv file type, e.g. 
“data.csv”. 
 
Data Legend: id = patient identifier; Diagnostic tests were coded as 1 for positive result 
and 0 for negative result. 
 
### R to read “tb_data.csv” spreadsheet data saved on C drive 
data<-read.csv("C:/data.csv",header=T) 
 
Step 2, part bi): R programming codes for Parameter Estimations 
 





## Correlated test 
y[1:4]~dmulti(p[1:4],n[1])  # multinomial distribution 
p[1]<-P*Se11+(1-P)*Sp11  # ++ 
p[2]<-P*Se12+(1-P)*Sp12  # +- 
p[3]<-P*Se21+(1-P)*Sp21  # -+ 










## covSp (covariance of specificity between related diagnostic tests) 
lSp<-(Sp[1]-1)*(1-Sp[2]);uSp<-min(Sp[1],Sp[2])-Sp[1]*Sp[2] 
covSp~dunif(lSp,uSp);rhoSp<-covSp/sqrt(Sp[1]*(1-Sp[1])*Sp[2]*(1-Sp[2])) 
##  Independent diagnostic test  
y[5]~dbin(p[5],n[2])  # binomial distribution 
p[5]<-P*Se[3]+(1-P)*(1-Sp[3]) 
 
##  Input of Prior specifications  
for(k in 1:3){ 
Se[k]~dbeta(beta_Se[k,1],beta_Se[k,2])  # informative beta prior distribution for 
sensitivity 
Sp[k]~dbeta(beta_Sp[k,1],beta_Sp[k,2])  # informative beta prior distribution for 
specificity 
PPV[k]<-Se[k]*P/(Se[k]*P+(1-Sp[k])*(1-P))  # calculation of PPV 
NPV[k]<-Sp[k]*(1-P)/(Sp[k]*(1-P)+(1-Se[k])*P)  # calculation of NPV 
} 





### Step 2b) Execute Bayesian model 




## Specification of informative beta priors for Sensitivity & Specificity of all 3 
diagnostic tests (in the order of TST, TspotTB, QFT) derived from previous literature 
mm=c(709,683,500,906,642,996)/1000  # prior – mean 
ml=c(658,522,334,882,593,989)/1000  # prior – lower limit 






beta_P=c(1,1)  # non-informative beta prior distribution for prevalence 
 
tem_data=data[,c("TspotTB","QFT")] 
y=table(tem_data);y=y[c(2,1),c(2,1)];y=c(y[1,],y[2,])  # cell counts for TspotTB & QFT 
n=sum(y)  # total counts, i.e. sample size 
tem_data=data[,"TST"] 
tem_data=tem_data[!is.na(tem_data)] 
y=c(y,sum(tem_data))  # to include positive counts for TST 
n=c(n,length(tem_data))  # to include sample size of TST 
 
dat=list("y","n","beta_Se","beta_Sp","beta_P") 
parameters=c("P","Se","Sp","PPV","NPV","rhoSe","rhoSp")  # parameters to be tracked 
for their posterior distributions 
inits=function(){list(P=0.5,Se=c(0.5,0.5,0.5),Sp=c(0.5,0.5,0.5))}  # initial values 
set.seed(1213)  # set seed number 
## R to launch JAGS software and load and run “model.txt” 
corr2ind1=jags.parallel(dat,inits,parameters,model.file="model.txt",n.chains=2,n.iter=25
000,n.burnin=5000,DIC=F,digits = 5,working.directory=getwd()) 
corr2ind1$BUGSoutput$summary[,c("2.5%", "50%", "97.5%")]  # display results 
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Step 2, part bii): To predict “true” cell counts and analyze discordant results 
###To include the below into model.txt in Step 2a above & re-run analyses 
 
###  TSpotTB & QFT (correlated tests) 
P_pred[1,1]<-P*Se11/p[1]  # ++ 
P_pred[1,2]<-P*Se12/p[2]  # +- 
P_pred[1,3]<-P*Se21/p[3]  # -+ 
P_pred[1,4]<-P*Se22/p[4]  # -- 
for(i in 1:4){N_pred[1,i]~dbin(P_pred[1,i],Y[1,i])} 
 
###  T-SPOT.TB & TST (independent tests) 
P_pred[2,1]<-(Se[1]*Se[3]*P)/(Se[1]*Se[3]*P+(1-Sp[1])*(1-Sp[3])*(1-P))  # ++ 
P_pred[2,2]<-(Se[1]*(1-Se[3])*P)/(Se[1]*(1-Se[3])*P+(1-Sp[1])*Sp[3]*(1-P))  # +- 
P_pred[2,3]<-(Se[3]*(1-Se[1])*P)/(Se[3]*(1-Se[1])*P+(1-Sp[3])*Sp[1]*(1-P))  # -+ 
P_pred[2,4]<-((1-Se[1])*(1-Se[3])*P)/((1-Se[1])*(1-Se[3])*P+Sp[1]*Sp[3]*(1-P))  # -- 
for(i in 1:4){N_pred[2,i]~dbin(P_pred[2,i],Y[2,i])} 
 
###  QFT & TST (independent tests) 
P_pred[3,1]<-(Se[2]*Se[3]*P)/(Se[2]*Se[3]*P+(1-Sp[2])*(1-Sp[3])*(1-P)) # ++ 
P_pred[3,2]<-(Se[2]*(1-Se[3])*P)/(Se[2]*(1-Se[3])*P+(1-Sp[2])*Sp[3]*(1-P)) # +- 
P_pred[3,3]<-(Se[3]*(1-Se[2])*P)/(Se[3]*(1-Se[2])*P+(1-Sp[3])*Sp[2]*(1-P)) # -+ 
P_pred[3,4]<-((1-Se[2])*(1-Se[3])*P)/((1-Se[2])*(1-Se[3])*P+Sp[2]*Sp[3]*(1-P)) # -- 
for(i in 1:4){N_pred[3,i]~dbin(P_pred[3,i],Y[3,i])} 
 
for(i in 1:3){Ratio[i]<-P_pred[i,2]/P_pred[i,3]} 
 
Step 2, part biii): Optimal choice of diagnostic test 
###To include the below into model.txt in Step 2a above & re-run analyses 
for(i in 1:NP){ 
for(k in 1:3){risk[k,i]<-(1-Se[k])*PP[i]+(1-Sp[k])*(1-PP[i])} 
} 
## Plot to illustrate sequential testing of QFT, TSpot.TB and TST 





rate)",xlab="Probability of Tuberculous Uveitis",lwd=2,lty=2)   
## To add risk line for TspotTB in plot 
i=2;temi=model$BUGSoutput$summary[paste("risk[",i,",",1:NP,"]",sep=""),"50%"] 
lines(PP,temi,lty=1,lwd=2) 





Part c) Step 3: Sensitivity analysis 
 






## Repeat model analysis documented above to investigate if our data or priors are 
driving model results. Varying posterior distributions should be observed with the 
application of multiple trial or mock data. 
 
## To re-run analyses using informative prior based on information obtained previous 













R Programming Codes for Chapter 5 
 
General steps in analyses: 
a) Build Hierarchical Bayesian model to pool overall and subgroup prevalence estimates:  
i. Ethnicity  
ii. Geographic regions 
b) Projection of number of people with AMD by regions 
c) Bayesian hypothesis testing to examine ethnicity effect  
(codes can be expanded/modified for analysis of gender, region, publication year effects) 
 
Step 1: Data input for R 
Data spreadsheet should be arranged in the below manner and saved as .csv file type, e.g. 
“amd_data.csv”. 
 
Data Legend: study = study name abbreviation; year = publication year; gender coded as 
1 for male, 2 for female and 3 for both; n = study sample size; ye = number of subjects 
with early amd; yl = number of subjects with late amd; yb = number of subjects with any 
amd; region_wl = geographical region coded as 1 for Africa, 2 for Asia, 3 for Europe, 4 
for Altin America & Caribbean, 5 for Northern America, 6 for Oceania; race_wl = 
ethnicity coded as 1 for African, 2 for Asian, 3 for European, 4 for Hispanic, 5 for Others. 
 
### R to read “amd_data.csv” spreadsheet data saved on C drive 
data_amd<-read.csv("C:/amd_data.csv",header=T) 
 
Step 2, part a): R programming codes for Meta-analysis 
 










## Data manipulation 
# Create agel variable – lower bound of age group 




# Create ageu variable – upper bound of age group 















for(i in 1:Ns){ 
  studyi=studyu[i]   
  ## Region  
  regioni=unique(tem_data$region_wl[tem_data$study==studyi]) 
  temi=tem_data[tem_data$study==studyi & tem_data$region_wl==regioni,] 
  if(sum(temi$gender==3)>0){   # Need to drop male only studies 
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    temi=temi[temi$gender==3,] 
    ybi=sum(temi$yb);yei=sum(temi$ye);yli=sum(temi$yl);ni=sum(temi$n) 
    ageuidi=max(temi$ageuid);ageui=max(temi$ageu);ageli=min(temi$agel) 
datai=data.frame(sname=studyi,n=ni,ye=yei,yl=yli,yb=ybi,agel=ageli,ageu=ageui,ageuid
=ageuidi,region=regioni)     
    data3=rbind(data3,datai) 
  }else if(sum(temi$gender==1)>0 & sum(temi$gender==2)>0){ 
    temi=temi[temi$gender==1 | temi$gender==2,]  
    ybi=sum(temi$yb);yei=sum(temi$ye);yli=sum(temi$yl);ni=sum(temi$n) 
    ageuidi=max(temi$ageuid);ageui=max(temi$ageu);ageli=min(temi$agel)    
datai=data.frame(sname=studyi,n=ni,ye=yei,yl=yli,yb=ybi,agel=ageli,ageu=ageui,ageuid
=ageuidi,region=regioni) 
    temi1=temi[temi$gender==1,];temi1=temi1[order(temi1$agegp),] 
    temi2=temi[temi$gender==2,];temi2=temi2[order(temi2$agegp),] 
    data3=rbind(data3,datai) 
  } 
   
  ## Ethnicity 
  racei=unique(tem_data$race_wl[tem_data$study==studyi]) 
  for(j in 1:length(racei)){ 
    temi=tem_data[tem_data$study==studyi & tem_data$race_wl==racei[j],] 
    if(sum(temi$gender==3)>0){   # Need to drop male only studies 
      temi=temi[temi$gender==3,]       
      ybi=sum(temi$yb);yei=sum(temi$ye);yli=sum(temi$yl);ni=sum(temi$n) 
      ageuidi=max(temi$ageuid);ageui=max(temi$ageu);ageli=min(temi$agel) 
datai=data.frame(sname=studyi,n=ni,ye=yei,yl=yli,yb=ybi,agel=ageli,ageu=ageui,ageuid
=ageuidi,race=racei[j]) 
      data4=rbind(data4,datai) 
      check4=c(check4,0) 
    }else if(sum(temi$gender==1)>0 & sum(temi$gender==2)>0){ 
      ybi=sum(temi$yb);yei=sum(temi$ye);yli=sum(temi$yl);ni=sum(temi$n) 





      temi1=temi[temi$gender==1,];temi1=temi1[order(temi1$agegp),] 
      temi2=temi[temi$gender==2,];temi2=temi2[order(temi2$agegp),] 
      data4=rbind(data4,datai) 
    } 
  } # j 
} # i 
 





### Step 2a) Building/Setting up model and save as text file in your R working 
directory 
## Prevalence estimation 
## Part a, i) By ethnicity (to use data4) 
## Model for overall pooled prevalence – saved as “pooledS_map.txt” 
model{ 






# Non-informative gamma prior distribution specified for tau 
tau~dgamma(0.01,0.01);sigma<-pow(tau,-1/2) 
# Non-informative normal prior distribution for regression coefficients 
for(i in 1:NZ){Zbeta[i]~dnorm(0,0.0001)} 
for(i in 1:NS){Sbeta[i]~dnorm(0,Stau)} 







## Model for pooled prevalence by ethnicity – saved as “pooledXS_map.txt” 
model{ 






# Non-informative gamma prior distribution specified for tau (residual variability) 
tau~dgamma(0.01,0.01);sigma<-pow(tau,-1/2) 
# Non-informative normal prior distribution for regression coefficients 
for(i in 1:NZ){Zbeta[i]~dnorm(0,0.0001)} 
for(i in 1:NS){Sbeta[i]~dnorm(0,Stau)} 
# Non-informative gamma prior distribution specified for Stau & Xtau (between study & 
between race variability) 
Stau~dgamma(0.01,0.01);Ssigma<-pow(Stau,-1/2) 
for(i in 1:NX){Xbeta[i]~dnorm(0,Xtau)} 
Xtau~dgamma(0.01,0.01);Xsigma<-pow(Xtau,-1/2) 
 
for(i in 1:NX){logit(P[i])<-Zbeta[1]+Xbeta[i]} 
} 
 
## Part a, ii) By regions (to use data3) 
## Model for overall pooled prevalence – saved as “pooled_map.txt” 
model{ 






# Non-informative gamma prior distribution specified for tau 
tau~dgamma(0.01,0.01);sigma<-pow(tau,-1/2) 
# Non-informative normal prior distribution for regression coefficients 
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## Model for pooled prevalence by regions – saved as “pooledX_map.txt” 
model{ 






# Non-informative gamma prior distribution specified for tau (residual variability) 
tau~dgamma(0.01,0.01);sigma<-pow(tau,-1/2) 
# Non-informative normal prior distribution for regression coefficients 
for(i in 1:NZ){Zbeta[i]~dnorm(0,0.0001)} 
for(i in 1:NX){Xbeta[i]~dnorm(0,Xtau)} 




for(i in 1:NX){logit(P[i])<-Zbeta[1]+Xbeta[i]} 
} 
 
### Step 2b) Execute HB model 
## Part b, i) By ethnicity 
data42=data4[data4$race!=5,]   # Drop “others” race data 
set.seed(1213) 
pools=list();pools_race=list() 
for(i in 3:5){ 
  cat(paste("\n\n...",i,"...",sep="")) 
  tem_data=data42[!(is.na(data42[,i])),] 
  y=tem_data[,i];n=tem_data$n;N=nrow(tem_data);study<-tem_data$study 
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  map=cbind((tem_data$agedl-mean(tem_data$agedl))/sd(tem_data$agedl), 
(tem_data$agedu-mean(tem_data$agedu))/sd(tem_data$agedu),tem_data$ageuid) 
   
  Z=cbind(1,map);NZ=ncol(Z);S<-dummy(study);NS<-ncol(S) 
  dat<-list("n","y","N","Z","NZ","S","NS") 
  parameters<-c("p","P") 
  inits<-function(){list(tau=1,Stau=1)} 
  pools[[i-2]]<-jags.parallel(dat, inits, parameters,  
model.file = "pooledS_map.txt",n.chains=2,n.iter=50000,n.burnin=5000,DIC=F, 
digits = 5,working.directory=getwd()) 
   
  X=dummy(tem_data$race);NX=ncol(X) 
  dat<-list("n","y","N","Z","NZ","S","NS","X","NX") 
  parameters<-c("P") 
  inits<-function(){list(tau=1,Stau=1,Xtau=1)} 
  pools_race[[i-2]]<-jags.parallel(dat, inits, parameters,  




## By ethnicity 
# Display overall pooled early amd prevalence 
pools[[1]]$BUGSoutput$summary["P", c("2.5%","50%","97.5%")]*100 
# Display overall pooled late amd prevalence 
pools[[2]]$BUGSoutput$summary["P", c("2.5%","50%","97.5%")]*100 
# Display overall pooled any amd prevalence 
pools[[3]]$BUGSoutput$summary["P", c("2.5%","50%","97.5%")]*100 
 
# Display pooled early amd prevalence by race 
pools_race[[1]]$BUGSoutput$summary[, c("2.5%","50%","97.5%")]*100 
# Display overall pooled late amd prevalence by race 
pools_race[[2]]$BUGSoutput$summary[, c("2.5%","50%","97.5%")]*100 









for(i in 3:5){ 
  cat(paste("\n\n...",i,"...",sep="")) 
  tem_data=data32[!(is.na(data32[,i])),] 
  y=tem_data[,i];n=tem_data$n;N=nrow(tem_data) 
   
  map=cbind((tem_data$agedl-mean(tem_data$agedl))/sd(tem_data$agedl), 
(tem_data$agedu-mean(tem_data$agedu))/sd(tem_data$agedu),tem_data$ageuid) 
   
  Z=cbind(1,map);NZ=ncol(Z) 
  dat<-list("n","y","N","Z","NZ") 
  parameters<-c("p","P") 
  inits<-function(){list(tau=1)} 
  pools[[i-2]]<-jags.parallel(dat, inits, parameters, model.file = "pooled_map.txt", 
n.chains=2,n.iter=50000,n.burnin=5000,DIC=F,digits = 5,working.directory=getwd()) 
    
  X=dummy(tem_data$region);NX=ncol(X) 
  dat<-list("n","y","N","Z","NZ","X","NX") 
  parameters<-c("P") 
  inits<-function(){list(tau=1,Xtau=1)} 
  pools_region[[i-2]]<-jags.parallel(dat, inits, parameters, 
 model.file = "pooledX_map.txt",n.chains=2,n.iter=80000,n.burnin=8000,DIC=F,digits = 
5,working.directory=getwd()) 
} 
# Display overall pooled early amd prevalence 
pools[[1]]$BUGSoutput$summary["P", c("2.5%","50%","97.5%")]*100 
# Display overall pooled late amd prevalence 
pools[[2]]$BUGSoutput$summary["P", c("2.5%","50%","97.5%")]*100 





# Display pooled early amd prevalence by region 
pools_region[[1]]$BUGSoutput$summary[, c("2.5%","50%","97.5%")]*100 
# Display overall pooled late amd prevalence by region 
pools_region[[2]]$BUGSoutput$summary[, c("2.5%","50%","97.5%")]*100 
# Display overall pooled any amd prevalence by region 
pools_region[[3]]$BUGSoutput$summary[, c("2.5%","50%","97.5%")]*100 
 
Step 3, part b: Projection of Number of People with AMD by Regions 
## Region-specific estimated prevalence rates obtained in part a) were multiplied to the 











for(j in 1:6){ 
  for(i in 1:length(years)){     
output_low[j,i]=sum(pools_region[[3]]$BUGSoutput$summary[j,c("2.5%")]*projs[whic
h(projs$year==years[i] & projs$region==regions[j]),c(8:14,16)])   
output_mid[j,i]=sum(pools_region[[3]]$BUGSoutput$summary[j,c("50%")]*projs[which
(projs$year==years[i] & projs$region==regions[j]),c(8:14,16)])   
output_upper[j,i]=sum(pools_region[[3]]$BUGSoutput$summary[j,c("97.5%")]*projs[w
hich(projs$year==years[i] & projs$region==regions[j]),c(8:14,16)]) 
  } #i 
} #j 
j=7 




js$year==years[i] & projs$region==regions[j]),c(8:14,16)])    
output_mid[j,i]=sum(pools [[3]]$BUGSoutput$summary["P",c("50%")]* 
projs[which(projs$year==years[i] & projs$region==regions[j]),c(8:14,16)])    
output_upper[j,i]=sum(pools [[3]]$BUGSoutput$summary["P",c("97.5%")]* 
projs[which(projs$year==years[i] & projs$region==regions[j]),c(8:14,16)]) 
  } #i 
} #j 
   





## To repeat for early and late AMD projections, i.e. “[[1]]” for early, “[[2]]” for late 
 
Step 4, part c: Bayesian hypothesis testing to examine effects 
### Step 4a) Building/Setting up model and save as text file in your R working 
directory 
## By ethnicity (to use data4) 
## Model – saved as “VSS.txt” 
model{ 








for(i in 1:NS){Sbeta[i]~dnorm(0,Stau)} 
Stau~dgamma(0.001,0.001);Ssigma<-pow(Stau,-1/2) 
 
for(i in 1:(NX+1)){gbeta[i]<-g[i]*Xbeta[i]} 
 153 
 
g[1]<-1;for(i in 2:(NX+1)){g[i]~dbern(0.5)} 
 
Xbeta[1:(NX+1)]~dmnorm(mb[1:(NX+1)],T[1:(NX+1),1:(NX+1)]) 
#Mu for Xbeta 
for(i in 1:(NX+1)){mb[i]<- (1-g[i])*prop.mean[i]}  # g[] is the variable selection variable 
#Tau for Xbeta 
for(i in 1:(NX+1)){ 








### Step 4b) Execute HB model 
## Execute model in similar manner as Step 2b above 
inits<-function(){list(tau=1,Stau=1)} 
parameters<-c("Xbeta","sigma","g","mm") 
vs<-jags.parallel(dat, inits, parameters, model.file = 
"VSS.txt",n.chains=2,n.iter=100000,n.burnin=10000,DIC=F,digits = 5, 
working.directory=getwd()) 
 













R Programming Codes for Chapter 6 
 
Steps to perform “one-stage” HB association analysis: 
a) Organize data spreadsheet and read into R  
b) Perform association analysis:  
i. Build the “one-stage” HB model  
ii. Execute the “one-stage” HB model 
(note that the validity of instrument should be determined before association analysis) 
 
Step 1: Data input for R 




Data Legend: sno = patient number; age_rec = age; gender coded as 0 for male, 1 for 
female; bmi = body mass index; smks_curr coded as 1 for current smoker and 0 for past 
or non-smoker; read coded as 1 for can read and 0 for can’t read; write coded as 1 for can 
write and 0 for can’t write; vfstair_rev to vftelbk_rev are the 9 items in modified VF-9 
questionnaire, each item graded on level of difficulty on scale of 1 to 4 where 4 = a little, 
3 = moderate, 2 = a great deal, 1 = unable to do activity.  
 
Step 2: R programming codes for Association analysis 
### Step 2a) Building/Setting up model and save as “model.txt” in your R working 
directory 
model { 
for (i in 1:N) { 
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for (k in 1:K) { 
for (c in 1:C) { q[i,k,c]<-exp(1.7*(c-1)*(theta[i]-eta[k])-sum(gamma[1:c])) }   ## 
Andrich model 
for (c in 1:C) { p[i,k,c]<-q[i,k,c]/sum(q[i,k,1:C]) }  
Y[i,k]~dcat(p[i,k,1:C]) 
}  
mutheta[i]<-inprod(X[i,],beta[])   ## Regression model 
theta[i]~dnorm(mutheta[i],tau)    
}  
## Difficulty or location parameter 





for (c in 2:C) { gamma[c]~dnorm(0,1) } 
## Beta and Sigma for Theta 




### Step 2b) Execute “one-stage” HB model 





N=3280  # specify the sample size of data 
K=9  # specify number of items in instrument/questionnaire 
C=4  ## specify number of categories in each item 
 














###  ONE - Stage  ### 
X=tem_data[,1:12]  # X: risk factors 
Y=tem_data[,13:21]  # Y: instrument items 
colnames(X)  # display variable names 
cats=c(1:2,4:15)  # variables that are categorical 
 
tem_X=NULL;name_X=NULL 
for(i in 1:ncol(X)){ 
  if(i %in% cats){ 
    tem_X=cbind(tem_X,dummy(X[,i])[,-1]) 
    name_X=c(name_X,paste(colnames(X)[i],2:length(unique(X[,i])),sep="")) 
  }else{ 
    tem_X=cbind(tem_X,X[,i]) 
    name_X=c(name_X,colnames(X)[i]) 
























## Output estimations of association effects (of latent trait) and its 95% credible intervals 
into Excel 



























Supplementary Table 3.1 Collapsed contingency table between LOCS III and 
Wisconsin system for nuclear opalescence, cortical and posterior subcapsular 
cataract (PSC). 
 
LOCS III Wisconsin system 
Nuclear      
 1 2 3 4 5 
0.1-2.9 64 1038 635 26 0 
3.0-3.9 34 867 1431 146 0 
4.0-4.9 4 93 559 493 5 
5.0-6.4 0 2 34 281 38 
6.5-6.9 0 0 0 13 26 
      
Cortical      
 0-4 5-44 45-74 75-79 80-100 
0.1-1.4 3750 134 0 0 0 
1.5-2.4 307 280 2 0 0 
2.5-3.9 89 764 17 0 3 
4.0-5.4 5 143 77 1 6 
5.5-5.9 0 3 5 0 9 
      
PSC      
 0-4 5-29 30-64 65-69 70-100 
0.1-2.9 5246 100 0 0 0 
3.0-4.4 20 98 27 0 0 
4.5-4.9 0 2 9 1 0 
5.0-5.4 1 12 14 0 8 
5.5-5.9 0 3 12 3 3 













Supplementary Table 4.1 Data for Meta-analysis for prevalence of tuberculous 
uveitis 






2008 Kazokoglu et al. 1 Turkey 761 3 0.3% 
2008 Pathanapithoon et 
al. 2 
Thailand 200 3 2.2% 
2007 Khairallah et al. 3 Tunisia 472 5 1.1% 
2007 Rathinam and 
Namperumalsamy4 
India 8759 488 5.6% 
2005 Yang et al. 5 China 1752 13 0.7% 
2005 Sengun et al. 6 Turkey 300 4 1.3% 
2004 Soheilian et al. 7 Iran 544 8 1.5% 
2004 Singh et al. 8 India 1233 125 10.1% 
2003 Wakabayashi et al. 
9 
Japan 189 13 6.9% 




200 21 10.5% 
2002 Morimura11 Japan 126 10 7.9% 
2001 Mercanti et al. 12 Italy 655 46 7.02% 
1998 Kaimbo wa 
Kimbo et al. 13 
Congo 336 30 6% 
1997 Kotake et al. 14 Japan 551 1 0.2% 
1997 Merrill et al. 15 USA 385 2 0.5% 
1996 Rodriguez et al. 16 USA 1273 8 0.06% 
1996 Thean et al. 17 UK 712 2 0.28% 
1995 Das et al. 18 India 465 3 0.6% 
1993 Smit et al.19 Netherland 750 20 2.7% 
1992 Rothova et al. 20 Netherland 865 12 1.4% 
1991 Weiner and 
BenEzra21 
Israel 400 3 0.7% 
1990 Palmares et al. 22 Portugal 450 10 2.2% 
1987 Henderly et al. 23 USA 600 1 0.2% 
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Supplementary Table 5.1 Global Population-Based Studies included in Meta-analysis  
* ‘-‘ represents prevalence data were not published and thus unavailable.  
† (1), International classification and grading system for age-related maculopathy and age-related macular degeneration; (2), Wisconsin Age-
related Maculopathy Grading System; and (3), Rotterdam Staging System.  
 
World 



















Asia Andhra Pradesh Eye Disease Study
1  
(Andhra Pradesh, India) APEDS 2005 40-70+ - - 71 86.7% 3723  (1) Asian 
 Beijing Eye Study (Beijing, China)2 Beijing 2006 40-75+ 63 9  - 83.4% 4376  (2) Asian 
 Funagata Study (Funagata, Japan)3 Funagata 2008 35-75+ 58 8  - 53.3% 1625  (1), (2) Asian 
 Hisayama Study (Fukuoka, Japan)4 Hisayama 2001 50-80+ 178 13  - 60.7% 1486  (1), (2) Asian 
 INDEYE Study (Haryana, North India)5 INDEYE 2007 50-80 77 15  - 
 
87.6% 1260 (2) Asian 
 Shihpai Eye Study (Taipei, Taiwan)6 Shihpai 2008 50-80+ 97 20  - 66.6% 1361 (2) Asian 
 Singapore Malay Eye Study (Singapore)7 SiMES 2008 40-80 160 23  - 
 
78.7% 3280  (2) Asian 
 Handan Eye Study (Hebei Province, China)8 Handan 2011 30-70+ 241 4  - 90.3% 6830  (2) Asian 
 Central India Eye and Medical Study
9  
(Nagpur, India) CIEMS 2011 30-80+ 215 7 
 
- 80.1% 4711  (2) Asian 
 
Thailand  
(7 regions: central, north, northeast, south, 
east, west, and Bangkok metropolitan area)10 
Thailand 2011 50-80+ 294 27  - 66.7% 21711  (1) Asian 
 Singapore Prospective Study Program (Singapore)11 SP2 2012 40-80+ - - 211 72.0% 5157  (2) Asian 





 Reykjavik Eye Study (Reykjavik, Iceland)13 RS 2003 50-80+ 338 32  75.8% 1045 (1), (2) European ancestry 
 Crete, Greece14 Crete 1999 40-80+ 76 15 - 70.6% 777 (2), (3) European ancestry 
 Oslo Macular Study (Oslo, Norway)15 Oslo 2006 51-90+ 197 13 - 59.6% 770  (1) European ancestry 
 Oulu Country, Finland16 Oulu 1995 70-90+ 160 39 - 89% 500 (1) European ancestry  
 Salandra, Southern Italy17 Salandra 1997 60-75+ - - 147 63.5% 366 (1) European ancestry  
 Copenhagen City Eye Study (Copenhagen,  Denmark)18 Copenhagen 1995 60-80+ 151 112 - 75% 946 (2) 
European 
ancestry 
 Tromso Eye Study (Tromso, Norway)19 Tromso 2012 65-87+ 892 92 - 87% 3025  (1) European ancestry 
 Spanish Eyes Epidemiological Study (Spain)20 SEE 2010 65-80+ 225 10 - 70.9% 2132  (1) European ancestry 





Londrina, Brazil22 Londrina 2008 60-80+ 66 6  80.5% 483  (1) Asian 
 Barbados Eye Study (Barbados, West Indies)23 BES 1995 40-80+ 561 19 - 83.4% 3444 (1) African ancestry 
Africa  Nakura, Kenya24 Kenya 2013 50-80+ 366 38 - 88.1% 4414 (1) African ancestry 
Northern 
America Greenland Inuit Study (Greenland)
25 GIES 2008 60-80+ 328 61 - 74.8% 695  (2) Others 






Atherosclerosis Risk in Communities Study 
(North Carolina, Minneapolis, Maryland, 
USA)27 





 Beaver Dam Eye Study (Wisconsin, USA)28 BDES 1992 43-75+ 773 79 - 83.1% 4771  (2) European ancestry 
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Cardiovascular Health Study (Pennsylvania, 
North Carolina, California and Maryland, 
USA)30 





 Los Angeles Latino Eye Study  (California, USA)31 LALES 2004 40-80+ 551 25 - 88.0% 6870  (2) Hispanic 
 
Multi-ethnic Study of Atherosclerosis 
(Maryland, Illinois, North Carolina, 
California, New York and Minnesota, USA)32 






 Proyecto VER (Arizona, USA)33 VER 2005 50-80+ 676 15 - 72% 4774  (2) Hispanic 
 Chesapeake Bay Watermen  (Maryland, USA)34 
Chesapeake 
Bay 1989 30-79 - 8 - 70% 755  (2) 
European 
ancestry 
 Vision Keepers Study (Oklahoma, USA)35 VKS 2011 48-82+ 339 21 - 66.7% 1019 (2) Others (Indian) 
 National Health and Nutrition Examination Survey (USA)36 
NHANES05-





 Beaver Dam Offspring Study  (Wisconsin, USA)37  BOSS 2010 21-84+ 95 0 - 66.2% 3285 (2) 
European 
ancestry 
Oceania Blue Mountains Eye Study  (Sydney, Australia)38 BMES 1995 49-85+ 423 101 - 82.4% 3654  (2) 
European 
ancestry 





References for Supplementary Table 5.1 
1. Krishnaiah S, Das T, Nirmalan PK, et al. Risk factors for age-related macular 
degeneration: findings from the Andhra Pradesh eye disease study in South India. Invest 
Ophthalmol Vis Sci 2005;46(12):4442-9. 
2. Li Y, Xu L, Jonas JB, et al. Prevalence of age-related maculopathy in the adult 
population in China: the Beijing eye study. Am J Ophthalmol 2006;142(5):788-93. 
3. Kawasaki R, Wang JJ, Ji GJ, et al. Prevalence and risk factors for age-related 
macular degeneration in an adult Japanese population: the Funagata study. 
Ophthalmology 2008;115(8):1376-81, 81 e1-2. 
4. Oshima Y, Ishibashi T, Murata T, et al. Prevalence of age related maculopathy in 
a representative Japanese population: the Hisayama study. Br J Ophthalmol 
2001;85(10):1153-7. 
5. Gupta SK, Murthy GV, Morrison N, et al. Prevalence of early and late age-
related macular degeneration in a rural population in northern India: the INDEYE 
feasibility study. Invest Ophthalmol Vis Sci 2007;48(3):1007-11. 
6. Chen SJ, Cheng CY, Peng KL, et al. Prevalence and associated risk factors of 
age-related macular degeneration in an elderly Chinese population in Taiwan: the Shihpai 
Eye Study. Invest Ophthalmol Vis Sci 2008;49(7):3126-33. 
7. Kawasaki R, Wang JJ, Aung T, et al. Prevalence of age-related macular 
degeneration in a Malay population: the Singapore Malay Eye Study. Ophthalmology 
2008;115(10):1735-41. 
8. Yang K, Liang YB, Gao LQ, et al. Prevalence of age-related macular 
degeneration in a rural Chinese population: the Handan Eye Study. Ophthalmology 
2011;118(7):1395-401. 
9. Nangia V, Jonas JB, Kulkarni M, Matin A. Prevalence of age-related macular 
degeneration in rural central India: the Central India Eye and Medical Study. Retina 
2011;31(6):1179-85. 
10. Jenchitr W, Ruamviboonsuk P, Sanmee A, Pokawattana N. Prevalence of age-
related macular degeneration in Thailand. Ophthalmic Epidemiol 2011;18(1):48-52. 
11. Cheung CM, Tai ES, Kawasaki R, et al. Prevalence of and risk factors for age-
related macular degeneration in a multiethnic Asian cohort. Arch Ophthalmol 
2012;130(4):480-6. 
12. Augood CA, Vingerling JR, de Jong PT, et al. Prevalence of age-related 
maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol 
2006;124(4):529-35. 
13. Jonasson F, Arnarsson A, Sasaki H, et al. The prevalence of age-related 
maculopathy in iceland: Reykjavik eye study. Arch Ophthalmol 2003;121(3):379-85. 
14. Kozobolis VP, Detorakis ET, Tsilimbaris MK, et al. Correlation between age-
related macular degeneration and pseudoexfoliation syndrome in the population of Crete 
(Greece). Arch Ophthalmol 1999;117(5):664-9. 
15. Bjornsson OM, Syrdalen P, Bird AC, et al. The prevalence of age-related 
maculopathy (ARM) in an urban Norwegian population: the Oslo Macular study. Acta 
Ophthalmol Scand 2006;84(5):636-41. 
16. Laatikainen L, Hirvela H. Prevalence and visual consequences of macular 
changes in a population aged 70 years and older. Acta Ophthalmol Scand 
1995;73(2):105-10. 
17. Pagliarini S, Moramarco A, Wormald RP, et al. Age-related macular disease in 
rural southern Italy. Arch Ophthalmol 1997;115(5):616-22. 
 166 
 
18. Vinding T. Age-related macular degeneration. An epidemiological study of 1000 
elderly individuals. With reference to prevalence, funduscopic findings, visual 
impairment and risk factors. Acta Ophthalmol Scand Suppl 1995(217):1-32. 
19. Erke MG, Bertelsen G, Peto T, et al. Prevalence of age-related macular 
degeneration in elderly Caucasians: the Tromso Eye Study. Ophthalmology 
2012;119(9):1737-43. 
20. Spanish Eyes Epidemiological Study G. Prevalence of age-related macular 
degeneration in Spain. Br J Ophthalmol 2011;95(7):931-6. 
21. Ngai LY, Stocks N, Sparrow JM, et al. The prevalence and analysis of risk 
factors for age-related macular degeneration: 18-year follow-up data from the Speedwell 
eye study, United Kingdom. Eye (Lond) 2011;25(6):784-93. 
22. Oguido AP, Casella AM, Matsuo T, et al. Prevalence of age-related macular 
degeneration in Japanese immigrants and their descendants living in Londrina (PR) - 
Brazil. Arq Bras Oftalmol 2008;71(3):375-80. 
23. Schachat AP, Hyman L, Leske MC, et al. Features of age-related macular 
degeneration in a black population. The Barbados Eye Study Group. Arch Ophthalmol 
1995;113(6):728-35. 
24. Mathenge W, Bastawrous A, Peto T, et al. Prevalence of age-related macular 
degeneration in Nakuru, Kenya: a cross-sectional population-based study. PLoS Med 
2013;10(2):e1001393. 
25. Andersen MV, Rosenberg T, la Cour M, et al. Prevalence of age-related 
maculopathy and age-related macular degeneration among the inuit in Greenland. The 
Greenland Inuit Eye Study. Ophthalmology 2008;115(4):700-7 e1. 
26. Klein R, Klein BE, Jensen SC, et al. Age-related maculopathy in a multiracial 
United States population: the National Health and Nutrition Examination Survey III. 
Ophthalmology 1999;106(6):1056-65. 
27. Klein R, Clegg L, Cooper LS, et al. Prevalence of age-related maculopathy in the 
Atherosclerosis Risk in Communities Study. Arch Ophthalmol 1999;117(9):1203-10. 
28. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The 
Beaver Dam Eye Study. Ophthalmology 1992;99(6):933-43. 
29. Friedman DS, Katz J, Bressler NM, et al. Racial differences in the prevalence of 
age-related macular degeneration: the Baltimore Eye Survey. Ophthalmology 
1999;106(6):1049-55. 
30. Klein R, Klein BE, Marino EK, et al. Early age-related maculopathy in the 
cardiovascular health study. Ophthalmology 2003;110(1):25-33. 
31. Varma R, Fraser-Bell S, Tan S, et al. Prevalence of age-related macular 
degeneration in Latinos: the Los Angeles Latino eye study. Ophthalmology 
2004;111(7):1288-97. 
32. Klein R, Klein BE, Knudtson MD, et al. Prevalence of age-related macular 
degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. 
Ophthalmology 2006;113(3):373-80. 
33. Munoz B, Klein R, Rodriguez J, et al. Prevalence of age-related macular 
degeneration in a population-based sample of Hispanic people in Arizona: Proyecto VER. 
Arch Ophthalmol 2005;123(11):1575-80. 
34. Bressler NM, Bressler SB, West SK, et al. The grading and prevalence of 
macular degeneration in Chesapeake Bay watermen. Arch Ophthalmol 1989;107(6):847-
52. 
35. Butt AL, Lee ET, Klein R, et al. Prevalence and risks factors of age-related 




36. Klein R, Chou CF, Klein BE, et al. Prevalence of age-related macular 
degeneration in the US population. Arch Ophthalmol 2011;129(1):75-80. 
37. Klein R, Cruickshanks KJ, Nash SD, et al. The prevalence of age-related macular 
degeneration and associated risk factors. Arch Ophthalmol 2010;128(6):750-8. 
38. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy 
in Australia. The Blue Mountains Eye Study. Ophthalmology 1995;102(10):1450-60. 
39. VanNewkirk MR, Nanjan MB, Wang JJ, et al. The prevalence of age-related 
















Supplementary Table 5.2 Sensitivity Analysis 
Data are % (95% credible intervals) 
  Any AMD Early AMD Late AMD 








































Supplementary Table 5.3 Bayesian Hypothesis Testing of Gender, Ethnicity, Region 
and Publication Year Effect on the Prevalence of AMD subtypes 
*Bayes factor describes level of statistical evidence: negative evidence (BF <1), weak (BF 1-3), 
substantial (BF 3-10), strong (BF 10-30), very strong (BF 30-100), and decisive (BF > 100). BFs 
of >1 are in bold. 
 
Bayes Factor* 
Early AMD Late AMD Any AMD 
Gender     
  Male vs. Female 0.03 0.04 0.03 
Ethnicity groups     
  European vs. African 12.16 3.74 31.26 
  European vs. Asian 3.94 0.20 4.31 
  European vs. Hispanic 0.06 0.34 0.08 
  African vs. Asian 0.15 0.41 0.10 
  African vs. Hispanic 0.24 0.11 0.19 
  Asian vs. Hispanic 0.33 0.18 0.26 
Geographic regions     
  Africa vs. Asia 0.24 0.17 0.20 
  Africa vs. Europe 0.28 0.20 0.30 
  Africa vs. Latin America & Caribbean 0.44 0.62 0.20 
  Africa vs. Northern America 0.14 0.16 0.15 
  Africa vs. Oceania 0.14 0.29 0.19 
  Asia vs. Europe 2.32 0.80 7.55 
  Asia vs. Latin America & Caribbean 0.52 0.12 0.76 
  Asia vs. Northern America 3.02 0.14 3.75 
  Asia vs. Oceania 0.24 0.62 0.14 
  Europe vs. Latin America & Caribbean 0.24 0.36 0.24 
  Europe vs. Northern America 0.12 0.26 0.16 
  Europe vs. Oceania 0.19 0.17 0.20 
  Latin America & Caribbean vs. Northern America 0.13 0.18 0.11 
  Latin America & Caribbean vs. Oceania 0.12 0.91 0.05 
  Northern America vs. Oceania 0.15 0.21 0.15 
Publication Year    
  1989 to 2013 0.12 0.47 0.12 
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Supplementary Table 5.4 Heterogeneity Analysis of Ethnicity and Geographical 
Regions Effects 
Data presented as mean (95% CrI) of percentage of total variability; posterior mean is 
used instead of median to ensure the sum of total between and within study equal to one 
*Variability between ethnic groups in the same study 
 
Percentage of total variability AMD 
Early Late Any 
Ethnicity    
Total between-study 99.5 (99.2, 99.8) 95.2 (91.6, 98.5) 99.5 (99.2, 99.8) 
   Ethnicity covariate (within ethnicity) 18.5 (1.7, 68.8) 23.1 (1.1, 73.7) 21.0 (2.2, 70.9) 
   Between ethnicity* 74.9 (23.3, 95.5) 32.6 (0.9, 81.1) 69.7 (15.4, 94.1) 
   Residual 6.2 (0.7, 25.6) 39.5 (2.0, 86.6) 8.8 (0.8, 37.5) 
Total within-study 0.5 (0.2, 0.8) 4.8 (1.5, 8.4) 0.5 (0.2, 0.8) 
        
Region    
Total between-study 99.7 (99.5, 99.9) 96.6 (94.3, 98.4) 99.7 (99.5, 99.9) 
   Region covariate (within region) 27.3 (1.4, 72.9) 11.6 (0.6, 50.4) 30.0 (2.2, 74.8) 
   Residual 72.4 (27.0, 98.2) 85.0 (47.0, 96.7) 69.7 (25.1, 97.5) 








Supplementary Table 5.5 Age-group Specific Prevalence Estimates of Any, Early and Late AMD by Ethnic Ancestry 
Groups 




African Asian European Hispanic Total 
45-49 3.73 (2.25, 6.04) 2.89 (1.67, 4.80) 3.67 (2.28, 5.76) 4.63 (2.82, 7.70) 3.53 (2.34, 5.25) 
50-59 5.10 (3.24, 7.83) 4.29 (2.60, 6.98) 5.86 (3.83, 8.83) 6.87 (4.29, 10.77) 5.39 (3.64, 7.93) 
60-69 7.45 (4.84, 11.14) 7.01 (4.36, 11.12) 10.40 (7.06, 14.95) 11.01 (7.05, 16.93) 9.04 (6.20, 12.92) 
70-79 10.73 (6.93, 16.45) 11.27 (6.97, 17.46) 17.68 (12.32, 24.42) 17.31 (10.77, 26.45) 14.71 (10.18, 20.83) 
80-84 13.88 (8.62, 21.52) 15.44 (9.43, 23.56) 24.91 (17.58, 33.65) 23.20 (14.22, 35.59) 20.26 (14.10, 28.33) 
Total 7.06 (3.41, 13.15) 6.81 (3.14, 13.94) 11.19 (5.63, 20.39) 9.87 (4.97, 18.90) 8.01 (3.95, 15.49) 
 Late AMD 
45-49 0.13 (0.06, 0.25) 0.06 (0.03, 0.11) 0.03 (0.02, 0.06) 0.04 (0.02, 0.09) 0.05 (0.03, 0.08) 
50-59 0.20 (0.10, 0.34) 0.14 (0.08, 0.24) 0.10 (0.06, 0.16) 0.10 (0.05, 0.20) 0.13 (0.08, 0.18) 
60-69 0.35 (0.20, 0.55) 0.41 (0.27, 0.63) 0.41 (0.27, 0.60) 0.35 (0.19, 0.58) 0.42 (0.30, 0.57) 
70-79 0.61 (0.31, 1.08) 1.26 (0.79, 1.96) 1.71 (1.17, 2.44) 1.19 (0.61, 2.12) 1.41 (1.00, 1.92) 
80-84 0.90 (0.42, 1.84) 2.69 (1.56, 4.61) 4.56 (2.96, 6.73) 2.75 (1.23, 5.69) 3.25 (2.21, 4.60) 
Total 0.28 (0.12, 0.63) 0.37 (0.17, 0.85) 0.50 (0.26, 1.08) 0.32 (0.13, 0.75) 0.37 (0.18, 0.77) 
 Any AMD 
45-49 4.06 (2.39, 6.47) 3.21 (1.98, 5.20) 3.10 (1.99, 4.79) 4.80 (2.90, 7.81) 3.49 (2.32, 5.23) 
50-59 5.65 (3.58, 8.35) 4.92 (3.14, 7.60) 5.66 (3.74, 8.41) 7.28 (4.62, 11.28) 5.66 (3.83, 8.26) 
60-69 8.41 (5.53, 12.21) 8.28 (5.35, 12.27) 11.63 (7.95, 16.36) 12.08 (7.73, 18.01) 10.19 (7.10, 14.29) 
70-79 12.35 (8.12, 18.14) 13.61 (8.96, 19.73) 22.50 (15.83, 29.93) 19.24 (12.37, 28.71) 17.61 (12.53, 23.87) 
80-84 16.06 (10.15, 24.09) 18.87 (12.27, 27.22) 33.57 (24.17, 42.86) 25.84 (16.25, 38.64) 24.96 (18.01, 33.25) 







Supplementary Table 5.6 Age-group Specific Prevalence Estimates of Early, Late and Any AMD by Geographic Regions 




Africa Asia Europe Latin America & Caribbean Northern America Oceania Total 
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Supplementary Table 5.7 Projection of Number of People with Early, Late and Any AMD by Regions 
97.5% Upper bound = Upper limit of 95% Credible Interval; 2.5% Lower bound = Lower limit of 95% Credible Interval 
 
Year 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2034 2036 2038 2040 
 Early AMD (millions) 
97.5% Upper bound               
   Africa 39.72 42.14 44.73 47.67 50.69 54.10 57.81 61.76 66.15 70.56 75.40 80.42 85.60 91.30 
   Asia 102.04 108.39 114.83 121.63 127.95 134.66 141.92 149.48 157.71 165.37 173.28 180.40 186.78 193.78 
   Europe 82.08 83.76 85.41 87.16 88.25 89.70 91.54 93.42 95.28 96.42 97.57 98.34 98.59 98.88 
   Latin America & Caribbean 48.69 51.54 54.42 57.52 60.61 63.93 67.24 70.60 74.10 77.32 80.61 83.72 86.64 89.63 
   Northern America 23.06 23.98 24.95 26.10 27.02 28.01 28.96 29.88 30.75 31.29 31.83 32.28 32.65 33.01 
   Oceania 2.51 2.64 2.78 2.94 3.07 3.22 3.35 3.49 3.63 3.73 3.84 3.95 4.06 4.18 
Total 221.19 231.43 242.29 255.12 266.88 279.60 292.31 305.48 320.45 333.56 346.57 359.16 370.22 381.98 
Mean               
   Africa 15.36 16.31 17.32 18.47 19.65 20.98 22.42 23.96 25.67 27.38 29.27 31.24 33.29 35.53 
   Asia 55.51 58.98 62.52 66.29 69.84 73.64 77.66 81.76 86.22 90.37 94.67 98.53 101.98 105.76 
   Europe 47.81 48.79 49.80 50.87 51.52 52.44 53.66 54.97 56.28 56.96 57.65 58.13 58.37 58.65 
   Latin America & Caribbean 19.87 21.05 22.27 23.59 24.86 26.22 27.61 29.01 30.47 31.81 33.18 34.48 35.69 36.95 
   Northern America 14.77 15.37 16.00 16.70 17.32 17.99 18.63 19.23 19.80 20.16 20.51 20.81 21.06 21.30 
   Oceania 1.21 1.28 1.35 1.43 1.50 1.57 1.65 1.72 1.79 1.84 1.90 1.96 2.01 2.07 
Total 154.55 161.79 169.27 177.35 184.69 192.84 201.63 210.64 220.22 228.53 237.18 245.14 252.40 260.26 
2.5% Lower bound               
   Africa 4.29 4.56 4.85 5.17 5.50 5.87 6.27 6.70 7.18 7.66 8.19 8.74 9.30 9.92 
   Asia 26.87 28.55 30.26 32.07 33.78 35.63 37.69 39.76 41.95 43.99 46.09 47.99 49.68 51.54 
   Europe 24.07 24.60 25.16 25.75 26.08 26.59 27.26 27.93 28.59 28.95 29.36 29.72 29.85 29.93 
   Latin America & Caribbean 5.78 6.10 6.42 6.79 7.18 7.60 8.04 8.48 8.95 9.40 9.83 10.25 10.63 10.98 
   Northern America 8.89 9.26 9.65 10.10 10.50 10.91 11.31 11.69 12.04 12.27 12.48 12.66 12.81 12.95 
   Oceania 0.44 0.47 0.49 0.52 0.55 0.58 0.61 0.64 0.66 0.68 0.70 0.73 0.75 0.77 
Total 104.97 110.11 115.35 120.35 125.01 130.35 136.01 142.13 148.27 153.50 159.04 164.13 168.77 173.52 
 Late AMD (millions) 
 175 
 
97.5% Upper bound               
   Africa 1.57 1.67 1.77 1.89 2.01 2.14 2.29 2.45 2.62 2.80 2.99 3.18 3.39 3.60 
   Asia 6.93 7.37 7.82 8.34 8.85 9.44 10.11 10.82 11.59 12.33 13.06 13.72 14.30 14.98 
   Europe 4.03 4.13 4.25 4.36 4.37 4.43 4.63 4.89 5.15 5.29 5.44 5.58 5.69 5.82 
   Latin America & Caribbean 1.71 1.80 1.89 2.00 2.11 2.22 2.34 2.44 2.55 2.65 2.76 2.86 2.96 3.05 
   Northern America 1.16 1.21 1.28 1.36 1.45 1.55 1.64 1.73 1.82 1.88 1.95 2.00 2.04 2.08 
   Oceania 0.17 0.18 0.19 0.21 0.22 0.24 0.25 0.27 0.29 0.30 0.31 0.32 0.34 0.35 
World 13.45 14.13 14.87 15.70 16.45 17.33 18.38 19.58 20.83 22.06 23.24 24.25 25.18 26.23 
Mean               
   Africa 0.77 0.82 0.87 0.93 0.99 1.06 1.13 1.21 1.30 1.38 1.48 1.58 1.68 1.80 
   Asia 4.59 4.88 5.18 5.52 5.86 6.25 6.69 7.15 7.66 8.15 8.64 9.08 9.46 9.92 
   Europe 2.57 2.64 2.72 2.79 2.79 2.84 2.96 3.13 3.29 3.38 3.46 3.55 3.61 3.69 
   Latin America & Caribbean 0.86 0.91 0.97 1.02 1.08 1.14 1.20 1.26 1.32 1.38 1.44 1.50 1.55 1.61 
   Northern America 0.76 0.80 0.84 0.90 0.95 1.02 1.08 1.14 1.20 1.24 1.28 1.31 1.34 1.36 
   Oceania 0.09 0.10 0.10 0.11 0.12 0.13 0.14 0.15 0.15 0.16 0.17 0.17 0.18 0.19 
World 9.64 10.14 10.68 11.26 11.79 12.42 13.19 14.03 14.92 15.69 16.47 17.19 17.83 18.57 
2.5% Lower bound               
   Africa 0.37 0.39 0.42 0.45 0.48 0.51 0.55 0.58 0.63 0.67 0.72 0.77 0.82 0.87 
   Asia 2.76 2.93 3.11 3.31 3.51 3.73 3.99 4.25 4.55 4.82 5.11 5.37 5.60 5.87 
   Europe 1.51 1.55 1.60 1.64 1.64 1.67 1.74 1.84 1.93 1.98 2.03 2.08 2.11 2.16 
   Latin America & Caribbean 0.39 0.41 0.44 0.47 0.50 0.53 0.56 0.59 0.62 0.65 0.68 0.71 0.73 0.76 
   Northern America 0.46 0.48 0.51 0.54 0.57 0.61 0.65 0.68 0.72 0.74 0.76 0.78 0.80 0.81 
   Oceania 0.05 0.05 0.05 0.06 0.06 0.06 0.07 0.07 0.08 0.08 0.08 0.09 0.09 0.09 
World 6.46 6.80 7.15 7.54 7.91 8.33 8.85 9.41 10.02 10.52 11.06 11.53 11.98 12.46 
 Any AMD (millions) 
97.5% Upper bound               
   Africa 40.50 42.98 45.63 48.63 51.72 55.20 58.98 63.01 67.48 71.99 76.93 82.08 87.41 93.21 
   Asia 106.65 113.33 120.17 127.49 134.41 141.59 149.43 157.37 165.91 173.86 182.07 189.46 196.09 203.32 
   Europe 88.76 90.61 92.51 94.55 95.82 97.58 99.86 102.26 104.64 105.89 107.15 107.93 108.31 108.99 
   Latin America & Caribbean 45.80 48.39 51.12 54.05 56.77 59.54 62.43 65.38 68.31 71.12 74.19 77.07 79.49 82.03 
   Northern America 26.57 27.68 28.86 30.08 31.17 32.33 33.50 34.47 35.43 36.05 36.65 37.16 37.58 38.00 
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   Oceania 2.85 3.00 3.17 3.34 3.50 3.66 3.83 4.01 4.18 4.30 4.43 4.56 4.69 4.83 
World 233.30 244.54 256.30 269.51 280.91 293.52 307.15 321.43 336.52 349.14 362.66 374.95 386.61 399.38 
Mean               
   Africa 16.87 17.92 19.03 20.29 21.59 23.05 24.64 26.32 28.20 30.09 32.16 34.33 36.58 39.06 
   Asia 59.16 62.87 66.65 70.68 74.50 78.58 82.92 87.33 92.14 96.62 101.24 105.40 109.13 113.21 
   Europe 54.98 56.18 57.43 58.78 59.58 60.75 62.35 64.10 65.82 66.75 67.67 68.37 68.80 69.32 
   Latin America & Caribbean 20.93 22.16 23.43 24.80 26.12 27.53 28.96 30.40 31.90 33.28 34.68 36.01 37.26 38.53 
   Northern America 17.07 17.79 18.55 19.41 20.18 21.01 21.81 22.55 23.25 23.70 24.13 24.50 24.79 25.08 
   Oceania 1.37 1.45 1.53 1.62 1.71 1.80 1.89 1.98 2.06 2.13 2.19 2.26 2.33 2.40 
World 170.38 178.36 186.62 195.58 203.67 212.72 222.56 232.68 243.38 252.55 262.08 270.87 278.88 287.59 
2.5% Lower bound               
   Africa 5.02 5.34 5.67 6.05 6.44 6.88 7.36 7.86 8.43 8.99 9.62 10.27 10.96 11.71 
   Asia 31.31 33.26 35.24 37.33 39.28 41.39 43.71 46.08 48.66 51.08 53.56 55.79 57.79 60.00 
   Europe 31.09 31.78 32.51 33.27 33.71 34.38 35.35 36.41 37.59 38.23 38.82 39.27 39.56 39.86 
   Latin America & Caribbean 7.98 8.46 8.96 9.48 10.02 10.57 11.14 11.73 12.29 12.82 13.40 13.94 14.46 14.97 
   Northern America 10.10 10.55 11.04 11.60 12.06 12.59 13.08 13.54 13.96 14.23 14.49 14.72 14.90 15.08 
   Oceania 0.56 0.59 0.63 0.67 0.71 0.74 0.78 0.82 0.86 0.89 0.92 0.95 0.98 1.01 

















Supplementary Table 5.8 Pairwise Comparison of Projected Number of People with Early, Late and Any AMD by Regions 
Data represented as indicator of whether 95% credible interval contains zero. If A-B=1, A>B; if A-B=0, A=B; if A-B=-1, A<B. 
 
Pairwise Comparisons, (A) – (B) 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2034 2036 2038 2040 
 Early AMD 
Africa - Asia -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 0 0 0 0 
Africa - Europe -1 -1 -1 -1 0 0 0 0 0 0 0 0 0 0 
Africa - Latin America & Caribbean 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Africa - Northern America 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Africa - Oceania 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Asia - Europe 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Asia - Latin America & Caribbean 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Asia - Northern America 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Asia - Oceania 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Europe - Latin America & Caribbean 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Europe - Northern America 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Europe - Oceania 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Latin America & Caribbean - Northern America 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Latin America & Caribbean - Oceania 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Northern America - Oceania 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
 Late AMD 
Africa - Asia -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 
Africa - Europe -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 0 
Africa - Latin America & Caribbean 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Africa - Northern America 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Africa - Oceania 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Asia - Europe 0 0 1 1 1 1 1 1 1 1 1 1 1 1 
Asia - Latin America & Caribbean 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Asia - Northern America 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Asia - Oceania 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
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Europe - Latin America & Caribbean 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Europe - Northern America 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Europe - Oceania 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Latin America & Caribbean - Northern America 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Latin America & Caribbean - Oceania 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Northern America - Oceania 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
 Any AMD 
Africa - Asia -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 0 
Africa - Europe -1 -1 -1 -1 -1 -1 -1 0 0 0 0 0 0 0 
Africa - Latin America & Caribbean 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Africa - Northern America 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Africa - Oceania 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Asia - Europe 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Asia - Latin America & Caribbean 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Asia - Northern America 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Asia - Oceania 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Europe - Latin America & Caribbean 1 1 1 1 0 0 0 0 0 0 0 0 0 0 
Europe - Northern America 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Europe - Oceania 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Latin America & Caribbean - Northern America 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Latin America & Caribbean - Oceania 1 1 1 1 1 1 1 1 1 1 1 1 1 1 












Supplementary Figure 5.1 Flowchart of the Article Selection Process 








































2751 published studies, letters, abstracts and 
review articles on the prevalence of AMD 
were identified using PubMed, Medline, 
Embase and Web of Science up to May 2013 
54 potentially eligible reports were 
retrieved after abstract review for 
detailed evaluation 
39 reports from 39 population-based 
studies (n = 129,664) were included in the 
meta-analysis (12,727 any, 12,931 early 
and 1,121 late AMD cases) 
15 excluded due to: 1) used only clinical 
examination by slit-lamp biomicroscopy for 
diagnosis of AMD without fundus photos nor 
standardized grading definitions for AMD; (2) 
reports not written in English; (3) reports 
numbers of eyes with AMD as opposed to 
number of individuals; (4) studies in which 
determination of AMD prevalence was not 
one of the primary study objectives; and (5) 
not population based, but interview based / 
audits of hospital eye departments 
2696 were excluded after abstract review 
as prevalence of AMD was not measured 
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Supplementary text 5.1 Heterogeneity Analysis 
Age groups, gender, ethnicity, geographic regions-specific data for early and late 
AMD types were the only information available from all 39 published studies and hence 
we were only able to investigate and account for heterogeneity derived from these sources 
in our statistical models. 
Some studies may comprise of more than one ethnic group, which may result in 
between-ethnicity heterogeneity in the study. Hence, the between-ethnicity variance ߪ௘ଶ in 
the same study was accounted as random effects with Normal distribution, i.e. 
ܰ݋ݎ݈݉ܽሺ0, ߪ௘ଶሻ , to describe this correlation. Conditioning on these random effects, 
ethnicity groups within the same study are considered independent. Similarly, for ethnicity 
covariate, its variability ߪ௫ଶ was accounted for as random effects with Normal distribution, 
i.e. ܰ݋ݎ݈݉ܽሺ0, ߪ௫ଶሻ. Other residual variability encompassing between study variance (after 
accounting for other sources of uncertainty) was explained by ߪଶ. The total between-study 
variability can be calculated as the sum of the above three variances, denoted by ߪଶ். When 
analyzing ethnicity effect, the between-study variability is ߪ௘ଶ ൅ ߪ௫ଶ ൅ ߪଶ if the two ethnic 
groups are from the same study; is ߪ௫ଶ ൅ ߪଶ if the two studies are in the same ethnic group; 
and is ߪଶ if the two studies are in different ethnic groups. These random effects were useful 
in pooling information together for sub-groups with small sample sizes or with few number 
of available studies, by borrowing strength from other covariate-specific groups. 
Each population-based study would originate from only one region, hence in 
performing analysis of region effect, there is no need for parameter ߪ௘ଶ in the model. As 
with ethnicity covariate, region effect was accounted as random effects with ߪ௫ଶ and the 
residual variance was explained by ߪଶ . The total between-study variability can be 
calculated as the sum of the above two variances, denoted by ߪଶ். When analyzing region 
effect, the between-study variability is ߪ௫ଶ ൅ ߪଶ if the two studies are in the same region 
group; and is ߪଶ if the two studies are from different region groups. 
As described by Higgins and Thompson (2002), within-study variance can be 
estimated by ݏଶ ൌ ∑ఠ೔ሺ௞ିଵሻሺ∑ఠ೔ሻమି∑ఠ೔మ, where ߱௜is the reciprocal of the estimate’s variance and ݇ 
is the number of study. As logit link function was used in our model, variance of the logit 
prevalence estimate can be obtained by using delta method, given by ଵ௣ሺଵି௣ሻ௡, where ݌ and 
݊  are the sample prevalence estimate and sample size respectively. Then the total 
variability is the sum of between and within study variance, ߪଶ் ൅ ݏଶ. ܫଶ ൌ ఙ೅మఙ೅మା௦మ (Higgins 
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and Thompson, 2002) was calculated to describe the proportion of total variability 
explained by the heterogeneity. Separate sources of heterogeneity (e.g. ethnicity and region) 
can be calculated accordingly. 
Fixed effect was used for age and gender. Age is a well-known risk factor for AMD 
and is strongly associated with AMD (Bayes factor > 100). Whereas for gender, Bayes 
factors were all < 1 (Supplementary Table 5.3), suggesting strong statistical evidence of 






























Supplementary text 5.2 Simulation Study 
Simulation data was derived from our estimated global prevalence of early AMD 
(pooled by region data) of 11.40% and the between and within study variations obtained 
from our meta-analysis. We generated 39 distributions with their own prevalence (݌௜ሻ and 
within study variance (ߪ௜ଶሻ with the between study variance obtained from our meta-
analysis. Binary AMD data was then created for a sample size of 100, with the probability 
of AMD for each data point (pseudo-subject) as ݌௜  for the ݅௧௛  pseudo-study (total 39 
pseudo-studies) to form our pseudo-global population data (i.e. generated 3,900 data points 
from the 39 pseudo-studies, representing the individual data for our pseudo-populations). 
Analysis of the pseudo-population data was performed with our HB model and the 
frequently used RE model. We perform such simulation 100 times to obtain the pooled 
prevalence estimates for both models and for a range of sample sizes (i.e. 100, 250, 500, 
750, 1000 and 1500). 
Our simulation results showed that based on simulated sample size of 1000, the 
prevalence of overall any AMD was estimated as 11.5% (95% CrI: 8.1, 15.9) by HB and 
15.1% (95% CI: 12.1, 18.1) by RE methods (Supplementary Figure 5.2). Estimation from 
HB model was always more accurate than RE model but the difference decreases as sample 
size increased. This result was expected because the inference made from RE model was 
based on asymptotic properties which requires very large sample sizes while HB model 
depends on the posterior distribution. Hence HB model would be preferred especially for 


















Supplementary Figure 6.1 Path Diagram for the Multilevel Rasch Model 
Path diagram for multilevel Rasch model: Item response data can be considered as level 0, 
nested within respondents with covariate information such as demographic or clinical data 
considered in level 1 that can be further nested in groups considered in level 2. Higher 
levels may be needed to model complex data structure which is common in survey research. 
The levels in the rectangular box illustrate the nesting of item observations in individuals 
and individuals in groups. Levels 1 and 2 constitute the multilevel model for ߠ௜௝. There are 
uncertainties involved at each level, i.e. at the level of observations, at the individual level 
and at the group level. Explanatory information ݔ௜௝  and ݓ௝  at levels 1 and 2 explain 
variability in the latent abilities between individuals within groups and across groups 
respectively. The dotted inverse L-box describes the Rasch model where item parameters, 
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Supplementary Table 6.1 Power Analysis: Comparison of Proposed One-Stage HB and Observed Two-Stage Analysis Framework from 
Simulation Results 
Based on 200 simulations using K=9; C=5 







Effect Size Effect Size 


























1% 0.245 0.250 0.970 0.970 1% 0.045 0.045 0.440 0.445 0.950 0.955 
5% 0.490 0.505 0.995 0.995 5% 0.150 0.135 0.670 0.675 0.990 0.990 
10% 0.610 0.605 1 1 10% 0.225 0.225 0.780 0.775 0.995 1 
 N=300  N=300 
1% 0.755 0.74 1 1 1% 0.130 0.145 0.900 0.910 1 1 
5% 0.915 0.905 1 1 5% 0.315 0.320 0.985 0.985 1 1 
10% 0.960 0.950 1 1 10% 0.475 0.470 0.995 1 1 1 
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Supplementary text 6.1 Simulation Study 
We simulated our data as follows: two independent covariates ( ௜ܺଵ,	 ௜ܺଶ), a continuous 
variable data such as standardized age was drawn from standard normal distribution and a 
binary variable such as gender drawn from binomial distribution with equal probability of 
being male or female gender (i.e. probability 0.5). The association effects (ߚଵ,	ߚଶ) of these 
two covariates with the latent visual functioning ability parameter were fixed for a range 
from -1 to 1 by steps of 0.5 (i.e. ߚ௦ = -1, -0.5, 0, 0.5, 1) and hence, these were considered 
as the “true” association effects for our simulated datasets. The calibration of nine item 
difficulty parameters, ߟ௞ was fixed according to Table 3 of a study conducted by Ecosse L. 
Lamoureux et. al.,36 that performed a systematic evaluation of the reliability and validity 
of the visual functioning questionnaire (VF-11) using Rasch analysis that was later 
modified to nine items (VF-9) to tailor fit to the Asian population. The threshold parameters 
were specified with normal distribution of mean 0 and standard deviation 1. Hence, 
multinomial response data for each of the nine items with five response categories were 
then generated for a sample size of 300 with probability of response determined by the 
Andrich rating scale model with the model parameters specifications described above, to 
form our pseudo-visual functioning questionnaire (modified VF-9) data (i.e. n = 300, k= 9 
and y in the range of integers 1 to 5 for five response categories for each item resulted in 
2,700 response data generated). 
Analysis of the generated pseudo-visual functioning sample data was performed with 
our one-stage HB approach and the frequently used two-stage procedure. Based on 100 
replicates for each pair of our specified “true” association effects (25 pairs of “ߚଵ,	ߚଶ”), 
average association estimates and their standard errors from the one and two-stage 
approach were computed to assess their performance in comparison to our pre-specified 
“true” effects. Finally, we performed another 200 simulations for continuous and 
categorical variable separately to investigate and compare the empirical power between 
one and two-stage approach. 
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